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Abstract
The concept of radioguided surgery, which was first developed some 60 years ago, involves the use
of a radiation detection probe system for the intraoperative detection of radionuclides. The use of
gamma detection probe technology in radioguided surgery has tremendously expanded and has
evolved into what is now considered an established discipline within the practice of surgery,
revolutionizing the surgical management of many malignancies, including breast cancer, melanoma,
and colorectal cancer, as well as the surgical management of parathyroid disease. The impact of
radioguided surgery on the surgical management of cancer patients includes providing vital and real-
time information to the surgeon regarding the location and extent of disease, as well as regarding
the assessment of surgical resection margins. Additionally, it has allowed the surgeon to minimize
the surgical invasiveness of many diagnostic and therapeutic procedures, while still maintaining
maximum benefit to the cancer patient. In the current review, we have attempted to
comprehensively evaluate the history, technical aspects, and clinical applications of radioguided
surgery using gamma detection probe technology.
Background
The concept of radioguided surgery using a radiation
detection probe system originated approximately 60 years
ago. Interestingly, the first recognized description of radi-
oguided surgery involving a radiation detection probe sys-
tem [1] did not involve a gamma detection probe, but
instead involved the use of a gaseous ionization detector
called a Geiger-Müller tube [2], which has a high sensitiv-
ity for beta radiation emitting radionuclides and a very
low sensitivity for gamma radiation emitting radionu-
clides.
In 1949, Selverstone et al [1] at Harvard Medical School
reported on 33 suspected brain tumor patients that were
intravenously injected with the beta radiation emitter,
phosphorus-32 (32P). At surgery, using a handheld Gei-
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ger-Müller tube device, counts in the area of suspected
tumor and normal brain tissue were obtained at various
time intervals and various depths beneath the cerebral
cortex. Following successful location of the tumor,
attempts were made to demarcate its tumor boundary
margins using the Geiger-Müller counter. Of 33 evaluated
patients, 23 brain tumors (88%) were localized using the
Geiger-Müller counter. In 12 patients, the Geiger-Müller
counter was used to facilitate total extirpation of tumor. In
four patients, tumor was not localized by means of the
Geiger-Müller counter. This included two false-negative
results that were attributed to the inability to place the
Geiger-Müller counter in close proximity to the tumor,
one patient with diffuse infiltration of the entire cerebral
hemisphere with tumor that precluded distinguishing it
from normal adjacent tissue, and one patient in which no
tumor was correctly identified.
It was then not until 1956, when Harris et al [3] at the Oak
Ridge Institute of Nuclear Studies Medical Hospital
reported the first description of radioguided surgery
involving a gamma detection probe system. In their pub-
lished report, a patient with a history of thyroid cancer
who had previously undergone a total thyroidectomy
some three years earlier and who had persistent iodine
uptake in the neck region was intravenously injected with
the gamma radiation emitter, iodine-131 (131I). At sur-
gery, using a handheld scintillation detector device as the
gamma detection probe, they localized and successfully
resected an area of residual thyroid tissue.
Since the time of these landmark reports by Selverstone et
al [1] and Harris et al [3], the concept of radioguided sur-
gery and its supporting technologies has tremendously
expanded and has evolved into what is now considered an
established discipline within the practice of surgery, revo-
lutionizing the surgical management of many malignan-
cies. Along the way, various milestones in radioguided
surgery have been reached (Table 1), and the clinical
application of this technology has, to varying degrees,
impacted upon almost every facet of cancer-related sur-
gery (Table 2). The impact of radioguided surgery on the
surgical management of cancer patients includes provid-
ing vital and real-time information to the surgeon regard-
ing the location and extent of disease, as well as regarding
the assessment of surgical resection margins. Addition-
ally, it has allowed the surgeon to minimize the surgical
invasiveness of many diagnostic and therapeutic proce-
dures, while still maintaining maximum benefit to the
cancer patient.
Gamma detection probe systems
Numerous handheld intraoperative radiation detection
probe systems have been developed and have been made
commercially available for use in radioguided surgery [4-
23]. Such intraoperative radiation detection probes are
Table 1: Historical timeline for milestones in radioguided surgery
Year Milestone
1949 Selverstone et al [1] at Harvard Medical School (Boston, Massachusetts, USA) were the very first to report the concept of radioguided 
surgery using of a Geiger-Müller tube device and 32P to detect brain tumors.
1956 Harris et al [3] at the Oak Ridge Institute of Nuclear Studies Medical Hospital (Oak Ridge, Tennessee, USA) were the first to report the 
application of a gamma detection probe during radioguided surgery using 131I to detect residual thyroid tissue.
1981 Harvey et al [743] at Presbyterian Hospital of Dallas (Dallas, Texas, USA) first reported the application of a gamma detection probe for 
radioguided biopsy of benign and metastatic bone lesions using 99mTc methylene diphosphonate.
1981 Ghelman et al [728] at The Hospital for Special Surgery (New York, New York, USA) first reported the application of a gamma detection 
probe for radioguided resection of a benign bone lesion using 99mTc methylene diphosphonate.
1984 Aitken et al [289,290] at The Ohio State University (Columbus, Ohio, USA) first reported radioimmunoguided surgery using 131I-labeled 
anti-CEA polyclonal antibody to detect colorectal cancer.
1984 Ubhi et al. [408] at Queen's Medical Center/University Hospital (Nottingham, England, UK) first reported radioguided surgery using 201Tl-
thallous chloride for the detecting a parathyroid adenoma.
1987 Sickle-Santanello et al [299] at The Ohio State University (Columbus, Ohio, USA) first reported radioimmunoguided surgery using 125I-
labeled anti-TAG-72 monoclonal antibody to detect colorectal cancer.
1993 Krag et al [135] at The University of Vermont (Burlington, Vermont, USA) first reported radioguided sentinel lymph node biopsy using 
99mTc radiocolloid for breast cancer.
1993 Alex et al [188] at The University of Vermont (Burlington, Vermont, USA) first reported radioguided sentinel lymph node biopsy using 
99mTc radiocolloid for malignant melanoma.
1995 Martinez et al [409] at The Ohio State University (Columbus, Ohio, USA) first reported use of 99mTc-MIBI for the detecting parathyroid 
gland pathology.
1997 Norman and Chheda [410] at The University of South Florida (Tampa, Florida, USA) popularized the technique of minimally-invasive 
radioguided surgery using 99mTc-MIBI for the surgical management of primary hyperparathyroidism.
1999 Desai et al [35,36] at The Ohio State University (Columbus, Ohio, USA) first reported use of 18F-FDG-directed surgery in the surgical 
management of colorectal cancer.
2008 Strong et al [29] at Memorial Sloan-Kettering Cancer Center (New York, New York, USA) first reported radioimmunoguided surgery 
using 124I-labeled monoclonal antibody specific for clear cell renal cell cancer.World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
Page 3 of 63
(page number not for citation purposes)
divided into two general categories (i.e., gamma detection
probes and beta detection probes), based upon the spe-
cific type of radiation detected. Gamma probes detect
photon radiation, consisting of either gamma rays or x-
rays [10,11,17]. Beta probes detect beta radiation, consist-
ing of either positrons (positively charged electrons) or
negatrons (negatively charged electrons) [10,11,18-23].
This includes some beta detection probe systems that are
reported to have gamma photon background rejection
capabilities [22,23]. However, the present review will spe-
cifically concentrate upon the use of gamma detection
probe technology in radioguided surgery. Additionally,
the present review will not specifically discuss or advocate
the use of any individual commercially-available brand
names of gamma detection probe technology.
Important performance variables of gamma detection 
probe systems
The most important performance variables of any given
gamma detection probe system consist of: (1) overall sen-
Table 2: Clinical applications of radioguided surgery using gamma detection probe technology
Clinical applications Specific type(s) of radioguided surgery applications
Breast cancer RGSLNB, RIGS, ROLL, RIME, FDGDS
Cutaneous malignancies
Malignant melanoma RGSLNB, FDGDS
Merkel cell carcinoma RGSLNB
Other cutaneous malignancies RGSLNB
Gastrointestinal malignancies
Colorectal cancer RIGS, RGSLNB, FDGDS
Anal cancer RGSLNB
Esophageal cancer RGSLNB
Gastric cancer RGSLNB, RIGS, FDGDS
Pancreatic cancer RIGS
GIST FDGDS
Head and neck malignancies
Squamous cell cancer RGSNLB, RIGS, FDGDS
Parathyroid disease RGS
Thyroid cancer RGS, FDGDS, RGSLNB
Parotid gland cancer RGSLNB
Gynecologic malignancies
Vulvar cancer RGSLNB
Vaginal carcinoma RGSLNB
Cervical cancer RGSLNB
Endometrial cancer RGSLNB
Ovarian Cancer RIGS, FDGDS
Urologic malignancies
Penile cancer RGSLNB
Prostate cancer RGSLNB, RIGS
Testicular cancer RGSLNB, FDGDS
Bladder cancer RGSLNB
Renal cell cancer RIGS
Thoracic malignancies
Lung cancer RGSLNB, RIGS, RGS, FDGDS
Pulmonary nodules RGS
Neuroendocrine tumors
GEP neuroendocrine tumors RGS
Bronchial carcinoids RGS
Neuroblastoma RGS
Pheochromocytoma RGS
Adrenocortical carcinoma FDGDS
Sarcoma RGSLNB
Brain tumors RGS
Bone lesions RGS
Lymphoma RGS
Monitoring of isolated limb perfusion RGS
RGS, radioguided surgery; RIGS, radioimmunoguided surgery; RGSLNB, radioguided sentinel lymph node biopsy; ROLL, radioguided occult lesion 
localization; RIME, radioguided intraoperative margins evaluation; FDGDS, 18F-FDG directed surgery; GIST, gastrointestinal stromal tumor; GEP, 
gastroenteropancreaticWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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sitivity (efficiency); (2) spatial selectivity (radial sensitiv-
ity distribution); (3) spatial resolution (lateral sensitivity
distribution); (4) energy resolution (spectral discrimina-
tion); and (5) contrast [9,11,13-15,17]. Overall sensitivity
(efficiency) is the detected count rate (photons detected)
per unit of activity (photons emitted) and is determined
at the tip of the probe profile. Spatial selectivity (radial
sensitivity distribution) is described by the width of the
resultant measurement cone out of which radiation is
being detected at a defined distance. With a wider meas-
urement cone, background signal may exceed target
source signal and can lead to interference with detection
of the target signal. With a narrower measurement cone,
background counts will be reduced and detection of the
target source signal will be more likely, even in the pres-
ence of an increased background signal or noise. Spatial
resolution (lateral sensitivity distribution) is the ability of
the gamma detection probe to accurately localize the posi-
tion of a target source of activity, as well as to separate and
distinguish two target sources of activity which are located
relatively close to each other. Energy resolution (spectral
discrimination) is the capacity of the gamma detection
system to discriminate between emitted radiation of dif-
fering energies. Such energy discrimination is critical in
two particular respects. First, it is critical for distinguishing
two simultaneously administered radionuclides that have
differing energies. Second, it is critical for distinguishing
primary photons from scattered photons when higher-
energy radionuclides are administered. Finally, contrast,
which is directly related to all of the above performance
variables of the gamma detection probe system, reflects
the ability of the gamma detection probe to distinguish
activity within the target tissue from that of the lower
background activity within the surrounding non-target
tissue.
Basic principles of the radiation detector source housed 
within the gamma detection probe system
Two general categories of gamma detection probe systems
exist that can be utilized within the operating room envi-
ronment. These include gamma detection probe systems
that utilize a scintillation detector and gamma detection
probe systems that utilize a semiconductor ionization
detector [4,6,8,10-12,15-17]. Only crystalline materials
are used as the detector source within commercially-avail-
able gamma detection probes.
Crystalline materials that have been utilized in scintilla-
tion detectors include thallium-activated sodium iodide
(NaI [Tl]), thallium-activated cesium iodide (CsI [Tl]),
samarium-activated lutetium ortho-oxysilicate (LSO),
and bismuth germanate (BGO). The basic principle
behind how a scintillation-type detection system works is
that the radiation emitted from the radionuclide excites
atoms within the scintillation crystal and produces visible
light in proportion to the energy absorbed. A photomulti-
plier tube is used to enhance the resultant visible light that
is produced and is then converted into an electrical pulse
that is collected by the detection unit. Crystalline materi-
als that have been utilized in semiconductor ionization
detectors include cadmium telluride (CdTe), cadmium
zinc telluride (CdZnTe), and mercuric iodide (HgI2). The
basic principle behind how a semiconductor ionization-
type detection system works is that the radiation emitted
from the radionuclide produces free electrons as it passes
through and ionizes the semiconductor crystal. The result-
ant free electrons that are produced then create an electri-
cal pulse that is collected and amplified by the detection
unit.
There are advantageous and disadvantageous features that
are specific to scintillation-type detection systems and to
semiconductor ionization-type detection systems
[4,6,8,10-12,15,17]. On one hand, scintillation-type
detection systems have higher sensitivity (especially for
medium-energy to high-energy gamma photons), but
have poorer energy resolution and scatter rejection. Like-
wise, scintillation-type detection probes tend to have a
much bulkier probe head profile design. On the other
hand, semiconductor ionization-type detection systems
have higher energy resolution and scatter rejection, but
have lower sensitivity (especially for medium-energy to
high-energy gamma photons). Likewise, semiconductor
ionization-type detection probes tend to have a much
more compact probe head profile design.
Factors important in the appropriate selection of a gamma 
detection probe system for its intended clinical application
Several factors are important in the appropriate selection
of a particular gamma detection probe system
[4,5,8,9,11,15,17].
First, the specific radionuclide utilized and its particular
gamma photon energy level is very important in the
appropriate selection of a particular gamma detection
probe system [8,11,17]. Whereas technetium-99m
(99mTc) labeled agents have been used almost exclusively
for radioguided sentinel lymph node biopsy (SNL) proce-
dures, various other radiopharmaceutical agents, such as
monoclonal antibodies bound to various radionuclides
(most commonly iodine radionuclides, indium-111
(111In), and 99mTc), as well as fluorine-18 (18F) bound to
a nonphysiologic analog of glucose have also been used in
radioguided surgical resection of tumors. While most
commercially available gamma detection probe systems
have relatively high sensitivity (efficiency) for predomi-
nantly lower energy gamma photon emitting radionu-
clides (such as iodine-125 (125I) and 99mTc), this may not
necessarily be the case for predominantly higher energy
gamma photon emitting radionuclides (such as 131I) orWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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positron emitting radionuclides that produce high-energy
gamma photons from resultant positron-electron annihi-
lation (such as iodine-124 (124I) and 18F). As such, these
resultant high-energy gamma photons remain an ongoing
challenge for the gamma detection probe systems that are
currently commercially available and has been the focus
of recent product development of gamma detection probe
systems that are specifically intended for the detection of
high-energy gamma photons.
Second, the nature of the surgical procedure to be per-
formed is important in the appropriate selection of a par-
ticular gamma detection probe system [8,9,11,15,17]. On
one hand, gamma detection probe systems used for radi-
oguided sentinel lymph node procedures require excep-
tional spatial resolution in order to allow for more precise
localization of small lymph node candidates. On the
other hand, gamma detection probe systems used for radi-
oguided surgical resection of tumors requires high sensi-
tivity in order to help guide the surgeon to the specific
sites of disease while rapidly searching over a relatively
large surgical field.
Third, the necessity for shielding and collimation of the
head of the probe housing the crystalline material is also
critical in the appropriate selection of a particular gamma
detection probe system [4,5,8,9,11,15,17]. These features
may already be built into the standard probe head or can
be added onto the existing standard probe head. The func-
tion of shielding (material such as lead, tungsten, gold, or
platinum) and collimation (length and aperture of the
collimator) is to prevent attenuated radiation from unin-
tended locations (i.e., scatter) from accessing the detector
source within the probe head and thus producing unin-
tended counts that are recognized by the gamma detec-
tion system. Side and back shielding of the probe head
can be rather important when there is a strong and local-
ized radiation source (i.e., the 99mTc-labeled agent injec-
tion site for a radioguided SLN procedure) which lies in
close proximity to the intended target (i.e., the SLN) or
when utilizing higher energy gamma photon emitting
radionuclides (such as 131I) or positron emitting radionu-
clides that produce high-energy gamma photons from
resultant positron-electron annihilation (such as 124I and
18F). It is clear that collimation of the gamma detection
probe head results in improved spatial resolution and
contrast between the emitted radiation from the intended
target as compared to emitted radiation from surrounding
non-target tissue (especially in areas of higher background
activity). However, at the same time, such collimation
produces a resultant loss in the sensitivity of the gamma
detection probe system by decreasing the effectual detec-
tion aperture and lengthening the distance to the actual
detection source. Thicker shielding and/or longer collima-
tion is generally necessary when using higher energy
gamma photon producing radionuclides. However, the
addition of thicker shielding and/or longer collimation
will increase the overall weight and size-dimensions of the
gamma detection probe.
Desirable design features of any given gamma detection 
probe system that are important to the surgeon
Many design features of any given gamma detection probe
system may be important to the surgeon
[8,9,11,12,15,17]. The presence or absence of such spe-
cific design features may make any particular gamma
detection probe system more or less attractive to the sur-
geon. First and foremost, the weight, shape, and ergo-
nomic design of the gamma detection probe are critical.
By far, surgeons favor sleekly designed, pencil-thin, light-
weight probes and angulation of the detector head for bet-
ter access to desired detection locations. While pencil-thin
probes may offer higher spatial resolution secondary to
their smaller detector size, they, unfortunately, yield a
lower sensitivity than do larger-sized detector probes and
can limit the degree of attainable shielding and collima-
tion. Second, the audible signal and digital display of the
gamma detection control unit are important variables for
providing critical output information to the surgeon as to
the localization of the radionuclide to the area of interest
without distracting the surgeon from the overall activities
within the surgical field [8]. Third, flexibility and adapta-
bility of any given system with regards to removable side
shielding, interchangeable collimators, interchangeable
detection probes, and user-adjustable energy windows for
different radionuclides is also critical to the overall design
of a given gamma detection probe system. Lastly, the
recent development of handheld, self-contained gamma
detection probe systems [24], as well as wireless gamma
detection probe technology that is adaptable to existing
gamma detection probe systems [25] may help to further
advance the technology involved in radioguided surgery
by eliminating the need for cables within the surgical field
that previously connected the gamma detection probe
itself to the gamma detection control unit [25]. All these
technology developments involving gamma detection
probe systems may ultimately provide the surgeon with
more flexibility for utilization of these innovative devices
within the operating room environment.
Properties of radionuclides utilized in 
radioguided surgery
Numerous radionuclides have been utilized with the
gamma detection probe in radioguided surgery. This
includes, in alphabetical order, cobalt-57 (57Co), 18F, gal-
lium-67 (67Ga),  111In, iodine-123 (123I),  124I,  125I,  131I,
99mTc, and thallium-201 (201Tl) [26]. The physical half-
life, principle gamma photon radiation emission(s), and
emission probability per decay (photon yield) of each of
these radionuclides are summarized in Table 3[27]. InWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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general, the gamma photon radiation emitted from each
radionuclide, which is expressed in kiloelectron volts
(keV), can be characterized as low-energy emission (0 keV
to 150 keV), medium-energy emission (150 keV to 400
keV), or high-energy emission (greater than 400 keV). To
date, the radionuclides that have been utilized most fre-
quently with the gamma detection probe for the specific
application of radioguided surgery have been 125I, 111In,
99mTc, and, most recently, 18F.
Radionuclides of iodine
Four radionuclides of iodine have been utilized in radi-
oguided surgery, including 123I,  124I,  125I, and 131I
[26,28,29]. In this regard, various radiopharmaceutical
agents have been developed using radionuclides of iodine
in conjunction with monoclonal antibody carriers as well
as receptor-specific carriers and tissue-specific carriers.
By far, 125I has been utilized most frequently in the past in
the form of a radiolabeled conjugate with various mono-
clonal antibodies for gamma probe detection of tumor in
radioguided surgery [26,28,30]. 125I has a relatively long
physical half-life of approximately 60 days and possesses
an extremely low gamma photon emission energy of 35
keV. Generally speaking, 125I is not suitable for diagnostic
nuclear medicine imaging due to its low gamma photon
emission energy, which results in weak tissue penetration
and high soft tissue attenuation, and a resultant poor
image quality. Instead, diagnostic gamma camera imaging
is more ideally suited for radionuclides with gamma pho-
ton emission energies in the 100 keV to 200 keV range.
However, the low gamma photon emission energy and
high soft tissue attenuation of 125I is highly advantageous
in gamma probe detection of tumor in radioguided sur-
gery, since the principle of gamma probe detection gener-
ally relies on close approximation of the gamma detection
probe to the source of the radioactivity for the facilitation
of accurate tumor detection. Additionally, the long physi-
cal half-life of 125I has been shown to be advantageous for
gamma probe detection of tumor in radioguided surgery
involving whole monoclonal antibodies due to the pro-
longed time of approximately 14 to 21 days that its takes
for such 125I-radiolabeled whole monoclonal antibody
conjugates to reach optimal pharmacokinetics and to
accomplish maximal tumor localization with maximum
background washout.
131I has a physical half-life of approximately 8 days and
was the first radionuclide used in the radiolabeling of
monoclonal antibodies [26,28,30]. The principle gamma
photon emission energy of 131I that is utilized in nuclear
medicine is that of the 364 keV gamma photon. The
highly energetic nature of these 364 keV gamma photons
increase background counts secondary to scatter and
resultantly complicates the tumor detection efficiency of
gamma probe detection of tumor during radioguided sur-
gery. Likewise, these highly energetic 364 keV gamma
photons require high-energy collimation and are gener-
ally less well-detected by diagnostic gamma camera imag-
ing secondary to the limited stopping ability of the crystal
element within the diagnostic gamma camera imaging
device. The beta particulate emissions of 131I contribute
significantly to the absorbed dose of radiation to the
patient, thus limiting the amount of 131I dose that can be
administered to the patient. The utilization of 131I has
principally been limited to that of therapeutic applica-
tions for obliteration of thyroid tissue and for radioguided
surgery for guiding the resection of recurrent thyroid can-
cer after diagnostic imaging.
123I has a physical half-life of approximately 13 hours, has
a principle gamma photon emission energy of 159 keV,
and has a relative absence of beta particulate emissions
[26,28,30]. These features allow one to administer rela-
tively larger doses of 123I dose to patients relative to other
radionuclides of iodine. Likewise, these features make 123I
relatively ideal for detection by diagnostic gamma camera
imaging with a number of different carrier agents, includ-
Table 3: Physical properties of radionuclides that have been utilized with the gamma detection probe in radioguided surgery
Radionuclides Physical half-life Principle gamma photon radiation 
emission(s)
Emission probability per decay 
(percent photon yield)
Cobalt-57 (57Co) 271.8 days 14, 122, 136 keV 9.2, 85.5, 10.7%
Fluorine-18 (18F) 110 minutes 511 keV* 19.3%
Galium-67 (67Ga) 78.3 hours (3.26 days) 91, 93, 184, 209, 300, 393 keV 3.0, 37.8, 20.1, 2.4, 16.8, 4.7%
Indium-111 (111In) 67.4 hours (2.81 days) 171, 247 keV 90.7, 94.1%
Iodine-123 (123I) 13.2 hours 159, 529 keV 83.4, 1.3%
Iodine-124 (124I) 100.3 hours (4.18 days) 511 keV* not easily characterized
Iodine-125 (125I) 1443.4 hours (60.14 days) 35 keV 6.7%
Iodine-131 (131I) 193.0 hours (8.04 days) 80, 284, 364, 637, 642, 723 keV 2.6, 6.1, 81.2, 7.3, 0.2, 1.8%
Technetium-99m (99mTc) 6.04 hours 140, 142 keV 88.5, 0.023%
Thallium-201 (201Tl) 73.0 hours (3.04 days) 71, 135, 167 keV 47.0, 2.7, 10.0%
* The 511 keV gamma photons are generated from positron-electron annihilation.World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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ing metaiodobenzylguanidine (MIBG), since diagnostic
gamma camera imaging is most ideally suited for radionu-
clides with gamma photon emission energies in the 100
keV to 200 keV range. Additionally, 123I-labeled MIBG has
been successfully used in gamma probe detection during
radioguided surgery. However, the short physical half-life
of approximately 13 hours for 123I makes it somewhat
unsuitable for radioiodination of 123I to whole mono-
clonal antibodies for use in gamma probe detection dur-
ing radioguided surgery, since such 123I-labeled whole
monoclonal antibody conjugates may take many days to
reach optimal pharmacokinetics and to accomplish maxi-
mal tumor localization with accompanying maximum
background washout. However, 123I labeled monoclonal
antibody fragments have been used in diagnostic gamma
camera imaging.
124I has a physical half-life of approximately 4 days [31-
33]. The emission spectrum and decay schema for 124I is
very complex and is beyond the scope of this review to
fully characterize. Only about 23% of disintegrations
from 124I result in positron emissions, and these are gen-
erally of relatively high energy [32]. There are also numer-
ous high-energy gamma photon emissions that occur,
some of which occur in cascade with the positron emis-
sions [32]. 124I has been used primarily in diagnostic pos-
itron emission tomography (PET) imaging [32,34], but is
currently under investigation in radioguided surgery with
gamma detection probes and PET probes (measuring both
high-energy gamma photon emissions and beta emis-
sions) [29].
111In
111In has a physical half life of approximately 2.8 days, has
two principle gamma photon emissions with energies of
171 keV and 247 keV, and has a relative absence of beta
particulate emissions [26,28]. These features make 111In a
relatively ideal radionuclide for detection by diagnostic
gamma camera imaging in conjunction with a number of
different carrier agents. However, the propensity of 111In-
containing radiopharmaceuticals, such as 111In-labeled
monoclonal antibodies, to accumulate within the reticu-
loendothelial system (such as the liver, spleen, and bone
marrow) result in relatively high background counts and
can limit its potential usefulness for gamma probe detec-
tion of tumor during radioguided surgery.
99mTc
99mTc has a physical half-life of approximately 6 hours,
has a principle gamma photon emission energy of 140
keV, and has a relative absence of beta particulate emis-
sions [26,28]. 99mTc remains the leading radionuclide
imaging agent used in diagnostic nuclear medicine sec-
ondary to several desirable characteristics, including: (1)
the principle gamma photon emission energy of 140 keV
that is ideal both for detection by diagnostic gamma cam-
era imaging and for gamma probe detection of tumor and
identification of SLNs during radioguided surgery; (2) a
low patient-absorbed radiation dose; (3) a low cost per
patient dose; and (4) widespread commercial availability.
18F
A radionuclide to more recently gain interest for radiogu-
ided surgery has been 18F [35-54]. 18F has a relatively short
physical half-life of approximately 110 minutes [55,56].
The radioactive decay of 18F is predominantly (97%) by
positron (positively charged electron) emission. The max-
imum positron radiation emission energy of 18F is 635
keV, giving 18F a relatively low positron radiation emis-
sion energy. As a result, the positron emitted from the
nucleus of this proton-rich/neutron-deficient radionu-
clide can travel only a short distance (approximately 2
millimeters) within the biological tissue before it interacts
(collides) with a negatively charged electron. It is the
interaction (collision) of the emitted positron from the
18F nucleus with a negatively charged electron within the
biological tissue and the resultant positron-electron anni-
hilation within the biological tissue that then generates
two high-energy 511 keV gamma photons. Therefore, the
resultant detection of 18F during radioguided surgery can
occur by one of two mechanisms: (1) a direct mechanism
of detection of positrons (beta particulate emissions) by a
positron detection probe or (2) an indirect mechanism of
detection of high-energy 511 keV gamma photons arising
from positron-electron annihilation by a gamma detec-
tion probe. These highly energetic 511 keV gamma pho-
tons, that are the basis of the indirect mechanism of
detection by a gamma detection probe, can result in rela-
tively high background counts and can potentially com-
plicate tumor detection efficiency of the gamma detection
probe during radioguided surgery.
Radiopharmaceutical agents utilized in 
radioguided surgery
Radioguided surgery using gamma detection probe tech-
nology has undergone an ever-changing evolution with
regards to which radiopharmaceutical agents have been
most frequently employed [49]. In the early years of
gamma probe detection in radioguided surgery, the radi-
opharmaceutical agents most frequently utilized were
radionuclides of iodine that were labeled to various mon-
oclonal antibodies. More recently, with the advent of radi-
oguided SLN biopsy technology and its application to
numerous surgically managed malignancies, the use of
99mTc-labeled radiopharmaceutical agents with the
gamma detection probe in radioguided surgery has
increased dramatically, and, at the present time, accounts
for the vast majority of the radioguided surgical proce-
dures performed. However, future directions for the
gamma probe in radioguided surgery are currently beingWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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evaluated and the use of 18F-fluorodeoxyglucose (18F-
FDG) as a radiopharmaceutical agent for gamma probe
detection of tumor in radioguided surgery holds exciting
promise [46,49].
Monoclonal antibodies and their tumor-associated 
antigens
The specific application of monoclonal antibodies to radi-
oguided surgery has been the basis for, and has repre-
sented the most important component to, the
development of the radioimmunoguided surgery (RIGS)
system [30,57]. This system was pioneered at The Ohio
State University in the early 1980s by the collaboration of
a surgical oncologist, Dr. Edward W. Martin, Jr., and a pro-
fessor emeritus of electrical engineering, Dr. Marlin O.
Thurston [58,59].
The production of a monoclonal antibody is the result of
a technique called hybridoma fusion technology [60].
Most simply stated, a B-cell lymphocyte (which recog-
nizes a single particular antigen and subsequently pro-
duces a single antibody targeting that specific antigen)
and a myeloma cell are fused together to create a hybrid-
oma cell. This immortalized hybridoma cell has the abil-
ity to survive and replicate outside of the animal. Such a
hybridoma cell is able to replicate and be maintained in
cell culture and will produce large amounts of a single
antibody, which is referred to as a monoclonal antibody.
Monoclonal antibodies used in RIGS can be targeted
against antigens expressed on the surface of tumor cells or
targeted against antigens expressed within the extracellu-
lar environment around tumor cells [30,49,57]. When
radiolabeled with various radionuclides, such resulting
radiolabeled monoclonal antibody conjugates can poten-
tially be utilized in both diagnostic gamma camera imag-
ing and gamma probe detection of tumors, as well as in
cancer therapeutics. In this regard, both whole mono-
clonal antibodies and monoclonal antibody fragments
have been investigated.
The most advantageous features of an ideal monoclonal
antibody are: (1) high affinity for its antigen (i.e., the ini-
tial ability to bind to the antigen); (2) high avidity for its
antigen (i.e., the ability of the antibody to remain bound
over an extended period of time); (3) rapid penetration
into the tumor tissue; (4) rapid clearance from the blood-
stream; (5) minimal accumulation within normal tissues;
and (6) the absence of a human antimouse antibody
(HAMA) response [8,17,30,58,59,61].
Nevertheless, the production of radiolabeled monoclonal
antibody is not necessarily a simple endeavor [26,30]. The
conjugation of a radionuclide to a monoclonal antibody
may potentially change the specific binding properties of
the monoclonal antibody. In such an instance in which
the specific binding properties of the monoclonal anti-
body are significantly altered, the resultant radiolabeled
monoclonal antibody may be left with significantly
reduced affinity and/or avidity for the intended target
antigen that ultimately renders the resultant radiolabeled
monoclonal antibody clinical ineffectual.
The particular form of the monoclonal antibody (i.e.,
whether it is a whole monoclonal antibody or a fragment
of a monoclonal antibody) can influence its ability to
localize tumor [30]. Monoclonal antibody fragments have
smaller molecular weight, have more rapid penetration
into tumors, and have more rapid clearance rate from the
bloodstream. As a result, the use of radiolabeled mono-
clonal antibody fragments can result in lower normal tis-
sue background activity and lead to increased tumor to
background ratio and improved tumor detections. How-
ever, monoclonal antibody fragments tend to accumulate
more within the kidneys and, as a result, they may not be
useful in the evaluation of the tumors within or around
the area of the kidneys or the bladder.
Numerous radiolabeled monoclonal antibodies have
been clinically investigated for radioimmunodetection
and in RIGS [30,49]. The most intensely investigated and
clinically evaluated monoclonal antibodies have been
those directed against tumor-associated glycoprotein-72
(TAG-72), carcinoembryonic antigen (CEA), and tumor-
associated antigen 17-1A. Several generations of anti-
TAG-72 monoclonal antibodies have been developed,
including two murine-derived anti-TAG-72 monoclonal
antibodies (B72.3, native murine CC49) and one human-
ized anti-TAG-72 monoclonal antibody (HuCC49).
TAG-72 is a tumor-associated glycoprotein with a molec-
ular weight of greater than 10 million Daltons [62,63].
TAG-72 contains approximately 80% carbohydrates, has
mucin-like biochemical and biophysical properties simi-
lar to colonic, small intestine, and gastric mucins, and is
thought to be secreted by epithelial tissues [62,63].
Numerous epithelial-derived cancers, including colorec-
tal, breast, gastric, pancreatic, ovarian, and non-small cell
lung cancers overexpress TAG-72 [62,64]. TAG-72 is pre-
dominantly located within mucin pools of the extracellu-
lar environment around the tumor cells and is not
specifically expressed on the tumor cell surface. Of partic-
ular importance, TAG-72 has been shown to be associated
with over 90% of the colorectal, gastric, and ovarian carci-
nomas and in approximately 70% of breast carcinomas
[65-68]. Finally, while it is rarely expressed in normal
human adult tissues or in benign disease processes, TAG-
72 is also expressed in some normal human fetal tissues,
including normal fetal intestine [69].World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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B72.3 was the first-generation murine anti-TAG-72 mon-
oclonal antibody that was developed and was interest-
ingly first derived from reaction with human mammary
tumor cells [70]. B72.3 was shown to be reactive with a
variety of human carcinomas, including colorectal (94%),
breast (84% of invasive ductal), ovarian (100% of com-
mon epithelial), as well as the majority of gastric, pancre-
atic, endometrial, and lung adenocarcinomas [30,65,67-
69,71]. In contrast, B72.3 was shown to have only a very
weak or a nonreactivity status to a variety of normal adult
human tissues [30]. The only exception to this rule has
been demonstrated for normal postovulatory (secretory
phase) endometrium which was shown to be reactive to
B72.3, in contrast to normal preovulatory (proliferative
phase) endometrium which was nonreactive [30,71].
Native murine CC49 was the second-generation murine
anti-TAG-72 monoclonal antibody that was developed
[30,63,72,73]. Native murine CC49 was found to have
only minimal reactivity to a variety of normal human tis-
sues, recognized a different epitope on the TAG-72 as
compared to B72.3, and exhibited higher reactivity than
B72.3 to a variety of human carcinomas, including color-
ectal, breast, ovarian, and lung carcinomas [30,72,73].
From a clinical perspective and as will later be discussed
in the clinical application section, native murine CC49
was also superior to B72.3 in tumor detection in RIGS for
colorectal carcinoma [74,75].
It is well characterized that a majority of patients will
develop some degree of a HAMA response to the adminis-
tration of murine monoclonal antibodies [30,64,76-78].
Despite the fact that the HAMA response has been well
characterized, its clinical impact on cancer patients,
whether deleterious or beneficial, remains very unclear
[79,80]. Nevertheless, in order to attempt to eliminate this
antiimmunoglobulin response, a third-generation
humanized anti-TAG-72 monoclonal antibody
(HuCC49) was genetically engineered [81]. HuCC49
demonstrated equivalent tumor-targeting for human
colon carcinoma xenografts but a tradeoff of slightly less
relative affinity to TAG-72 as compared to native murine
CC49 and chimeric CC49 [81]. However, HuCC49 was
shown to not produce a HAMA response [82]. Further
refinements were made in HuCC49 by the development
of a higher affinity HuCC49 possessing a CH2 domain
deletion (i.e., HuCC49ΔCH2) [83]. HuCC49ΔCH2 dem-
onstrated a more rapid blood clearance, a higher affinity
constant (5.1 × 10-9 versus 2.1 × 10-9), and significantly
lower percent of the injected dose in normal tissues com-
pared to intact HuCC49 [83], thus indicating the potential
utility of the HuCC49ΔCH2 monoclonal antibody for
diagnostic and therapeutic clinical applications. Further-
more, population pharmacokinetic modeling studies
have demonstrated that HuCC49ΔCH2 had more rapid
clearance (65% increase) from bloodstream and a result-
ant shorter "residence time" (24% shorter) than that of
native murine CC49 [84].
Carcinoembryonic antigen (CEA) represents another
well-studied and potentially useful target antigen for
which radiolabeled monoclonal antibodies have been
developed and investigated for RIGS [30]. CEA is a tumor-
associated glycoprotein with a molecular weight of
approximately 200,000 Daltons [85,86]. It is highly
expressed on the cell surface of both embryonic colonic
mucosa as well as a wide range of human adenocarcino-
mas, including colorectal, gastric, pancreatic, breast, ovar-
ian, endometrial, and lung [30,85-87]. Specific to
colorectal adenocarcinomas, it has been previously
reported that anywhere from 66% to 100% express CEA
[30].
Numerous murine monoclonal antibodies have been
developed to target CEA [30,85,88-93]. Those most well
studied have included COL-1, A5B7, IMMU-4, and CL58.
COL-1 monoclonal antibody was first derived from reac-
tion with LS-174T human colon carcinoma xenograft in
athymic mice, has a very high affinity to CEA, and has
been shown to have a high reactivity to significant
number of colon, breast, and lung carcinomas
[30,85,88,89]. Likewise, A5B7, IMMU-4, and CL58 repre-
sent three additional anti-CEA murine monoclonal anti-
bodies that have shown clinical relevance by possessing a
high reactivity to CEA-producing malignancies [30,88,90-
93].
Lastly, 17-1A (also called EpCAM) is a tumor-associated
glycoprotein with a molecular weight in the range of
approximately 30, 000 to 40,000 Daltons [94-96] which
is thought to represent a cell-cell adhesion molecule. It
was first characterized on a human colorectal adenocarci-
noma cell line SW1083 [97]. It is broadly distributed in
normal epithelial tissues and in various carcinomas,
including colorectal, gastric, and breast [94,95,98].
Murine monoclonal antibodies against the tumor-associ-
ated antigen 17-1A were originally developed in the hybri-
doma SW1083-17-1A [57,99,100]. The localization and
clearance properties of the 17-1A murine monoclonal
whole antibody and its monoclonal antibody fragment
were previously evaluated in a mice xenograft model by
Martin et al [101], demonstrating high tumor-to-normal
tissue ratios with highest tumor-to-normal tissue ratios
seen at 72 hours and 24 hours, respectively, for the 17-1A
murine monoclonal whole antibody and monoclonal
antibody fragment [57,101].
The most common challenges facing the utility of mono-
clonal antibodies in radioimmunodetection relate to theWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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activity ratio between tumor and normal surrounding tis-
sues and the time interval between the initial administra-
tion of the radiopharmaceutical agent and performance of
diagnostic gamma camera imaging or radioguided surgi-
cal detection. In an attempt to increase the activity ratio
between tumor and normal surrounding tissues and to
decrease the time interval between the initial administra-
tion of the radiopharmaceutical agent and performance of
diagnostic gamma camera imaging or radioguided surgi-
cal detection, pretargeting strategies for monoclonal anti-
bodies and radionuclides have been investigated [102].
Most such pretargeting strategies utilize the principle of
the avidin-biotin binding system. This avidin-biotin pre-
targeting strategy allows for the complete temporal sepa-
ration of the systemic administration of the monoclonal
antibody from that of the systemic administration of the
radionuclide. The monoclonal antibody is labeled with
biotin and the radionuclide is labeled with avidin. This
will ultimately result in a reduction of nonspecific bind-
ing. The biotin-labeled monoclonal antibody is first
administered, allowing binding of the biotin-labeled
monoclonal antibody to the tumor and allowing the non-
specific uptake of the biotin-labeled monoclonal anti-
body to be cleared. The avidin-labeled radionuclide is
then administered and resultantly localizes in the tumor
secondary to the high affinity and specificity of the avidin-
labeled radionuclide for the biotin-labeled monoclonal
antibody. More recently, an additional pretargeting strat-
egy utilizing a bispecific antibody and radiolabeled biva-
lent hapten system has been investigated that bind
cooperatively to target cells [103].
Radioactive iodine-labeled radiopharmaceutical agents
The vast majority of radioactive iodine-labeled radiophar-
maceutical agents that have been utilized with the gamma
detection probe for tumor detection in radioguided sur-
gery have been those radionuclides of iodine that have
been labeled to various monoclonal antibodies [30]. The
predominant iodine radionuclide that has been labeled to
various monoclonal antibodies and utilized with the
gamma detection probe for tumor detection in radiogu-
ided surgery has been 125I, and to a much lesser degree
131I. The radiolabeling of 123I to monoclonal antibodies
has not been proven useful for tumor detection in radi-
oguided surgery for the reasons previously discussed. Both
131I and 123I are used with MIBG, a molecule similar to
norepinephrine, for identification of neuroendocrine
tumors.
99mTc-labeled radiopharmaceutical agents
Numerous  99mTc-labeled radiopharmaceutical agents
have been formulated for use in diagnostic nuclear medi-
cine by radiolabeling the radionuclide 99mTc to various
compounds [26,104]. The list of compounds that have
been radiolabeled with 99mTc for diagnostic nuclear med-
icine use is extensive and includes, in alphabetical order,
antimony trisulfide colloid, bicisate dihydrochloride, col-
loidal human albumin (i.e., nanocolloid), colloidal rhe-
nium sulfide, dextran, diethylenetriaminepentaacetic acid
(DTPA)-mannosyl-dextran, disofenin, hydroxyl-ethyl
starch, exametazime, gluceptate, glucoheptonate, hexakis-
2-methoxy-isobutyl-isonitrile (methoxyisobutylisonitrile,
MIBI, or sestamibi), hydroxymethylene diphosphonate
(HMDP or oxidronate), hydroxyethylene diphosphonate
(HDP), lidofenin, mebrofenin, mertiatide (mercap-
toacetylglyclyglyclyglycine), methylene diphosphonate
(MDP or medronate), pentetate (diethylenetri-
aminepentaacetic acid), sodium pertechnetate, sodium
phytate (D-myo-inositol 1,2,3,4,5,6-hexakisphosphate
dodecasodium), sodium pyrophosphate, stannous
phytate, succimer, sulfur colloid, teboroxime, tetrofos-
min, and tin colloid. The primary 99mTc-labeled radiop-
harmaceutical agents that have been used for radioguided
SLN biopsy include 99mTc sulfur colloid, 99mTc colloidal
human albumin, and 99mTc antimony trisulfide colloid.
The primary 99mTc-labeled radiopharmaceutical agents
that have been used for tumor detection during radiogu-
ided surgery include 99mTc MIBI (sestamibi), 99mTc
diphosphonates, and 99mTc sodium pertechnetate. The
application of 99mTc-labeled monoclonal antibody frag-
ments, such as99mTc-labeled arcitumomab (IMMU-4
murine monoclonal antibody fragments against CEA)
and  99mTc-nofetumomab merpentan (monoclonal anti-
body fragment of the pancarcinoma murine antibody NR-
LU-10) have been used in nuclear medicine imaging but
have only been very limitedly investigated for tumor
detection during radioguided surgery [105-107].
111In-labeled radiopharmaceutical agents
Several  111In-labeled radiopharmaceutical agents have
been formulated for use in diagnostic nuclear medicine by
radiolabeling the 111In with various compounds
[26,30,108,109]. This includes the 111In-labeled somato-
statin analogue, 111In-diethylenetriaminepentaacetic acid-
D-phenylalanine1-octreotide (111In-DTPA-D-Phe1-octre-
otide or 111In-pentetreotide), as well as various 111In-
labeled monoclonal antibodies. 111In-(DTPA)-D-Phe1-
octreotide binds to somatostatin receptors, predomi-
nantly of somatostatin receptor subtype sst2 and sst5, and
have been useful for diagnostic nuclear medicine imaging
of neuroendocrine tumors and of non-neuroendocrine
tumors which express somatostatin receptors [26,108].
Likewise, 111In-labeled monoclonal antibodies have been
investigated in colorectal cancer [30,109]. However, 111In-
labeled monoclonal antibodies have been of somewhat
limited usefulness secondary to the previously discussed
nonspecific accumulation of 111In within reticuloen-
dothelial organs, such as within the liver and spleen. This
resultant nonspecific binding generally interferes with the
detection of tumor within or around the liver and spleenWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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during radioguided surgery and is therefore undesirable
[26,30].
18F-fluorodeoxyglucose (18F-FDG)
Malignant tumors have long been known to have an accel-
erated rate of glucose metabolism and have an increased
rate of glucose transport and glucose utilization [110-
112]. The mechanism of 18F-FDG within malignant cells
is well described in the literature [113-115]. 18F-FDG is an
18F-labeled nonphysiologic analog of glucose. 18F-FDG
within the bloodstream is transported into cells (both
malignant cells and normal cells) by a facilitated diffusion
mechanism involving specific glucose transporters (i.e.,
GLUT transporters). Once within the cell, 18F-FDG is
phosphorylated to 18F-FDG-6-phosphate by the enzyme
hexokinase. Unlike 18F-FDG,  18F-FDG-6-phosphate can
not be readily transported across the cellular membrane
of either malignant cells or normal cells. The enzyme glu-
cose-6-phosphatase is responsible for dephosphorylating
18F-FDG-6-phosphate to 18F-FDG. Because the enzyme
glucose-6-phosphatase is present in relatively low
amounts within malignant cells and within normal cells,
18F-FDG-6-phosphate cannot be readily dephosphor-
ylated back to 18F-FDG once 18F-FDG has been phospho-
rylated within the intracellular environment. Therefore,
once 18F-FDG is transported into the malignant cell or the
normal cell via the GLUT transporters and is subsequently
phosphorylated, the resultant 18F-FDG-6-phosphate is
essentially trapped within the cell. Additionally, 18F-FDG-
6-phosphate cannot be utilized in the metabolic steps of
glycolysis, and, this further lends to the accumulation of
18F-FDG-6-phosphate within the cell. This entire process
is thought to occur more readily in malignant cells than in
normal cells due to the overexpression of the glucose
transporters GLUT 1 and GLUT 3 by malignant cells and
due to higher levels of hexokinase within malignant cells.
The overall result of this entire process of an accelerated
rate of glucose metabolism and an increased rate of glu-
cose transport and glucose utilization by malignant cells
is that of a relatively greater accumulation of 18F-FDG-6-
phosphate within malignant cells as compared to normal
cells. Even more simply stated, malignant cells are much
more efficient at accumulating glucose molecules within
their intracellular environment than are normal cells. This
elegantly elucidated process represents the overall basis
for the clinical application of 18F-FDG for the detection of
tumor by both diagnostic PET imaging and gamma detec-
tion probe technology.
However, limitations do exist in regards to the utilization
of 18F-FDG in both diagnostic PET imaging and gamma
detection probe technology. These limitations are: (1) the
accumulation of 18F-FDG within certain normal tissues
with an elevated rate of glucose metabolism (most strik-
ing in the brain and heart, and to a lesser degree in the
mucosa and smooth muscle of the stomach, small intes-
tine and colon, as well as in thyroid, liver, spleen, and
skeletal muscle); (2) the accumulation of 18F-FDG within
in inflammatory/granulomatous processes and infectious
processes; (3) the excretion and accumulation of 18F-FDG
within the urinary tract (kidneys, ureters, and bladder);
and (4) the impaired uptake of 18F-FDG in patients with
elevated blood glucose levels and with impaired glucose
metabolism [113,116,117].
Occupational radiation exposure from 
radiopharmaceutical agents utilized during 
radioguided surgery
The assessment of occupational radiation exposure to sur-
gical personnel involved in radioguided surgical proce-
dures is important to maintaining a safe work
environment for such personnel. This has been evaluated
to varying degrees for 125I,  111In,  99mTc, and, 18F. The
United States Nuclear Regulatory Commission (USNRC)
has set the annual occupational exposure limit for adults
as a total effective dose equivalent of 50,000 μSv [118].
The International Commission on Radiological Protec-
tion (ICRP) has set the annual occupational exposure
limit for adults as a total effective dose equivalent of
20,000  μSv per year, averaged over a five year period
(100,000 μSv in five years), with further provision that the
total effective dose equivalent should not exceed 50,000
μSv in any single year [119,120].
For  125I-labeled monoclonal antibodies, the radiation
exposure to the surgeon has been previously assessed dur-
ing RIGS [78,121]. For a mean dosage of 2 mCi (74 MBq)
of 125I that was radiolabeled to 1 mg of B72.3 monoclonal
antibody and was injected at a mean of 23.4 days prior to
surgery, the mean dose equivalent for the surgeon was
determined to be only 0.2 μSv per hour of exposure and
was not significantly different from that of the environ-
mental (operating room) background.
For  111In radiopharmaceuticals, no data on radiation
exposure to surgical personnel is currently available.
However, in this regard, limited data from one study
reported that staff members and technologists involved in
treating patients with somatostatin receptor positive
tumors with a therapeutic dosage (216 mCi or 8000 MBq)
of an 111In-labeled somatostatin analogue received a
mean whole body dose equivalent of only 45 μSv per case
[122].
Radiation exposure to surgical personnel members from
99mTc-labeled radiopharmaceutical agents used for radi-
oguided SLN biopsy has been well-documented [123-
127]. There was significant variability in the whole body
dose equivalent incurred by the surgeon and this value
was highly dependent upon the injection dose of theWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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99mTc-labeled radiopharmaceutical agent and the total
duration of time from the injection to the start of the radi-
oguided SLN biopsy procedure. On one hand, Wadding-
ton et al reported mean whole body dose equivalent of
only 0.34 μSv per case when 0.27 mCi (10 MBq) to 0.41
mCi (15 MBq) of 99mTc colloidal albumin was injected 24
hours prior to the start of the radioguided SLN biopsy pro-
cedure [124]. On the other hand, Stratmann et al reported
a mean whole body dose equivalent of 13.3 μSv per case
when 0.7 mCi (26 MBq) to 1.1 mCi (41 MBq) of 99mTc
sulfur colloid was injected 90 to 180 minutes prior to the
start of the radioguided SLN biopsy procedure [123]. Nev-
ertheless, the data supports the fact that the whole body
dose equivalent incurred by a surgeon during any given
radioguided SLN biopsy procedure using a 99mTc-labeled
radiopharmaceutical agent is extremely low.
Radiation exposure to surgical personnel members from
99mTc-MIBI used for radioguided brain tumorectomy has
been previously investigated [128]. The dosage of 99mTc-
MIBI that was intravenously administered on the day of
surgery was not specified. The mean exposure time was
6.1 hours for all surgical personnel members. The mean
whole body dose equivalent per case was 27.9, 25.8, and
14.9 μSv, respectively, for the surgeon, nurse, and anes-
thetist. More recently, Bekis ¸ et al [129] evaluated radiation
exposure to surgical staff from 99mTc-MIBI used in two
cases of radioguided parathyroidectomy. When 20 mCi
(740 MBq) of Tc-99m MIBI was intravenously injected 3
hours prior to the operation and with a mean operative
time of 83 minutes, the least and highest exposure of the
surgical staff were calculated as 1.01 and 3.63 μSv for the
anesthetist, 8.78 and 11.00 μSv for the senior surgeon,
7.60 and 10.00 μSv for the first assistant surgeon, 6.75 and
8.20 μSv for the second assistant surgeon, and 3.64 and
8.00 μSv for the nurse.
The issue of radiation exposure to intraoperative and peri-
operative personnel involved in radioguided surgery cases
utilizing 18F-FDG has become a topic of recent interest.
However, data on this topic is currently very limited
[42,47,50,51,130-132]. In a recent comprehensive evalu-
ation, our group at The Ohio State University has deter-
mined that after a mean dosage of 18.9 mCi (699 MBq) of
18F-FDG injected at a mean of 142 minutes prior to sur-
gery that the mean deep dose equivalent per case was 164,
119, 92, 63, 54, and 48 μSv, respectively, for the surgeon,
anesthetist, scrub technologist, postoperative nurse, circu-
lating nurse, and preoperative nurse [132]. This data
clearly illustrates that the absorbed radiation dose
received by both intraoperative and perioperative person-
nel involved in 18F-FDG radioguided surgery cases is rela-
tively low per case and allows for all these personnel to
participate in multiple such cases and still remain well
below standards set for occupational exposure limits.
Clinical applications (Table 2)
Breast cancer
There are numerous reported applications of gamma
detection probe technology during radioguided surgery
for breast cancer. However, by far, the single most impor-
tant and most widely utilized application of the gamma
detection probe in breast cancer surgery has been for radi-
oguided SLN biopsy.
Radioguided SLN biopsy
It is clearly evident that SLN biopsy has become widely
accepted as a standard of care in the surgical staging of the
axillary lymph nodes during breast cancer surgery
[133,134]. The intraoperative use of the gamma detection
probe for radioguided SLN biopsy in breast cancer was
first described in 1993 by Krag et al [135] at The Univer-
sity of Vermont (Table 1). Since that time, over 3,300 arti-
cles have been published which have been sited in
PUBMED under the search descriptors of "breast cancer"
and "sentinel lymph node".
Worldwide, numerous 99mTc-based agents have been uti-
lized for radioguided SLN biopsy for breast cancer
[133,136]. This includes 99mTc sulfur colloid, 99mTc anti-
mony trisulfide colloid, 99mTc colloidal human albumin
(i.e., 99mTc nanocolloid), 99mTc tin colloid, 99mTc labeled
dextran, 99mTc hydroxyl-ethyl starch, and 99mTc stannous
phytate. However, within the United States, 99mTc sulfur
colloid represents the only registered and licensed radio-
colloid for use SLN biopsy. The dosing of these radiocol-
loid agents varies considerably within the literature and
have been reported as low as 0.1 mCi (3.7 MBq) [137]
and as high as 10 mCi (370 MBq) [138]. Generally, in cur-
rent practice, these radiocolloid agents are most com-
monly administered on the day of surgery in a dosing
range from 0.4 mCi (14.8 MBq) to 1 mCi (37 MBq) [133].
These radiocolloid agents are generally administered one
to six hours prior to the planned breast cancer surgery,
although prior-day injection of radiocolloid has been
shown to be technically feasible [137,139,140].
The administration of a radiocolloid agent for SLN biopsy
in breast cancer surgery has been described by numerous
injection routes, including intraparenchymal (peritu-
moral), intradermal, subdermal, subareolar, and intratu-
moral [133]. Within the United States, the three
predominant injection routes have been intraparenchy-
mal, intradermal, and subareolar. Until recently, all data
comparing these injection routes has been retrospective in
nature. However, recently, the first prospective rand-
omized clinical trial comparing the intraparenchymal,
intradermal, and subareolar injection routes was con-
ducted among 400 breast cancers at The Ohio State Uni-
versity and utilizing a dose of approximately 0.4 mCi
(14.8 MBq) of 99mTc sulfur colloid [141]. This recentlyWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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reported study demonstrated superior intraoperative
gamma probe localization of 99mTc sulfur colloid within
the axillary lymph nodes for the intradermal route
(100%), as compared to the subareolar route (95%) and
intraparenchymal route (90%) [141]. Additionally, this
study demonstrated that intradermally injected 99mTc sul-
fur colloid resulted in the greatest maximum sustainable
ex vivo counts within the hottest axillary SLN and the
shortest intraoperative time to harvest the axillary SLN.
The determination of an adequate intraoperative assess-
ment of the axilla with the gamma detection probe during
breast cancer surgery is clearly related to the number of
SLN candidates harvested and meticulous intraoperative
attention to attempting to identify all potential sentinel
lymph node candidates with counts of at least 10% of the
counts of the hottest SLN. The most compelling argument
for this is based on the results of two reports published by
the University of Louisville Breast Cancer Sentinel Lymph
Node Multiinstitutional Study Group [142,143] which
evaluated patients undergoing SLN biopsy and a concom-
itant confirmatory axillary lymph node dissection. In
2001, Wong et al [142] demonstrated a false negative rate
of 14.3% in patients who had a single SLN was harvested
as compared to 4.3% in patients who had two or more
SLNs were harvested (P = 0.0004). Identically, in 2005,
Martin et al [143] reproduced those same results, demon-
strating a false negative rate of 13.7% in patients who had
a single SLN harvested as compared to 5.4% in patients
who had two or more SLNs harvested (P < 0.0001). A re-
emphasis of this concept has been brought back to our
attention in several more recently published reports [144-
147]. In 2007, Povoski et al [144] demonstrated that
although 83% of cases had the first positive SLN identified
as the hottest SLN, 17% of cases had the first positive SLN
identified as the second, third, fourth, or fifth hottest SLN.
Additionally, in this report, the SLN was positive in a sig-
nificantly greater frequency of cases in which two or more
SLNs were identified as compared to when only a single
SLN was identified (34% versus 18%, P = 0.003). Like-
wise, Woznick et al [145] reported in 2006 that although
77% of cases had the first positive SLN identified as the
first removed SLN, 23% of cases had the first positive SLN
identified as the second, third, fourth, fifth, or sixth SLN
removed. Similarly, Wada et al [146] reported in 2007
that although 76% of cases had the first positive SLN iden-
tified as the hottest SLN, 14% of cases had the first posi-
tive SLN node identified as the second and third hottest
removed SLN, with an additional 3% having the positive
SLN identified as a non-radioactive, blue-stained SLN,
and an additional 7% having false-negative results.
Finally, Krag et al [147], in the NSABP (National Surgical
Adjuvant Breast and Bowel Project) B-32 randomized
phase 3 trial, clearly demonstrated a significant associa-
tion of the reduction in the observed false-negative rate as
the total number of SLNs that were removed increased
(i.e., with a 17.7%, 10.0%, 6.9%, 5.5%, and 1.0% false-
negative rate when one, two, three, four, and five or more
SLNs were removed, respectively). These six studies [142-
147], when taken together, raise significant concern with
the scenario in which only a single negative SLN candidate
is intraoperatively identified with the gamma probe and
emphasizes the importance of a meticulous intraoperative
search for additional SLN candidates with counts of at
least 10% of the counts of the hottest SLN.
RIGS
The application of RIGS technology to the breast has been
previously investigated and reported in a very limited
fashion [148-152]. In 1989, Nieroda et al [148,149] intra-
operatively evaluated 14 patients with breast cancer with
the gamma detection probe after injection 5 mCi (185
MBq) of 125I-labeled monoclonal antibody B72.3 at a
time of six to 24 days prior to the surgical procedure. In
1996, and again identically re-reported in 1998, Percivale
et al [150] and Badellino et al [151] intraoperatively eval-
uated 21 patients with locally advanced breast cancer with
the gamma detection probe after injection of either 1.5
mCi (56 MBq) of 125I-labeled monoclonal antibody
B72.3 or 1.5 mCi (56 MBq) of 125I-labeled fragments of
the murine anti-CEA monoclonal antibody F023C5 at a
mean time of 21.7 days or 10.3 days, respectively, prior to
the surgical procedure. In 2001, Burak et al [152] intraop-
eratively evaluated 10 patients with breast cancer with the
gamma detection probe after injection 2 mCi (74 MBq) of
125I-labeled NR-LU-10 antibody fragments at a time of
two to seven days prior to the surgical procedure. In all
three instances, specific binding to histologically con-
firmed sites of breast cancer was noted. However, the clin-
ical impact of this technology in the context of these 125I-
labeled-antibody complexes has not been more recently
further investigated in the arena of breast cancer surgery.
Radioguided occult lesion localization (ROLL)
Radioguided occult lesion localization (ROLL), using
gamma detection probe technology, is well described in
the literature as an alternative to conventional wire local-
ization for nonpalpable breast lesions, including breast
cancer [153-181]. Most commonly, this ROLL technique
involves an intratumoral injection (using preoperative
same-day or prior-day mammographic or ultrasound
guidance) of a 99mTc-based agent (such as colloidal
human serum albumin, nanocolloid, macroaggregate
albumin, or dextran) in a dosing range from 0.05 mCi
(1.8 MBq) to 4.0 mCi (148 MBq) [153-155,157,158,160-
171,173-181]. As a result of the intratumoral injection of
a 99mTc-based agent, this ROLL technique allows for
simultaneous performance of a radioguided SLN biopsy
procedure. In the largest retrospective series to date, Monti
et al [168], 959 patients with cytologically or histologi-World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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cally proven breast cancer underwent ROLL plus radiogu-
ided SLN biopsy, with successful breast lesion localization
in 99.6% of cases and negative surgical margins obtained
in 91.6% of cases. Additionally, a ROLL technique involv-
ing placement of a radioactive seed (consisting of a 4.5
mm by 0.8 mm titanium seed containing 0.125 mCi (4.6
MBq) to 0.29 mCi (10.7 MBq) of 125I) up to five days in
advanced to the date of surgery [156,159] has been
described. Finally, and most recently, ROLL techniques
have been described utilizing an intravenous intraopera-
tive injection of 20 mCi (740 MBq) of 99mTc sestamibi
[167] on the day of surgery and utilizing an intravenous
injection of 6 mCi (222 MBq) of 111In pentetreotide [172]
at approximately 24 hours prior to surgery. In a systematic
review detailing the available data in the literature on the
ROLL technique, it was concluded that the ROLL tech-
nique compared favorably to that of conventional wire
localization for nonpalpable breast lesions [176]. A large-
scale (over 300 patients), multicenter, prospective clinical
trial in the Netherlands to evaluate the ROLL technique
compared to conventional wire localization for nonpalpa-
ble breast cancers is currently being planned [182].
Radioguided intraoperative margins evaluation (RIME)
Radioguided intraoperative margins evaluation (RIME),
using gamma detection probe technology, is limitedly
described in the literature as a technique for not only
guiding resection of the primary tumor but also for intra-
operative assessment and determination of the adequacy
of surgical margins [183,184]. The feasibility of this tech-
nique was first described utilizing a preoperative same-
day intravenous injection of 0.172 mCi (6.4 MBq) of 125I-
labeled Lanreotide (a radiolabeled somatostatin analog)
[183]. More recently, feasibility of the RIME technique
was described utilizing a preoperative same-day intrave-
nous injection of 20 mCi (740 MBq) of 99mTc sestamibi
[184].
18F-FDG-directed surgery
Very recently, the application of gamma detection probe
technology in radioguided surgery after a preoperative
same-day injection of 18F-FDG has been reported in a lim-
ited number of selected cases of breast cancer
[43,45,47,51]. In this regard, and of most recent note, our
own group at The Ohio State University has recently
reported a combined approach of perioperative 18F-FDG
PET/CT imaging (using a triad of preoperative PET/CT
imaging, specimen PET/CT imaging, and postoperative
PET/CT imaging) and intraoperative gamma detection
probe technology, using a dose of approximately 14 to 19
mCi (518 to 703 MBq) 18F-FDG injected intravenously
approximately 120 minutes prior to the anticipated time
of surgery for two selected cases of breast cancer for guid-
ing tumor localization and for verifying complete tumor
resection [51].
Cutaneous malignancies
Malignant melanoma
The single most important and most widely utilized appli-
cation of gamma detection probe technology for the sur-
gical management of malignant melanoma is radioguided
SLN biopsy. More recently, the application of 18F-FDG-
directed surgery to the management of appropriately
selected cases of metastatic or recurrent malignant
melanoma has received increasing interest within the sur-
gical community.
Radioguided SLN biopsy
The application of SLN biopsy for the surgical staging of
the regional lymph node basins during cutaneous malig-
nant melanoma surgery has become widely accepted as a
standard of care for cutaneous malignant melanoma of
the trunk, extremities, and head and neck region [185]. To
date, over 1,800 articles have been published which have
been sited in PUBMED under the search descriptors of
"melanoma" and "sentinel lymph node".
SLN biopsy in cutaneous malignant melanoma was first
described in 1992 by Morton et al [186] using a technique
of intradermally injected vital blue dye alone. In 1993,
Uren et al [187] described a combined technique, consist-
ing of preoperative lymphoscintigraphy (using 99mTc anti-
mony sulfide colloid) for identification of all sites of
location that are simply marked on the skin surface with
an indelible marker and of intraoperative intradermally
injected vital blue dye (but without use of an intraopera-
tive gamma detection probe), for SLN detection. Shortly
thereafter in 1993, the intraoperative use of the gamma
detection probe for radioguided SLN biopsy in cutaneous
malignant melanoma was first reported by Alex et al [188]
at The University of Vermont in ten patients using intra-
dermally injected 99mTc sulfur colloid (Table 1). Since that
time, it has been clearly demonstrated that the use of radi-
oguided SLN biopsy is superior to the vital blue dye alone
technique for the surgical evaluation of at-risk nodal
basins for cutaneous malignant melanoma [189-198].
The most compelling and well-respected international
evidence for this comes from the Multicentric Selective
Lymphadenectomy Trial Group results that were pub-
lished in 1999 by Morton et al [193] on 570 melanoma
patients. They demonstrated that the success of SLN iden-
tification was significantly improved by a combined radi-
ocolloid and vital blue dye technique (n = 217) as
compared to a vital blue dye alone technique (n = 352)
(99.1% versus 95.2%, respectively; p = 0.014).
The primary 99mTc-based agents utilized for radioguided
SLN biopsy for cutaneous malignant melanoma are either
99mTc sulfur colloid or 99mTc colloidal human albumin
(i.e., 99mTc nanocolloid) [199-206]. Generally, these radi-
ocolloid agents are most commonly administered one toWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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six hours prior to the planned surgical procedure in a dos-
ing range from 0.4 mCi (14.8 MBq) to 1 mCi (37 MBq).
Radiocolloid is exclusively injected intradermally and is
administered in one to four sites around the intact pri-
mary lesion or around the resultant excisional biopsy scar.
It is clearly evident that preoperative lymphoscintigraphy
plays as important of a role as does intraoperative radi-
oguided SLN biopsy for the successful identification of all
potential SLN candidates during the surgical management
of cutaneous malignant melanoma secondary to the
potential for localization to multiple nodal basins
[196,203,207-214] and for localization to in-transit
(interval) SLNs [215-219]. For cutaneous malignant
melanoma of the truncal region, preoperative lympho-
scintigraphy localization to multiple nodal basins has
been demonstrated in 17% to 32% of patient undergoing
radioguided SLN biopsy [196,203,207-214]. Likewise,
preoperative lymphoscintigraphy localization to in-tran-
sit (interval) SLNs has been demonstrated in 3% to 10%
of patient undergoing radioguided SLN biopsy for cutane-
ous malignant melanoma of the extremities and of the
head and neck region [215-219]. Therefore, unlike other
malignancies in which radioguided SLN biopsy can be
performed without the antecedent need of preoperative
lymphoscintigraphy, the radioguided surgical approach
to cutaneous malignant melanoma should include both
preoperative lymphoscintigraphy and intraoperative utili-
zation of the gamma detection probe.
The determination of an adequate intraoperative assess-
ment of any given nodal basin with the gamma detection
probe during radioguided SLN biopsy for cutaneous
malignant melanoma is clearly related to the meticulous
intraoperative attention to attempting to identify all
potential SLN candidates with counts of at least 10% of
the counts of the hottest SLN [220-225]. The first compel-
ling argument for the 10% rule for malignant melanoma
came from work published by McMasters et al [221] from
the Sunbelt Melanoma Trial in which they found that
within 13.1% of positive lymph node basins that the most
radioactive SLN was negative for tumor while a less radio-
active sentinel lymph node was positive for tumor. Addi-
tionally, in 50% of such cases, they found that these less
radioactive positive SLNs contained 50% or less of the
radioactive counts of the hottest non-positive SLN. Simi-
larly, Carlson et al [222] in 2002, Jacob et al [223] in
2003, and Kroon et al [224] in 2007 found in 19.1%,
19.0%, and 11.0% of all positive SLN cases, respectively,
that the hottest SLN was negative for tumor. As a result, all
these reports have strongly advocated applying the 10%
rule to reduce the risk of a missed lymph node metastasis
during radioguided SLN biopsy for cutaneous malignant
melanoma [220-225].
In addition to the vast body of data in the literature on the
application of radioguided SLN biopsy for the surgical
staging of conventional sites of cutaneous malignant
melanoma (i.e., trunk, extremities, and head and neck
region), various case reports and small series reports exist
on the potential application of radioguided SLN biopsy
for the surgical staging of less conventional sites of malig-
nant melanoma, such as the ocular conjunctiva and peri-
ocular skin [226-234], the vulvar region [235-240], the
vagina [236,238,240-242], and the anal canal [243-248].
For all these less conventional sites of malignant
melanoma, the feasibility of radioguided SLN biopsy has
been demonstrated. However, larger scale evaluation of
this technology for these less conventional sites of malig-
nant melanoma is obviously necessary in order to better
assess its clinical relevance.
18F-FDG-directed surgery
The  18F-FDG avidity of malignant melanoma has made
the application of 18F-FDG PET imaging paramount to the
accurate staging and restaging of malignant melanoma
[185]. Likewise, 18F-FDG PET imaging and 18F-FDG PET/
CT imaging have been shown to lead to a change in the
clinical management of 17% to 39% of malignant
melanoma patients, which is far greater than with other
conventional imaging techniques alone [249-253]. While
preoperative utilization of 18F-FDG PET imaging has
become a standard of care for the clinical management of
selected cases of malignant melanoma, the intraoperative
use of 18F-FDG in combination with gamma detection
probe technology has also been proposed and described
in the clinical management of selected cases of metastatic
malignant melanoma and has received increasing interest
within the surgical community [38,40,41,43,47,52].
The intraoperative use of 18F-FDG in combination with
gamma detection probe technology for selected cases of
metastatic malignant melanoma was first reported in
2001 by Essner et al  [38]. Six patients were intravenously
injected with 7 to 10 mCi (259 to 370 MBq) of 18F-FDG
within three hours of the planned time of surgery. They
reported that the tumor to background count ratio varied
from 1.16:1 to 4.67:1, with eight of 13 melanoma metas-
tases having a tumor-to-background count ratio of greater
than 1.5:1. In 2005, Franc et al  [41] reported on 5 patients
with recurrent malignant melanoma that were injected
with 14.6 ± 3.2 mCi (540 ± 118 MBq) of 18F-FDG. They
found that the use of gamma detection probe technology
had a sensitivity of 89% and a specificity of 100% for the
detection of tissues containing recurrent malignant
melanoma. More recently in 2006, Gulec et al [43]
reported on 26 patients with either recurrent or metastatic
malignant melanoma that were intravenously injected
with 7 to 10 mCi (259 to 370 MBq) of 18F-FDG within
one to four hours of the planned time of surgery. TheyWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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found that the tumor-to-background ratio ranged from
1.5:1 to 2.5:1, with a mean of 1.8:1, and metastatic lesions
as small as 5 mm were detected.
The specific application of a combined approach of pre-
operative  18F-FDG PET/CT imaging and intraoperative
gamma detection probe technology for recurrent malig-
nant melanoma was first described in 2005 by Carrera et
al [40] in a patient intravenously injected with 6.8 mCi
(250 MBq) of 18F-FDG at approximately four hours prior
to the planned time of surgery, illustrating the potential
advantage to a combination of these technologies. Fur-
thermore, the added benefit to such combination technol-
ogies for 18F-FDG-directed surgery was most recently
illustrated by our own group at The Ohio State University
in which a multimodality approach of perioperative 18F-
FDG PET/CT imaging (preoperative patient imaging, spec-
imen imaging, and postoperative patient imaging), intra-
operative gamma detection probe technology, and
intraoperative ultrasound were utilized for tumor locali-
zation and resection of all sites of hypermetabolic activity
in a case of occult recurrent metastatic malignant
melanoma [52]. In this case, the patient was intravenously
injected with 12.8 mCi (474 MBq) of 18F-FDG at approx-
imately 80 minutes prior to the planned time of surgery
and this multimodality approach allowed for successful
identification and resection of all three occult sites of
recurrent metastatic malignant melanoma. Such refine-
ments in multimodal 18F-FDG-directed surgery [40,52]
may allow this approach to further positively impact
upon the established survival advantage of complete sur-
gical resection for malignant melanoma patients with lim-
ited metastatic disease [254].
Merkel cell carcinoma
The application of the gamma detection probe in radiogu-
ided surgery for Merkel cell carcinoma has been limited to
radioguided SLN biopsy. In this regard, SLN biopsy for the
surgical staging of the regional lymph node basins is gen-
erally accepted as a standard of care for previously
untreated, clinical stage I Merkel cell carcinoma
[255,256]. The utilization of radioguided SLN biopsy for
Merkel cell carcinoma was first reported in 1997 by
Messina et al [257]. Since that time, multiple reports have
been published on the application of radioguided SLN
biopsy in the surgical management of Merkel cell carci-
noma [258-274].
The technique of radioguided SLN biopsy for Merkel cell
carcinoma is very similar to that for malignant melanoma.
The primary 99mTc-based agents utilized for radioguided
SLN biopsy for Merkel cell carcinoma are either 99mTc sul-
fur colloid or and 99mTc colloidal human albumin. These
radiocolloid agents are generally administered on the
morning of the planned surgical procedure in a dosing
range from 0.3 mCi (11 MBq) to 4 mCi (150 MBq), are
exclusively injected intradermally, and are administered
in one to four sites around the intact primary lesion or
around the resultant excisional biopsy scar [257-274].
The two largest radioguided SLN biopsy series for Merkel
cell carcinoma reported to date were published by Allen et
al in 2001 [264] and Maza et al in 2006 [272]. Allen et al
[264] reported on 26 patients with clinical stage I Merkel
cell carcinoma in which a SLN was detected in all patients
using  99mTc sulfur colloid and metastatic disease was
found in five (19%) patients. Maza et al [272] reported on
23 patients with clinical stage I Merkel cell carcinoma in
which a SLN was detected in all patients using 99mTc col-
loidal human albumin and metastatic disease was found
in eleven (48%) patients.
Other cutaneous malignancies
Radioguided SLN biopsy has been limitedly investigated
in other cutaneous malignancies. It has been described for
high risk squamous cell carcinoma of the facial region
(face, ears, nose, and lips) [268,269,275-278] and of the
trunk and extremities [268,269,279-283], for high risk
basal cell carcinoma [284,285], for sweat gland carcinoma
[269,286-288], and for cutaneous lymphoma [269]. The
technique described in the literature for radioguided SNL
biopsy for these other cutaneous malignancies is identical
to the technique described for malignant melanoma and
Merkel cell carcinoma.
Gastrointestinal malignancies
Colorectal cancer
RIGS overview
The concept of RIGS in colorectal cancer [58] was first
introduced in 1984 by the work of Aitken and colleagues
[289,290] at The Ohio State University (Table 1). Using
CEA-producing human colonic adenocarcinoma cells
(CX-1) grown as tumor xenografts that were subcutane-
ously implanted on the flank in Swiss nude mice, they
demonstrated the feasibility of gamma probe detection of
131I-labeled anti-CEA polyclonal baboon antibodies
within such subcutaneous implants and demonstrated the
greater sensitivity of the gamma detection probe as com-
pared to gamma camera imaging for small tumor
implants [289,290]. In addition to these experimental
results in mice, they also reported the first clinical applica-
tion of RIGS in a case study of a 59 year-old male with a
rectal carcinoma [290]. The handheld gamma probe
detected an increased level of the 131I-labeled anti-CEA
polyclonal baboon antibody in the rectal tumor (135
counts/minute) compared to the sigmoid colon (111
counts/minute).
Shortly thereafter, Martin et al. [291] reported the results
of the first RIGS clinical series involving 28 patients withWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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primary (n = 12) and recurrent (n = 16) colorectal cancer.
Each patient was injected intravenously with 2.2 mCi
(81.4 MBq) of 131I baboon polyclonal anti-CEA antibody
at approximately 48 to 72 hours prior to surgery. Twenty-
three patients underwent preoperative scintigraphy. In all
patients, intraoperative counts (20 seconds per count) of
gross tumor and adjacent tissues were obtained using a
prototype handheld gamma detection probe and a com-
mercial control unit. Preoperative scintigraphy yielded
correct results in 33% and 64% of the patients with pri-
mary and recurrent disease, respectively. In comparison,
high intraoperative tumor-to-background ratios were
achieved in all patients with primary tumors (3.91:1) and
recurrent tumors (4.18:1). This clinical feasibility study
demonstrated the ability of RIGS technology to provide
immediate intraoperative information for the assessment
of colorectal cancer. In addition, this study was an early
indication of the application of the inverse square law and
the advantage of a gamma detection probe [8]. The
inverse square law states the sensitivity or specificity will
increase as the distance from the detector is decreased.
Hence, the intraoperative use of the gamma detection
probe increased the probability of tumor detection due to
its proximity to the source of radioactivity.
In all subsequent RIGS clinical studies, 125I was selected to
replace 131I [26,101,292]. 125I was selected as the radionu-
clide of choice for RIGS since the handheld gamma detec-
tion probe was more efficient at detecting 125I than 131I
secondary to the lower energy level of the primary gamma
photon emitter of 125I (35 keV) as compared to the pri-
mary gamma photon emitter of 131I (364 keV). Such lower
energy gamma photons were more likely to be detected
because the radiation was less likely to pass through a
small detector without being counted. Likewise, in tumor-
bearing mice, higher tumor-to-background ratios were
achievable with 125I labeled antibodies than with 131I
labeled antibodies [293]. This resultant improved tumor-
to-background ratio was a function of greater tissue atten-
uation and lesser scatter that occurs because of the lower
energy gamma photon emission of 125I [8,26]. Likewise,
the majority of clinical trials for RIGS in the detection of
colorectal cancer have specifically utilized 125I-labeled
anti-TAG-72 monoclonal antibodies. As previously dis-
cussed, such anti-TAG-72 monoclonal antibodies have
evolved from first generation 125I-labeled murine B72.3
monoclonal antibodies, to second-generation 125I-labeled
murine CC49 monoclonal antibodies, and finally to
third-generation  125I-labeled humanized CC49
(HuCC49) monoclonal antibodies [49].
RIGS with 17-1A murine monoclonal antibody
The availability of the monoclonal antibody 17-1A and its
antibody fragment provided preliminary indication of the
utility of 125I and a gamma detection probe to discrimi-
nate between tumor and background tissue and detect
occult disease [101]. In 1986, O'Dwyer and colleagues
[294] at The Ohio State University reported a 75% intra-
operative tumor localization rate among patients with pri-
mary and recurrent colorectal cancer. Higher tumor-to-
background ratios were observed in patients intrave-
nously injected with the 125I-17-1A whole monoclonal
antibody (3.4:1) compared to its radiolabeled mono-
clonal antibody fragment F(ab')2 (2.3:1). Of the 16 evalu-
able patients (two patients excluded due to a probe
malfunction), histologically confirmed occult or subclini-
cal disease was detected in 18% of these patients that
would have otherwise not been clinically detected by nor-
mal intraoperative inspection and palpation. This early
study was useful in shedding light on the optimal timing
between injection and surgery for enhancing intraopera-
tive gamma detection.
Petty and colleagues [295] at The Ohio State University
continued the investigation of the 125I-17-1A monoclonal
antibody in thirteen patients with colorectal cancer and
optimized the use of the gamma detection probe to deter-
mine the clearance of the blood-pool background
between the time of injection and surgery. The scheduling
of the operative procedure was dependent on external pre-
cordial counts of ≤ 10 per second obtained by the gamma
detection probe. Intraoperative detection by the gamma
detection probe was facilitated by the incorporation of a
microprocessor into the control unit. The microprocessor
maintained a running average of the count rate and made
a synthetic siren sound when the count rate exceeds the
background count by a statistically significant amount [8].
The squelching feature of the control unit allowed for a
siren sound and no sound discrimination between nor-
mal tissues and areas of increased radioactivity without
interfering with the count rates. Overall tumor localiza-
tion rate of 125I-17-1A monoclonal antibody was 61%
[295]. Localization was 33% among primary tumor
patients and 85% among recurrent tumor patients. Of the
12 tumor sites localized and biopsied, histologically con-
firmed tumor was identified in 8 (66%) using hematoxy-
lin and eosin (H&E) staining. Additional studies using
immunohistochemical staining and autoradiography
identified malignant cells in all specimens. In comparison
to the study reported by O'Dwyer et al [294], a higher
occult disease detection rate was attributed to a lower
blood-pool background at operation and improvements
in the gamma detecting probe [295]. Predictability of 125I-
17-1A monoclonal antibody blood clearance was feasible
using precordial counts. The majority of patients (85%)
demonstrated adequate clearance by 10 days post-injec-
tion of 125I-17-1A monoclonal antibody. Of the seven
patients with recurrent disease, occult disease was identi-
fied in 43% of these patients. The finding of occult disease
altered the surgical management (i.e., extended resection)World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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of six patients. This study demonstrated the ability of the
RIGS system to provide immediate intraoperative infor-
mation regarding the extent and localization of disease by
identifying tissues that did not look or feel abnormal but
which were worthy of attention due to a siren signal/
sound generated by the gamma detection probe.
RIGS with B72.3 murine monoclonal antibody
The first generation of radiolabeled anti-TAG-72 mono-
clonal antibodies utilized the B72.3 murine monoclonal
antibody. From preclinical studies on human colon carci-
noma xenografts, significant tumor uptake of 131I-B72.3
monoclonal antibody was found to occur within 48 hours
and subsequently increased over time [296]. Although
blood-pool background clearance yielded higher tumor-
to-background ratios, the activity within the xenograft
tumors remained constant over the 19 day period. This
prolonged retention of the radiolabeled B72.3 mono-
clonal antibody and high degree of tumor targeting dem-
onstrated in preclinical studies resulted in the selection of
the B72.3 monoclonal antibody for subsequent use in
RIGS [296,297].
Martin et al [298] reported the use of the 125I-B72.3 mon-
oclonal antibody and an improved gamma detection
probe in human clinical trials initiated at The Ohio State
University in 1986 [299] (Table 1). Of the 66 patients
with gastrointestinal, breast, and ovarian carcinoma, six
and 39 had primary and recurrent colon cancer, respec-
tively [298]. Each patient was injected intravenously with
4 to 5 mCi (148 to 185 MBq) of 125I-B72.3 monoclonal
antibody at approximately 5 to 42 days prior to surgery.
Adequate clearance of the blood-pool background yielded
a high percentage of tumors identified using RIGS. The
mean interval between injection and surgery of 19 days
demonstrated long retention of B72.3 monoclonal anti-
body and adequate amount of the radionuclide for intra-
operative gamma probe detection. Tumor localization of
125I-B72.3 monoclonal antibody was observed in 83%
and 79% of the patients with primary and recurrent color-
ectal cancer, respectively. Increasing the size of the probe
detector crystal and modifications in the crystal mounting
improved the counting rate by a factor of approximately
2.5.
Prolonged retention of the radiolabeled B72.3 mono-
clonal antibody and adequate clearance of the blood-pool
background at the time of operation was further demon-
strated in a study of primary colon cancer [300]. Thirty
primary colon cancer patients were intravenously injected
with 1 to 5 mCi (37 to 185 MBq) of 125I-B72.3 mono-
clonal antibody and then underwent surgery after ade-
quate clearance of the blood-pool background was
determined by precordial gamma detection probe counts
(mean 22.3 days, range 8 to 34 days). The 125I-B72.3 mon-
oclonal antibody localized in histologically confirmed
tumor among 23 of the 30 patients (77%). Of the 23
patients, 30% had occult disease in the liver, lymph
nodes, and/or invasion in adjacent tissues identified by
RIGS. In 23% of these patients, the surgical plan was mod-
ified due to the finding of occult disease. RIGS provided
adequate information (i.e., gamma detection probe
counts comparable to background) regarding tumor mar-
gins and histologically confirmed benign lesions of the
liver and ovaries. Therefore, the RIGS system provided a
more accurate intraoperative staging of disease and imme-
diate confirmation of tumor margins.
In 1991, Martin and Carey [301] reported the relationship
between the survival of 86 patients with recurrent colorec-
tal cancer undergoing a second-look procedure and use of
the RIGS system. All patients received a preoperative intra-
venous injection of 2 mCi (74 MBq) of 125I-B72.3 mono-
clonal antibody at approximately 24 days prior to surgery.
The abdomen and pelvis were explored using traditional
surgical techniques of inspection and palpation. Prior to
the use of the gamma detection probe, sites of tumor were
noted and the surgeon declared his surgical plan. The sur-
gical field was reexplored using the gamma detection
probe to identify areas of increased radioactivity com-
pared to normal adjacent tissues and to determine
whether the findings would alter the planned procedure.
Fifty-three patients (62%) were deemed resectable by tra-
ditional techniques. However, only 40 patients (47%)
were determined to be resectable by RIGS. Retroperitoneal
disease was a common finding for RIGS nonresectability.
Two-, three-, four-, and five-year survival data were
reported for three classifications of patients: RIGS resecta-
ble (n = 40), traditional nonresectable (n = 33), and RIGS
nonresectable (n = 13). Overall survival rate for the RIGS
resectable group was 83%, versus 21% and 31% for the
traditional nonresectable and RIGS nonresectable groups,
respectively. Significant differences in survival were
observed in the RIGS resectable versus traditional nonre-
sectable, p < 0.0001; RIGS resectable versus RIGS nonre-
sectable, p < 0.0008; and non-significant differences were
noted in the traditional nonresectable versus RIGS nonre-
sectable groups (p = 0.24). A two- and five-year survival
comparison is provided in Table 4 for RIGS using 125I-
B72.3 monoclonal antibody.
The safety and efficacy of 125I-B72.3 monoclonal antibody
to localize in tumor and detect occult disease was evalu-
ated in a multicenter clinical trial of 104 patients with pri-
mary or recurrent colorectal cancer [302]. All patients
received a preoperative an intravenous injection of 2 mCi
(74 MBq) of 125I-B72.3 monoclonal antibody at approxi-
mately 24 days prior to surgery. Tumor localization
occurred in 78% of the patients. A total of 30 occult tumor
sites were identified in 26 patients. Of all histologicallyWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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confirmed tumor sites, 9.2% represented clinically occult
sites identified only by the gamma detection probe. Loca-
tion of occult disease in primary patients included retro-
peritoneum, pelvis, periportal, and liver. Of the 72
patients with recurrent disease, 37 were deemed unresect-
able. In 27% of these patients, data provided by the RIGS
led to the decision to abandon an attempted resection. In
addition, the operative resection was extended in the
remaining 35 patients due to RIGS positive findings. One
patient developed an acute hypersensitivity reaction to the
skin test using unlabeled B72.3 monoclonal antibody.
Although 40% of the patients injected with 125I-B72.3
monoclonal antibody developed human anti-murine
antibodies, the occurrence did not impact upon tumor
localization. Serum TAG-72 levels analysis demonstrated
no relationship between the circulating antigen and local-
ization of 125I-B72.3 monoclonal antibody. The safety
analysis of 125I-B72.3 monoclonal antibody did reveal sta-
tistically significant changes in body temperature, systolic
blood pressure, and hemoglobin concentration; however,
these changes were clinically insignificant. This multi-
institutional study confirmed a relatively low toxicity pro-
file for 125I-B72.3 monoclonal antibody and its utility in
identifying occult disease and impact on the surgical man-
agement of patients with primary and recurrent colorectal
cancer.
Additional investigations into RIGS with 125I-B72.3 mon-
oclonal antibody were reported in 1998 by the group at
The University of Genoa in Italy [303,304]. They evalu-
ated RIGS in both 16 asymptomatic patients with a his-
tory of previously treated colorectal cancer who has a
rising CEA [303] and in 64 patients with recurrent or met-
astatic colorectal cancer [304]. In the group of 16 asymp-
tomatic patients with a history of previously treated
colorectal cancer who has a rising CEA, they found recur-
rent disease in only nine of 16 patients (56.2%) by tradi-
tional surgical exploration alone, but in 14 of 16 patients
(87.5%) using a combined approach of traditional surgi-
cal exploration and RIGS, thus demonstrating that RIGS
detected over-looked recurrent disease in five of 16
patients (31.3%) [303]. In the group of 64 patients with
recurrent or metastatic colorectal cancer, they nonran-
domly compared 125I-B72.3 monoclonal antibody in 30
patients to 125I-F023C5 monoclonal antibody fragment
that reacts with CEA in 34 patients [304]. They deter-
mined that the correct RIGS identification of tumor sites
occurred in 80.4% of the 125I-B72.3 monoclonal antibody
group and in 92.6% of the 125I-F023C5 monoclonal anti-
body fragment group, with additional occult sites of
tumor identified by RIGS that would modify surgical strat-
egy in 23.3% of the 125I-B72.3 monoclonal antibody
group and in only 8.8% of the 125I-F023C5 monoclonal
antibody fragment group. They concluded that 125I-B72.3
monoclonal antibody is the first choice for RIGS in recur-
rent or metastatic colorectal cancer.
The use of 111In-B72.3 murine monoclonal antibody
[107,305,306] in radioguided surgery for colorectal can-
cer has been limitedly investigated. Renda et al [305]
investigated the detection of 111In-B72.3 monoclonal
antibody by RIGS in 8 patients with colorectal cancer,
reporting one false-positive and an overall sensitivity of
62.5%. Muxi et al [306] investigated the detection of
111In-B72.3 monoclonal antibody by radioimmunoscin-
tigraphy and RIGS in 28 patients with colorectal cancer
(18 primary and 10 recurrent) and demonstrated an over-
all sensitivity of radioimmunoscintigraphy and RIGS of
71.4% and 82.1%, respectively. More recently, Hladik et
al [107] investigated the combined use of 111In-B72.3
monoclonal antibody and 99Tc-anti-CEA monoclonal
antibody fragment (99Tc-IMMU-4 monoclonal antibody
fragment) and compared the findings yielded by preoper-
ative immunoscintigraphy, RIGS, and histology (H & E
and immunohistochemistry). Of the 121 patients, 106
and 15 had primary and recurrent colorectal cancer,
respectively. A more accurate diagnosis was achieved
using preoperative immunoscintigraphy and RIGS. Of the
55 RIGS-positive lymph node patients, 43 cases (78%)
were confirmed by histologically, including 9 cases in
which RIGS-positivity was recognized by immunohisto-
chemistry alone. Of 66 patients with RIGS-negative
results, 62 cases (94%) were confirmed by negative histol-
ogy. The authors concluded a potential use of RIGS in the
surgical management of primary colorectal patients
includes better intraoperative assessment of the extent of
disease and staging by identifying occult lymph node dis-
ease. Nevertheless, the major drawback to the use of 111In-
B72.3 monoclonal antibody in radioguided surgery for
the detection of colorectal cancer has been the nonspecific
accumulation of the 111In-B72.3 monoclonal antibody
conjugate within the liver, thus making it difficult to iden-
tify liver metastases and limiting its usefulness to the iden-
tification of extrahepatic disease [307].
RIGS with CC49 murine monoclonal antibody
The second generation of radiolabeled anti-TAG-72 mon-
oclonal antibodies utilized the CC49 murine monoclonal
Table 4: Two-year and five-year survival for RIGS with 125I-B72.3 
monoclonal antibody
PATIENT
GROUP
SURVIVAL: 2-YEAR
(% PATIENTS)
SURVIVAL: 5-YEAR
(% PATIENTS)
RIGS resectable 95% 60%
Traditional nonresectable 36% 0%
RIGS nonresectable 57% 0%World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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antibody. CC49 murine monoclonal antibody demon-
strated a higher affinity constant (Ka 16.18 × 109 m-1)
compared to B72.3 monoclonal antibody (Ka 2.54 × 109
m-1) [72]. In 1992, Arnold et al [74] at The Ohio State
University evaluated the efficiency of 125I-CC49 mono-
clonal antibody and its impact on the RIGS system in a
clinical trial of colorectal cancer patients, including 24 pri-
mary tumors and 30 recurrent tumors. All patients
received a preoperative intravenous injection of 2 mCi (74
MBq) of 125I-CC49 monoclonal antibody with a varying
monoclonal antibody dosage at approximately 14 to 21
days prior to surgery. Tumor localization of the 125I-CC49
monoclonal antibody occurred in 86% and 97% of the
primary and recurrent tumors, respectively. In compari-
son to 125I-B72.3 monoclonal antibody, 125I-CC49 mono-
clonal antibody tumor localization was superior in
targeting primary and recurrent colorectal tumors. The
intraoperative findings from RIGS altered the planned
surgical procedure in 50% and 47% of the primary and
recurrent patients, respectively. Likewise, the intraopera-
tive identification of occult disease by RIGS resulted in
upstaging of cancer and abandonment of hepatic resec-
tions in three patients undergoing a second-look proce-
dure. In this study, tissue specimens were classified by
whether they were detected by RIGS and by the presence
or absence of histologically confirmed carcinoma. Speci-
mens were divided into tissue types I through IV, based on
antibody localization and hematoxylin and eosin stain-
ing: type I, RIGS negative and histologically negative; type
II, RIGS negative and histologically positive; type III, RIGS
positive and histologically negative; and type IV, RIGS
positive and histologically positive. Of interest to the
authors were the type III lymph nodes. The intraoperative
detection of type III lymph nodes by RIGS was a function
of the presence of the TAG-72 within the extracellular
environment. At surgery, all RIGS-positive tissue was con-
sidered malignant and excised whenever possible. Type III
lymph nodes were detected in both primary cases (n = 40
specimens) and recurrent cases (n = 16 specimens). In this
regard, Quinlan et al [308] reported a relationship
between the presence of CC49 monoclonal antibody in
the germinal centers of lymph nodes and early death
among patients with colorectal cancer.
The role of RIGS as an intraoperative prognostic indicator
of survival in patients with primary colorectal cancer was
investigated by Arnold et al [309]. Patients were intrave-
nously injected with 2 mCi (74 MBq) of 125I-CC49 mon-
oclonal antibody at approximately 21 days prior to
surgery. Thirty-one primary colorectal cancer patients
with  125I-CC49 monoclonal antibody localization were
assessed for the presence or absence of residual RIGS-pos-
itive tissue at the completion of the operative procedure.
Patients were classified as RIGS-positive (i.e., residual
RIGS-positive tissue) or RIGS-negative (i.e., no residual
RIGS-positive tissue). Tumor localization was observed in
86% of the patients. One-hundred and nine extra-regional
sites of RIGS-positivity were identified using RIGS, includ-
ing but not limited to the gastrohepatic ligament, celiac
axis, retroperitoneum, liver, omentum, and sites above
the diaphragm. Seventeen and 14 patients were assessed
as RIGS-positive and RIGS-negative, respectively, follow-
ing the completion of the operative procedure. Follow up
of patients ranged from 30 to 54 months. Of the 17
patients with residual RIGS-positive tissue, 15 (88%) suc-
cumbed to their disease. In comparison, all 14 patients
with no residual RIGS-positive tissue were alive at last fol-
low-up (24 to 48 months after surgery) (p < 0.0001).
Therefore, the presence or absence of residual RIGS-posi-
tive tissue provided immediate and accurate prognostic
information regarding the behavior of the tumor and
patient outcomes in patients with primary colorectal can-
cer.
Likewise, in the recurrent colorectal cancer population,
Bertsch et al [310] reported an improved survival relative
to the use of the RIGS system. One hundred and thirty-
one patients with recurrent colorectal cancer were injected
with  125I-B72.3 monoclonal antibody (n = 86) or 125I-
CC49 monocloncal antibody (n = 45) and underwent a
surgical exploration using traditional inspection and pal-
pation and the RIGS system. Of the 49 patients deemed
resectable (i.e., successful removal of all traditionally evi-
dent disease and all RIGS-positive tissue), 55% (27
patients) were alive at 2 to 8 years following surgery, with
a minimal follow-up of 28 months. In contrast, only 2.4%
of all patients (2 of 84 patients) with unresectable disease
were alive at the time of this report. None of the patients
determined to be traditionally resectable but unresectable
by the RIGS system were alive. A significant increase in
survival (p < 0.0001) was observed among patients with
recurrent colorectal cancer undergoing a resection of all
disease found by a combination of both traditional means
and by RIGS.
A long-term survival analysis of 97 patients with primary
colorectal cancer supports the use of RIGS as an intraoper-
ative prognostic tool [311]. Survival was assessed using
the traditional staging (TNM) and the presence or absence
of RIGS-positive tissue at the end of the operative proce-
dure. The mean follow-up among the 52 evaluable
patients was 62 months (range 34 to 89 months). Based
on TNM staging 13, 18, and 28 patients were Stage, I,
Stage II, and Stage III, respectively. By RIGS status, 24 and
35 were RIGS-negative and RIGS-positive, respectively.
The RIGS status was not significantly related to the tradi-
tional pathologic staging (p = 0.73). No significant differ-
ence in survival was observed using standard pathologic
staging (p = 0.12). However, a significant difference in
survival was observed by the using the RIGS status (p <World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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0.0002), with 87% of RIGS-negative patients alive and
only 40% of RIGS-positive patients alive at a mean follow-
up of 62 months.
The extended survival (i.e., 10-year survival) of 90 color-
ectal cancer patients undergoing RIGS, based on the pres-
ence or absence of residual RIGS-tissue at the time of
surgery, was recently analyzed by Sun et al [49]. At 10
years after RIGS, survival differences remained significant
(p = 0.001), with 49% of the RIGS-negative patients
(median survival of 106.5 months) still alive as compared
to only 21% of the RIGS-positive patients (median sur-
vival of 26 months) still alive. These extended follow-up
data support the accuracy of utilizing the RIGS status at
the time of surgery as a predictor of long-term survival in
colorectal cancer patients.
Additional investigations into RIGS with 125I-CC49
murine monoclonal antibody were reported in 2000 and
2001 by the group at Tel-Aviv University in Israel [312-
314]. Overall, they evaluated a total of 58 patients with
recurrent colorectal cancer who were intravenously
injected with of 2 mCi (74 MBq) of 125I-B72.3 mono-
clonal antibody at approximately 24 days prior to surgery.
Traditional surgical exploration and RIGS were per-
formed. While traditional surgical exploration identified
117 suspected tumor sites, RIGS identified 177 suspected
tumor sites. In 17 of 58 patients (29.3%), at least one
occult tumor site that was not identified by traditional
surgical exploration was identified by RIGS, and was sub-
sequently confirmed by pathology with H&E staining.
This resulted in a major change in the surgical plan in 16
cases. RIGS performance was found to vary between lym-
phoid tissue and non-lymphoid tissue, with a positive
predictive value and a negative predictive value of 96%
and 90% in non-lymphoid tissue and 40% and 100% in
lymphoid tissue, respectively.
RIGS with humanized CC49 monoclonal antibody
A phase I study of 125I-HuCC49ΔCH2 monoclonal anti-
body conducted at The Ohio State University determined
the feasibility of the humanized monoclonal antibody as
a component of the RIGS system and evaluated the opti-
mal timing interval between injection and surgery [315].
Study eligibility included patients with recurrent colorec-
tal cancer undergoing a surgical exploration and excluded
those with prior exposure to murine antibodies. Patients
underwent a surgical exploration at variable time intervals
following the intravenous administration of 2 mCi (74
MBq) of 125I-HuCC49  ΔCH2 monoclonal antibody or
after the precordial counts measured by a handheld
gamma detecting probe were less than 30 counts per two
seconds. HAMA determinations were obtained at base-
line, as well as at 4 to 6 weeks and 12 weeks post-injection
of the 125I-HuCC49ΔCH2 monoclonal antibody. At sur-
gery, traditional exploration (i.e., inspection and palpa-
tion) and subsequent RIGS exploration were performed.
Suspicious tissues were biopsied or excised to determine
the presence of absence of carcinoma. The findings were
analyzed to determine the sensitivity and positive predic-
tive value for each modality. Of the twenty recurrent
colorectal cancer patients evaluated, the first 15 operative
procedures were performed at various time intervals (3, 5,
7, 9, 11, and 13 days) after the injection of 125I-
HuCC49ΔCH2 monoclonal antibody and independent of
the precordial counts. In the five remaining patients, the
timing of surgery was determined by the demonstration of
precordial counts of less than 30 counts per two seconds,
indicating optimal clearance of 125I-HuCC49 ΔCH2 mon-
oclonal antibody from the blood-pool background. This
occurred at 10 to 24 days after the injection of 125I-
HuCC49ΔCH2 monoclonal antibody. The adequate clear-
ance of the blood-pool background in these five patients
allowed for intraoperative differentiation of RIGS-positive
tissue compared to normal adjacent tissue. Among those
five patients with optimized clearance conditions based
on precordial counts of less than 30 counts per two sec-
onds, 17 and 21 sites were identified using traditional
techniques (i.e., inspection and palpation) and RIGS sys-
tem, respectively. Approximately 90% of the excised tis-
sues identified by traditional techniques and by RIGS
were histologically positive for tumor. Of the six sites
identified exclusively by RIGS, five were excised and all
contained tumor. Table 5 provides the sensitivity of tradi-
tional exploration and RIGS exploration using 125I-
HuCC49ΔCH2 monoclonal antibody for identifying
recurrent colorectal cancer and the positive-predictive
value. No significant HAMA response was detected in
these patients. Despite the small number of evaluable
patients, the study demonstrated the safety and utility of
125I-HuCC49ΔCH2 monoclonal antibody in RIGS. The
rate of tumor localization and detection of occult disease
was comparable to murine CC49 previously reported by
Arnold et al [74], but without a detectable HAMA
response. The use of HuCC49ΔCH2 monoclonal antibody
as a component of RIGS technology suggests that it is wor-
thy of continued investigations in colorectal cancer
patients.
Table 5: Traditional exploration and RIGS exploration with 125I-
HuCC49ΔCH2 monoclonal antibody
Traditional exploration RIGS
exploration
Sensitivity 64% 92%
Positive predictive value 90% 100%World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
Page 22 of 63
(page number not for citation purposes)
RIGS with 125I-anti-CEA monoclonal antibody (125I-A5B7) and 99Tc-
anti-CEA monoclonal antibody fragment (99Tc-IMMU-4)
Limited information is available on use radiolabeled anti-
CEA monoclonal antibody in RIGS for colorectal cancer
[90,91,107,316]. Dawson et al [91] evaluated 43 patients
undergoing surgery with primary colorectal cancer and 9
patients undergoing second look laparotomy for recurrent
colorectal cancer who were intravenously injected with 2
mCi (74 MBq) of 125I-anti-CEA monoclonal antibody
(125I-A5B7) three to ten days before surgery. They deter-
mined that RIGS assessment of 125I-A5B7localized in
97.8% of primary tumors and in 88.8% of most principle
tumor sites found at the time of the second look proce-
dure. Likewise, they determined that the use of RIGS influ-
enced the overall surgical procedure performed in 2 of 43
cases (4.6%) of primary colorectal cancer and in three of
nine cases (33%) of recurrent colorectal cancer. Lechner et
al [316] evaluated 20 patients with primary colorectal
cancer who were intravenously injected with 25 mCi (925
MBq) of 99Tc-anti-CEA monoclonal antibody fragment
(99Tc-IMMU-4) on the day before RIGS. They determined
that RIGS assessment of 99Tc-IMMU-4 led to up-staging of
disease in 7 of 20 patients (35%). Hladik et al [107] eval-
uated 65 patients with either primary or recurrent colorec-
tal cancer who were intravenously injected with 99Tc-
IMMU-4 in a dose range of 18.9 to 24.3 mCi (700 to 900
MBq) on the day before RIGS. They determined that RIGS
assessment of 99Tc-IMMU-4 led to a sensitivity and accu-
racy for the detection of tumor or local recurrence of 92%
and 92%, for the detection of hepatic metastases of 75%
and 92%, and for the detection of extrahepatic metastases
of 57% and 78%, respectively. Finally, Gu et al [90] eval-
uated 29 patients with primary colorectal cancer who were
injected with 0.5 mCi (18.5 MBq) of 125I-anti-CEA mono-
clonal antibody (125I-CL58) into the colonic submucosa
at the tumor-surrounding areas (at 2, 4, 6, 8,10, and 12
o'clock locations) via colonoscopy at a time of approxi-
mately three to 14 days before RIGS. The sensitivity of
RIGS in detecting primary lesions was 93.1%, and the spe-
cificity of RIGS to correctly identify negative surgical mar-
gins was 95.5%. For detection of lymph node metastases,
the sensitivity and specificity of RIGS was 92.0% and
87.8%, respectively.
Radioguided SLN biopsy
The application of SLN biopsy technology to colorectal
cancer has been thoroughly studied. While the vast major-
ity of the information available for SLN biopsy for color-
ectal cancer is on the application of the blue dye alone
technique, the radioguided application of 99mTc sulfur
colloid technique with intraoperative gamma probe
detection has been limitedly investigated [317-324]. The
results of the two largest reported series are strikingly
divergent [319,323]. In 2003, Bilchik et al [319] evaluated
120 patients using a combined blue dye and 99mTc sulfur
colloid (dose not reported) technique in 32 such patients.
They reported successfully identifying a SLN in 115 of 120
(96%) patients, with a false-negative SLN biopsy results
identified in only 5 of 115 (4%) patients. In contrast, in
2007, Lim et al [323] evaluated 120 patients using a com-
bined blue dye and 99mTc sulfur colloid (0.5 mCi; 19
MBq) technique in all patients. They reported successfully
identifying a SLN in 119 of 120 (99%) patients, with a
falsely negative SLN biopsy results identified in 20 of 119
(17%) patients. As a consequence of these strikingly dif-
ferent results with regards to the false-negative rate, we can
realistically say that at the current time we are no closer to
elucidating the clinical relevance of SLN biopsy technol-
ogy for colorectal cancer surgery.
18F-FDG-directed surgery
The most recent application of the gamma detection
probe for radioguided surgery in colorectal cancer has
been directed towards to identification of 18F-FDG-avid
tumors [35-39,45,50]. This technique was first described
by Desai et al [35,36] at The Ohio State University (Table
1). Fourteen colorectal cancer patients received an intrave-
nous injection of 4.0 to 5.7 mCi (148 to 211 MBq) of 18F-
FDG at a time of 58 to 110 minutes prior to intraoperative
evaluation with the gamma detection probe. Single or
multiple tumor foci were correctly identified in 13 of 14
patients with the gamma detection probe as 18F-FDG-avid
tissue and this correlated to hypermetabolic activity on
prior preoperative diagnostic 18F-FDG PET imaging. These
results have been further corroborated since that time in
several other clinic reports [37-39,45,50]. Most recently, a
combined approach of preoperative diagnostic 18F-FDG
PET imaging and intraoperative gamma probe detection
has been advocated to potentially provide the surgeon
with a real-time, intraoperative roadmap for accurately
locating and determining the extent of tumor recurrence
in patients with colorectal cancer [50]. In this series,
patients received an average dose of 10 to 15 mCi (370 to
555 MBq) of 18F-FDG at a time of 30 to 60 minutes prior
to intraoperative evaluation with the gamma detection
probe. It was determined that intraoperative evaluation
with the gamma detection probe appeared to be more
sensitive in detecting the extent of abdominal and pelvic
recurrence, while preoperative 18F-FDG PET imaging was
more sensitive in detecting liver metastases and other dis-
tant metastases [50].
Anal cancer
The application of the gamma detection probe in radiogu-
ided surgery for anal cancer has been limited to radiogu-
ided SLN biopsy [324-337]. In general, 99mTc sulfur
colloid, 99mTc colloidal human albumin, 99mTc colloidal
rhenium sulphide, and 99mTc antimony trisulfide colloid
have been utilized and are injected into four subdermal or
submucosal sites around the primary tumor in a total dos-World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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age range from 0.135 mCi (5 MBq) to 1.0 mCi (37 MBq).
Localization to a SNL was generally demonstrated in 75%
to 100% of cases. There were three common pathways of
lymphatic drainage (including drainage to inguinal, iliac,
and mesorectal lymphatic basins) and the very frequent
finding of bilaterality of such lymphatic drainage, empha-
sizing the importance of preoperative lymphoscintigra-
phy in most effectively performing radioguided SLN
biopsy in anal cancer. The inguinal region was the pre-
dominant lymphatic drainage pathway, representing the
site of localization most accessible to performance of a
minimally invasive radioguided SLN biopsy procedure.
Radioguided SLN biopsy to the inguinal region was useful
in identifying inguinal lymph node metastases in approx-
imately 10% to 40% of such patients. However, there is
yet to be a large scale prospective clinical trial to assess the
clinical efficacy of radioguided SLN biopsy in anal cancer.
Esophageal cancer
The application of the gamma detection probe in radiogu-
ided surgery for esophageal cancer has been limited to
radioguided SLN. In this regard, it is interesting to note
that there have been as many review papers written that
have debated the pros and cons of the potential clinic effi-
cacy of radioguided SLN biopsy for esophageal cancer
[324,338-343] as there have been actual papers written on
the clinical results of this technology in esophageal cancer
surgery. Clinical data on radioguided SLN biopsy for
esophageal cancer are restricted to those reports from
Japan [344-350], the United Kingdom [351], and Ger-
many [352]. Central to the debate with regards to the
potential clinical efficacy of radioguided SLN biopsy for
esophageal cancer are the complex and extensive lym-
phatic networks located throughout cervical, mediastinal,
and abdominal nodal basins and the concern for skip
metastases [324,338,339,341-343]. In this regard, the
routine use of radioguided SLN biopsy for esophageal
cancer surgery remains controversial and is yet to be
widely adopted.
Most frequently, 99mTc tin colloid has been used as the
radiocolloid, especially in Japan [344-350]. However,
99mTc colloidal human albumin [351], 99mTc sulfur col-
loid [352], and 99mTc colloidal rhenium sulfide [347]
have also been utilized. The dosing of these radiocolloid
agents vary from as low as 0.54 mCi (20 MBq) [351] to as
high as 5.0 mCi (185 MBq) [346,350]. These radiocolloid
agents are injected endoscopically in up to four submu-
cosal sites around the tumor on either the day before sur-
gery [344-350] or on the day of surgery [351,352].
The two largest series reported are by Lamb et al [351] and
Kato et al [347]. In 2005, Lamb et al [351] identified a
SLN in all 40 patients evaluated with adenocarcinoma of
the lower esophagus. They identified a total of 77 SLNs
from a combination of both the mediastinal and abdom-
inal nodal stations, with 51% of these SLNs being located
within the mediastinal nodal stations and with 38% of
proven metastatic lymph nodes residing within the medi-
astinal nodal stations. Noteworthy from this study was
the fact that if patients did not have a mediastinal SLN
identified at the time of radioguided SLN biopsy that a
negative abdominal SLN accurately predicted the absence
of mediastinal lymph node involvement. Such a predic-
tive property of SLN biopsy may help to alter the surgical
strategy by possibly omitting a cervical nodal dissection
for mid-esophageal tumors or by making the option of
transhiatal esophagectomy more appropriate when medi-
astinal nodal clearance is not indicated. In 2003, Kato et
al [347] identified a SLN in 23 of 25 (92%) patients eval-
uated with squamous cell carcinoma of the thoracic
esophagus. The accuracy of radioguided SLN biopsy was
91.3% (21 of 23 patients), the sensitivity was 86.7% (13
of 15 patients), and the false-negative rate was 8.7% (2 of
23 patients). Despite the promising clinical results seen
with radioguided SLN biopsy for esophageal cancer, tech-
nical difficulties can be encountered with regards to iden-
tifying SLNs within the peritumoral nodal stations,
particularly the lower paraesophageal, paracardial, and
left gastric nodes, which are common sites of lymphatic
metastases for lower esophageal cancers. As with other
malignancies, the proximity of the SLN to the radiocolloid
injection site creates an artifact shine through effect which
can make identification of such located SLN with the
gamma detection probe very difficult.
Gastric cancer
Although radioguided surgery is not routinely utilized in
the current surgical management of gastric cancer, the
application of the gamma detection probe for gastric can-
cer surgery has been investigated in the areas of radiogu-
ided SLN biopsy, RIGS, and 18F-FDG-directed surgery.
Radioguided SLN biopsy
The necessary extent of lymphadenectomy during gastric
cancer surgery remains a controversial issue, with two ran-
domized trials demonstrating no survival advantage for
patients treated with D2 lymphadenectomy as compared
to a D1 lymphadenectomy [353,354] compared with
other retrospective reviews showing a survival benefit for
patients treated with D2 lymphadenectomy [355,356]. In
this regard, the potential application of SLN biopsy for
gastric cancer remains an active avenue of clinical research
and debate amongst surgeons who treat gastric cancer.
This is most relevant for those clinicians in eastern Asia
that primarily treat early stage gastric cancers, which by
definition should have a less than 10% chance of nodal
involvement [357].World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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Multiple reports exist in the literature on the feasibility of
radioguided SLN biopsy for gastric cancer
[338,344,345,358-383]. Many of these reports from east-
ern Asia specifically target a purely laparoscopic approach
to radioguided SLN biopsy in the treatment of cases of
early stage gastric cancer [338,361,367,371,377,378,380-
382].
Most frequently, 99mTc tin colloid [338,344-346,359-
361,363-367,369,371,375-378,380,382] has been used
as the radiocolloid, especially in eastern Asia. However,
99mTc colloidal rhenium sulfide [362,368,374,379], 99mTc
sulfur colloid [352,358,370,372], and 99mTc colloidal
human albumin [381] have also been utilized. The dosing
of these radiocolloid agents vary from as low as 0.5 mCi
(18.5 MBq) [374] to as high as 6.0 mCi (222 MBq)
[364,369]. These radiocolloid agents are generally
injected endoscopically in up to four submucosal sites
around the tumor at a time period from two to 24 hours
before surgery.
The two largest series reported are by Kitagawa et al [359]
and Uenosono et al [369]. In 2002, Kitagawa et al [359]
identified a SLN in 138 of 145 patients (95.2%) with pre-
sumed cT1N0 or cT2N0 gastric cancer. A SLN was positive
in 22 of 24 patients who had lymph node metastases and
this demonstrated a diagnostic accuracy of assessment of
the regional lymph node status on the basis of the SLN
status of 98.6%. In 2005, Uenosono et al [369] identified
a SLN in 99 of 104 patients (95.2%) with presumed cT1
or cT2 gastric cancer. Excluding three technical failures in
radiocolloid injection, identification rates were 99% (78
of 79) and 95% (21 of 22) for cT1 and cT2 lesions, respec-
tively. Lymph node metastases and/or micrometastases
were found in 28 patients (15 cT1 and 13 cT2) and the
resultant false-negative rate, sensitivity, and accuracy were
significantly better for cT1 tumors than for cT2 tumors (P
< 0.001, P = 0.004, and P < 0.001, respectively). While the
possibility exists for radioguided SLN biopsy to help indi-
vidualize the surgical therapy for patients with early stage
gastric cancer, additional studies are needed to determine
its utility.
RIGS
The feasibility of RIGS for gastric cancer has been evalu-
ated by several groups of investigators [149,383-387]. In
1988, Martin et al [149] evaluated 125I-B72.3 murine
monoclonal antibody in five patients with gastric cancer,
finding positive gamma detection probe counts in four
patients. In 1994, Xu et al [383] and Lui et al [384] evalu-
ated  131I-3H11 murine monoclonal antibody, a mouse
antibody raised against human gastric cancer cells, in 25
patients with gastric cancer. They reported detection of
metastatic lymph nodes with a sensitivity of 99.2%, a spe-
cificity of 97.7%, and an accuracy of 98.8%, and reported
the detection of tumor infiltration of the gastric wall with
a sensitivity of 94.6%, a specificity of 96.7%, and an accu-
racy of 95.9%. In 1998, Lucisano et al [385] evaluated
125I-B72.3 murine monoclonal antibody in 7 patients
with gastric cancer. The correct RIGS identification of the
primary tumor was seen in four of seven patients (57.1%)
and of metastatic lymph nodes in two of four patients
(50%). Also, in 1998, Mussa et al [386] evaluated 111In-
B72.3 murine monoclonal antibody in 3 patients with
gastric cancer, confirming intraoperative tumor-to-back-
ground counts of greater than 2 in all three cases and dem-
onstrating a sensitivity of 100%, a specificity of 72%, and
no false-negative findings with RIGS. Finally, in 2000,
Wang et al [387] evaluated 125I-3H11 murine monoclonal
antibody in 35 patients with gastric cancer. For the detec-
tion of lymphatic metastases, they demonstrated a sensi-
tivity of 83.6%, a specificity of 95.0%, and an accuracy of
91.3%. The existence of lymphatic micrometastatic dis-
ease was verified immunohistochemically in 10 of 19
patients (52.6%) that were RIGS-positive but that had
H&E histologically negative lymph nodes. Despite these
early promising results, no further investigations into
RIGS for gastric cancer have been published since that last
report.
18F-FDG-directed surgery
The use of 18F-FDG-directed surgery has been very limit-
edly reported in the literature for the surgical manage-
ment of gastric cancer [45,47]. Gulec et al [45] reported on
a single case of gastric cancer in which 18F-FDG-directed
surgery was utilized for the identification and resection of
a hypermetabolic metastatic lymph node during a gastec-
tomy and extended node dissection. Piert et al [47]
reported on the use of 18F-FDG-directed surgery in three
gastric adenocarcinomas and two adenocarcinomas of the
gastroesophageal junction.
Pancreatic cancer
Radioguided surgery using the gamma detection probe
has surprisingly been previously investigated in only the
most limited fashion for pancreatic cancer [388]. No data
are currently available on radioguided sentinel lymph
node biopsy or on 18F-FDG-directed surgery for pancreatic
adenocarcinoma. Only a single report exists in the litera-
ture from 1997 by LaValle et al [388] from The Ohio State
University on RIGS for the assessment of extent of disease
in ten cases of pancreatic adenocarcinoma that were
deemed resectable by preoperative CT scan. Each patient
was intravenously injected with 2 mCi (74 MBq) of 125I-
CC-49 murine monoclonal antibody and then underwent
surgery after adequate clearance of the blood-pool back-
ground was determined by precordial gamma detection
probe counts (mean 26.1 days, range 7 to 35 days). Tradi-
tional assessment of the abdomen was compared to RIGS
assessment of the abdomen. Three patients underwentWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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pancreatic resection for locoregional disease. The other
seven patients had visceral metastases, carcinomatosis, or
both detected at the time of laparotomy. All sites suspi-
cious for tumor by traditional assessment of the abdomen
were found to be RIGS positive. Occult pancreatic adeno-
carcinoma identified only by RIGS assessment was found
to be disseminated to both the abdominal viscera and
lymphatics. RIGS detected significantly more total sites
(viscera and lymphatics) of metastatic disease than tradi-
tional assessment (73 site versus 31 sites for RIGS versus
traditional assessment, respectively, p < 0.05), with the
greatest difference being observed for dissemination to
the lymphatics (44 site versus 6 sites for RIGS versus tradi-
tional assessment, respectively, p < 0.001). Despite these
very encouraging early results, no further work has been
done on RIGS for pancreatic cancer.
Gastointestinal stromal tumors (GIST)
The use of the gamma detection probe in radioguided sur-
gery for GIST is virtually nonexistent. Only one report
exists in the literature that describes two GIST cases in
which  18F-FDG-directed surgery was employed [45]. In
this report, 18F-FDG-directed surgery was used during
exploratory cytoreduction and during liver resection for
GIST.
Head and neck malignancies
Squamous cell cancer of the oral cavity, oropharynx, hypopharynx, 
and laryngeal regions
Radioguided SLN biopsy
While SLN biopsy had become a widely accepted diagnos-
tic technique in the evaluation of the lymph node status
in breast cancer and melanoma, it has been met with
much more limited enthusiasm for squamous cell cancers
of the head and neck region, including the oral cavity,
oropharynx, hypopharynx, and laryngeal region, second-
ary to the complicated lymphatic drainage pathways of
the head and neck region [389]. In 1996, Alex and Krag
[390] first described successful radiolocalization of SLNs
with 99mTc sulfur colloid in the aerodigestive system in a
patient with supraglottic squamous cell cancer. Since the
time of this initial report, the sensitivity and specificity of
radioguided SLN biopsy has become greater than that of
physical exam, computed tomography, magnetic reso-
nance imaging, or positron emission tomography for
assessing the N0 neck [391]. Additionally, the overall fea-
sibility of radioguided SLN biopsy has gradually
improved, with most recently reported success of localiza-
tion of 99.3% in 137 patients by American College Of Sur-
geons Oncology Group Z0360 [392] and 100% in 79
patients by Stoeckli [393] for early (T1/T2) squamous cell
cancers of the oral cavity and oropharynx.
The overall methodology for performing radioguided SLN
biopsy for squamous cell cancers of the head and neck
region, including the oral cavity, oropharynx, hypophar-
ynx, and laryngeal region is not that dissimilar as to that
for breast cancer and melanoma. However, there are some
unique features that are worth further discussing [392-
397].
Recently, Vigili et al [396] have outlined one such proto-
col for performing radioguided SLN biopsy for squamous
cell cancers of the oral cavity and oropharynx. Topical
anesthetic (10% lidocaine spray) was administered to the
oral cavity. Then, 0.8 mCi (30 MBq) to 1.4 mCi (50 MBq)
of 99mTc human nanocolloidal albumin within 0.3 ml of
normal saline solution was injected superficially into the
subepithelial stroma in four points around the tumor.
Injection into deeper tissues resulted in a poorer image
quality, increased blood accumulation of the tracer, and a
lower success rate for SLN localization. The mouth was
immediately washed out in order to prevent pooling and
swallowing of any residual 99mTc human nanocolloidal
albumin. Immediate dynamic lymphoscintigraphy imag-
ing and 30 minute static images were performed with lat-
eral and/or anterior views. The skin overlying the area of
the identifiable SLNs seen on lymphoscintigraphy were
marked with a permanent marking pen. Subsequent
appropriate surgery and radioguided SLN biopsy with the
gamma detection probe were performed approximately
three hours after completion of lymphoscintigraphy. They
defined a SLN as any lymph node containing activity
counts of at least three times that of the background count
activity.
Likewise, recently, Tomifuji et al [397] have outlined one
such protocol for performing radioguided SLN biopsy for
squamous cell cancers of the hypopharynx and laryngeal
region. On the day before surgery, topical anesthetic (4%
lidocaine spray) was administered to the oral cavity. Then,
a 2.0 mCi/mL (74 MBq/mL) solution of 99mTc phytate was
submucosally injected in 0.2 mL quantities into three to
four sites adjacent to the tumor using a 23-gauge endo-
scopic puncture needle that was passed through the chan-
nel of a flexible laryngohypopharyngeal endoscope with a
transparent hood. Three hours after the injection, static
lymphoscintigraphy images were obtained from lateral
and anterior views. The skin overlying the area of the iden-
tifiable SLNs seen on lymphoscintigraphy were marked
with a permanent marking pen. The following day, appro-
priate surgery and radioguided SLN biopsy with the
gamma detection probe were performed. They defined a
SLN as any lymph node containing activity counts of at
least ten times that of the background count activity.
The determination of the adequacy of the intraoperative
assessment of the neck with the gamma probe during radi-
oguided SLN biopsy for squamous cell cancers of the oral
cavity and oropharynx has been recently assessed. In aWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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recent study of 31 patients undergoing radioguided SLN
biopsy, resection of the primary tumor, and a concomi-
tant neck dissection, Atula et al [398] reported that all
patients could be accurately staged based upon the find-
ings within the hottest three SLNs removed.
Despite encouraging results, controversy still exists as to
whether SLN biopsy will ultimately replace the standard
clinical practice of selective neck dissection for squamous
cell cancers of the head and neck region, as previously
described [399,400]. Potential disadvantages of SLN
biopsy include a limited exposure and the potential injury
to neural structures, such as cranial nerve XI and the man-
dibular branch of cranial nerve VII [401]. Additionally, if
neck nodal metastases are not identified with frozen sec-
tion, then a subsequent operation within a recently open
and inflamed surgical field could increase morbidity
[393]. Furthermore, it has been observed that lymph
nodes predominately replaced by metastatic disease do
not accumulate radiotracer and may result in altered lym-
phatic pathways, thereby increasing false negatives [402].
Finally, the proximity of the primary tumor and the SLN
can be problematic. Kovács et [401] al reported that 6 of
104 known sites of radiotracer localization seen on preop-
erative lymphoscintigraphy were intraoperatively missed
using the gamma detection probe secondary to shine-
through radioactivity from a nearby injection site. This
proximity issue likely explains why the radioguided SLN
identification frequency is less for carcinomas of the floor
of mouth as compared to other sites of carcinomas within
the oral cavity, oropharynx, hypopharynx, and laryngeal
region [392,395-397].
Regardless of these potential disadvantages, radioguided
SLN biopsy has proven value especially in management of
the N0 neck in squamous cell cancers of the head and
neck region [278,392,395,396]. One advantage of radi-
oguided SLN biopsy is for guiding selective nodal harvest-
ing in carcinomas situated at or adjacent to the midline,
since in such situations the lymphatic drainage may be
bilateral in up to 10% of cases [403]. In this setting, lym-
phoscintigraphy and intraoperative gamma probe detec-
tion of SLNs may provide a suitable alternative in these
patients, in whom the management of the contralateral
neck is debatable. Another advantage of SLN biopsy is the
allowance of a concentrated and extensive pathologic
examination of a limited number of lymph nodes versus
that of a limited pathologic examination of numerous
lymph nodes from selective neck dissections where find-
ing a metastasis is similar to the proverbial needle in a
haystack [392]. Because of this required meticulous his-
topathologic examination, Kovács [404] has discouraged
the use of frozen section, but admits its intraoperative
availability and diagnostic accuracy are important in
shortening the time to deciding on a therapeutic neck dis-
section. SLN biopsy has been reported to aid in the iden-
tification of skip metastases, defined by Byers et al [405]
as metastases that bypass level I and II lymph nodes and
go directly to levels III through V. They demonstrated that
skip metastases were the only manifestation of disease in
the neck after selective neck dissection in approximately
16% of 277 patients evaluated. Such a finding can clearly
explain disease relapse after surgeries which do not
include all five levels. A final potential benefit of radiogu-
ided SLN biopsy is the upstaging of early tumors from N0
to N1 which occurs in 16% to 34% [392,395] of patients
with early squamous cell carcinomas (T1/2) of the oral
cavity and oropharynx. This finding has led to appropriate
therapy of the neck (i.e., neck dissection or radiation), and
unlike in melanoma where lymphatic metastases portend
an extremely poor prognosis, squamous cell carcinomas
of the head and neck region with lymphatic metastases
remain potentially curable.
RIGS
Only one available report can be found in the literature on
the application of RIGS to squamous cell cancers of the
head and neck region [406]. In this report, Argenzio et al
described the intravenous administration of 15 mCi (555
MBq) of 99mTc-labeled anti-CEA monoclonal antibody
fragments in two cases with squamous cell cancer of the
head and neck, with one to the cheek and one to the scalp
[406]. Diagnostic gamma camera imaging was performed
4 and 12 hours after intravenous administration of 99mTc-
labeled anti-CEA monoclonal antibody fragments and
then intraoperative gamma probe detection was used to
assist in the resection of the primary tumor and the assess-
ment of surgical margins at a time approximately 36 hours
after the initial intravenous dosage of this radiopharma-
ceutical. They defined tumor to healthy tissue background
ratio of greater than two as a discriminate value for defin-
ing diseased tissue.
18F-FDG-directed surgery
Only one report is currently available in the literature on
the application of gamma probe detection during 18F-
FDG-directed surgery to squamous cell cancer of the head
and neck region [45]. In this report, Gulec et al [45]
describe a single case in which 18F-FDG-directed surgery
was used the localize a nonpalpable target from a head
and neck cancer at approximately 4 hours after intrave-
nous injection of a unknown dose of 18F-FDG. In an addi-
tional report by Meller et al [44], they describe the use of
a high energy gamma detection probe to preoperatively
identify metastatic lymph nodes in 36 patients with can-
cers of the oral cavity and oropharynx which was per-
formed within a two week period prior to their definitive
surgery and specifically at the time of their diagnostic
whole body PET scan. Patients were intravenously
injected with 6.8 mCi (250 MBq) to 9.5 mCi (350 MBq)World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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of 18F-FDG for the purpose of the preoperative diagnostic
whole body PET scan and for the formalized preoperative
survey of the lymph node levels within the bilateral neck
with a high energy gamma detection probe. Nevertheless,
this high energy gamma detection probe was not utilized
within the intraoperative setting during their definitive
surgical procedure.
Parathyroid disease
Aside from radioguided SLN biopsy for breast cancer and
melanoma, the gamma detection probe has not been uti-
lized more frequently in any other arena than it has in
minimally-invasive radioguided parathyroid surgery for
primary hyperparathyroidism. The traditional surgical
approach to primary hyperparathyroidism has included
bilateral neck exploration with visualizing all parathyroid
tissue and removing the enlarged gland(s). In the hands of
an experienced parathyroid surgeon, this approach has a
success rate of over 95% [407]. However, since a single
adenoma is responsible for at least 85% of all cases of pri-
mary hyperparathyroidism, the use of bilateral neck
exploration has been deemed by some surgeons to repre-
sent vast over treatment of such cases. Coupled with
advances in preoperative localization of parathyroid tis-
sue with preoperative 99mTc-MIBI imaging and intraoper-
ative quick parathyroid hormone assay, minimally-
invasive radioguided parathyroid surgery has become a
viable and widely accepted alternative to that of tradi-
tional bilateral neck exploration in appropriately selected
cases.
Minimally-invasive radioguided parathyroidectomy for primary 
hyperparathyroidism secondary to parathyroid adenomas
In 1984, Ubhi et al [408] first described the use of the
gamma detection probe for intraoperative identification
of 201Tl-thallous chloride in a case of mediastinal parath-
yroid adenoma (Table 1). Then, in 1995, Martinez et al
[409] first described the use of the gamma detection probe
for intraoperative identification of 99mTc-MIBI in patients
with parathyroid gland pathology (Table 1). Later in
1997, the University of South Florida group [410,411]
popularized this technique of using 99mTc-MIBI for the
surgical management of primary hyperparathyroidism
(Table 1). Since that time, multiple other groups of inves-
tigators have published reports describing their experi-
ence with minimally-invasive radioguided
parathyroidectomy for primary hyperparathyroidism
[412-431].
In their initial report, Norman and Chheda from The Uni-
versity of South Florida [410] described their technique of
minimally-invasive radioguided parathyroidectomy in 15
patients and utilized an approach of same-day MIBI imag-
ing and radioguided parathyroid surgery. Patients were
intravenously injected with 20 to 25 mCi (740 to 925
MBq) of 99mTc-MIBI [411]. After completion of preopera-
tive scintigraphic localization of the presumed parathy-
roid adenoma (at approximately 3 hours after the MIBI
injection), patients underwent radioguided parathyroid
surgery. A gamma detection probe was then used to sys-
tematically assess radioactivity in all four quadrants of the
neck. An initial 2 cm skin incision was then made overly-
ing the location of the radioactive parathyroid gland, the
platysma muscle and strap muscles were retracted, and
dissection proceeded with guidance from the gamma
detection probe for identification of the radioactive par-
athyroid gland representing the presumed parathyroid
adenoma. After resection of the radioactive gland, counts
were recorded of the four quadrants of the neck, along
with excised radioactive parathyroid gland, excised fat,
and excised lymph nodes. Parathyroid adenomas were
consistently found to have counts exceeding the postexci-
sional background counts by more than 20%, whereas the
counts of fat and lymph nodes never exceeded 3% of the
postexcision background counts [411]. This finding has
subsequently led to the abandonment of frozen section
pathology for confirmation of the presence of parathyroid
tissue [411]. In their initial report [410], a single parathy-
roid adenoma was located by this technique in 14 of 15
patients, with an average time of approximately 19 min-
utes to find the radioactive parathyroid gland and an aver-
age total operating time of approximately 48 minutes. The
one failed patient was intraoperatively found to have four-
gland hyperplasia as diagnosed by increased background
counts after successful excision of the first targeted radio-
active parathyroid gland. The first 5 procedures were done
under general anesthesia, with all subsequent procedures
being done under local anesthetic.
Instead of utilizing a same-day protocol for MIBI imaging
and radioguided parathyroid surgery, other investigators
have described and recommended utilizing separate days
for MIBI imaging and radioguided parathyroid surgery in
order to allow for more efficient use of operative time by
preselecting those individuals with confirmed localiza-
tion to a solitary parathyroid adenoma on MIBI imaging
for determination of the appropriateness of minimally-
invasive radioguided parathyroidectomy [412,419]. Flynn
et al [412] previously described performing preoperative
MIBI imaging electively before the day of surgery and sub-
sequent intravenous injection of 20 mCi (740 MBq) of
99mTc-MIBI on the day of surgery at a time approximately
60 to 90 minutes preoperatively. In order to decrease the
radiation dose at the time of surgery, Rubello and col-
leagues have developed a low dose 99mTc-MIBI technique
[418-424]. As originally described, Rubello et al [419]
reported performing preoperative double-tracer (99mTc-
pertechnetate and 99mTc-MIBI) subtraction scanning at a
time several days before the proposed surgery to identify
those individuals with a presumed solitary parathyroidWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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adenoma and then, on the day of surgery, those individu-
als who preoperatively localized were subsequently intra-
venously injected with a low dose of 1 mCi (37 MBq) of
99mTc-MIBI just a few minutes prior to the start of surgery.
Both the Flynn et al series [412] and the Rubello et al
series [419] reported excellent intraoperative localization
rates with the gamma detection probe for demonstrating
an abnormal parathyroid gland. Additionally, with the
low dose 99mTc-MIBI technique that was administered just
a few minutes prior to the start of surgery, Rubello et al
[419] demonstrated that all excised parathyroid adeno-
mas had ex vivo radioactivity that was more than 40% of
the postexcision background counts, further confirming
completeness of surgical excision beyond that of the 20%
rule previously established by Murphy and Norman
[411]. Finally, both the Flynn et al series [412] and the
Rubello et al series [419] used an intraoperative quick par-
athyroid hormone assay to aid in the surgical decision-
making process. While Rubello and colleagues [419-
422,424] and Chen et al [428] have strongly advocated
the routine use of the intraoperative quick parathyroid
hormone assay for further confirming completeness of
removal of all hyperfunctioning parathyroid tissue (espe-
cially to aid in the recognition of previously unrecognized
double adenomas or multiple-gland hyperplasia), Flynn
et al [412], Goldstein et al [427], Caudle et al [429], and
Norman and Politz [430] have not. In their series of 112
patients with preoperative localization on an MIBI scan,
Goldstein et al [427] reported a 98% success rate for iden-
tification of a radioactive parathyroid gland based upon
the intraoperative use of the gamma detection probe
alone during minimally-invasive radioguided parathyroid
surgery.
Several authors have discussed the potential advantages of
a minimally-invasive radioguided parathyroid surgical
approach as compared to standard bilateral neck explora-
tion for the surgical management of primary hyperparath-
yroidism. Rubello and colleagues [418-424] have
emphasized several potential advantages of a minimally-
invasive radioguided parathyroid surgical approach for
the surgical management of primary hyperparathy-
roidism. This includes minimizing the invasiveness of the
surgical approach for identifying and resecting solitary
parathyroid adenomas (thus allowing for maximal cos-
metic outcome and the ability to perform such cases with-
out the need of general anesthesia), as well as enhancing
the accuracy of the surgeon to specifically locate ectopic
parathyroid adenomas and ensure complete operative
success by intraoperatively evaluating the postresectional
field for residual radioactivity. Additionally, Flynn et al
[412] has emphasized a modest cost savings of almost one
thousand dollars per patient, particularly due to shorter
operative time, avoidance of general anesthesia, elimina-
tion of the need for both frozen section pathology and
intraoperative quick parathyroid hormone assays, and
earlier hospital discharge. A similar effect on cost was
reported by Goldstein et al. [413] in which they described
a reduction in hospital charges by nearly 50% for the min-
imally-invasive radioguided parathyroid surgical
approach as compared to that of standard neck explora-
tion. Furthermore, a potential benefit of a minimally-
invasive radioguided parathyroid surgical approach for
reoperative parathyroid surgery has been reported in cases
where a failed initial surgical exploration without the use
of the gamma detection probe resulted from what was
labeled as a "false-positive" MIBI scan [414]. In this series
of 17 patients in which a minimally-invasive radioguided
parathyroid surgical approach was utilized for reoperative
parathyroid surgery, Norman et al [414] reported that a
repeat MIBI scan again demonstrated the same focus of
radioactivity and intraoperative use of the gamma detec-
tion probe correctly identified and aided in the excision of
a radioactive parathyroid gland in all 17 patients who
were previously presumed to have an initial "false-posi-
tive" MIBI scan.
Throughout the development of minimally-invasive radi-
oguided parathyroid surgery, identification of an ade-
noma on preoperative MIBI scintigraphic imaging has
been the most important criteria for the determination of
the appropriateness of this surgical approach. However, if
an initial negative MIBI scan is encountered in a patient
with primary hyperparathyroidism, there may still be a
viable role for consideration of MIBI-directed intraopera-
tive gamma probe detection at the time of minimally-
invasive radioguided parathyroid surgery. Lal and Chen
[431] recently described an algorithm for patients with
primary hyperparathyroidism in whom an initial negative
MIBI scan is encountered. In a group of 90 such patients,
this algorithm involved the use of further preoperative
testing with thallium subtraction scanning and neck ultra-
sound, as well as intraoperative bilateral internal jugular
sampling of parathyroid hormone, along with intraopera-
tive quick parathyroid hormone assay, and/or intraopera-
tive MIBI-directed gamma probe detection. Their results
indicated that despite an initial negative MIBI scan, that
67% of such patients had a single adenoma as the cause of
their primary hyperparathyroidism, and 23% of such
patients had successful utilization of intraoperative MIBI-
directed gamma probe detection at the time of minimally-
invasive radioguided parathyroid surgery.
Radioguided parathyroidectomy for hyperparathyroidism secondary 
to hyperplastic parathyroid glands
While the role of utilizing intraoperative gamma probe
detection during radioguided parathyroid surgery is well
established for parathyroid adenomas, few reports have
focused on its effectiveness for hyperplastic parathyroid
glands demonstrated in either primary or secondary/terti-World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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ary hyperparathyroidism [432-440]. This approach was
first successfully reported in 2000 by Rossi et al [432] in
11 patients with persistent hyperparathyroidism undergo-
ing reoperative neck exploration for localizing residual
hyperfunctioning parathyroid tissue and by Navarra et al
[433] in a single patient with recurrent secondary renal
hyperparathyroidism. The largest series to date has been
reported by Chen et al [436], in which they compared the
results of minimally-invasive radioguided parathyroid
surgery in 25 patients with secondary/tertiary hyperpar-
athyroidism with that of 77 patients with primary hyper-
parathyroidism. Their results demonstrated in vivo counts
of parathyroid adenomas and hyperplastic parathyroid
glands did not significantly differ; however, ex vivo counts
were highest in single gland adenomas and lowest in
hyperplastic parathyroid glands. Nevertheless, all hyper-
plastic parathyroid glands still registered ex vivo counts >
20% of postexcision background counts in a setting where
each patient received an intravenous dosage of 10 mCi
(370 MBq) of 99mTc-MIBI at approximately 30 to 60 min-
utes before surgery. Despite this, Rubello et al [424] still
recommend use of the intraoperative quick parathyroid
hormone assay at the time of radioguided parathyroidec-
tomy by the low dose 99mTc-MIBI technique in order to
establish the completeness of removal of additional foci
of hyperfunctioning parathyroid tissue secondary to the
persistence of previously unrecognized hyperplastic par-
athyroid glands.
Radioguided surgical approach to recurrent parathyroid cancer
Parathyroid cancer is an extremely rare entity that has
been reported to occur in 0.1% to 0.4% of patients with
primary hyperparathyroidism [441]. The incidental find-
ing of parathyroid cancer at the time of minimally-inva-
sive radioguided surgery for primary hyperparathyroidism
presumed secondary to a parathyroid adenoma is well-
described in the literature [424]. Nevertheless, only one
report in the literature exists which describes the use of an
intraoperative gamma probe detection of 99mTc-MIBI-avid
tissue during radioguided surgery that is specifically
directed toward parathyroid cancer [442]. In this report,
they describe a case of recurrent parathyroid carcinoma in
which the patient was intravenously injected with 10 mCi
(370 MBq) of 99mTc-MIBI at one hour prior to surgery and
an intraoperative gamma detection probe was used to
localize and aid in the resection of the area of recurrent
disease. In this case, successful resection was verified by
normalization of the postresection parathyroid hormone
level on intraoperative quick parathyroid hormone assay
and for which they report that the patient remains asymp-
tomatic at 17 months after surgery.
Thyroid cancer
Radioguided surgery for thyroid cancer has gained some
attention in recent years. While radioguided SLN biopsy
has been limitedly investigated [443], the mainstay of
radioguided surgery for thyroid cancer has been directed
towards the utilization of iodine-based and 99mTc-labeled
radiopharmaceutical agents for identifying recurrent dis-
ease in both differentiated thyroid cancer and medullary
thyroid cancer.
Despite the standard practice of using total thyroidectomy
and selective 131I remnant ablative therapy for the initial
therapeutic strategy for differentiated thyroid cancer, loco-
regional neck recurrence occurs in approximately 5% to
20% of such patients [444-446]. The application of addi-
tional courses of 131I ablative therapy alone has not
proven adequate for the control of disease recurrence of
differentiated thyroid cancer [444]. In this regard, radi-
oguided surgery offers a mechanism to achieve complete
tumor extirpation of recurrent or persistent disease with a
relatively high degree of sensitivity and specificity. Such a
technique is important in aiding in the detection of occult
disease not readily apparent from a preoperative diagnos-
tic evaluation that may be closely approximated to vascu-
lar structures or that is found within areas of scar tissue
and sclerosis resulting from previous surgeries, external
beam radiation therapy, or high-dose 131I ablative therapy
[446]. This approach allows for the systematic evaluation
of the completeness of surgical resection in extended
operations for recurrent or persistent disease, particularly
in anatomically difficult areas [447].
Numerous radiopharmaceutical agents have been
described for radioguided surgery for recurrent thyroid
cancer. The most logical choices for recurrent differenti-
ated thyroid cancer would include 131I and 123I. However,
a previous history of 131I ablative therapy has been shown
to abolish subsequent uptake of radioiodine in approxi-
mately 65% of previously ablated patients with recurrent
differentiated thyroid cancer [448]. These iodine-negative
recurrent tumors, being resistant to further 131I therapy,
carry a worse prognosis, with reported 2-, 5-, and 10-year
survival rates of 55%, 16%, and 11%, respectively, com-
pared to 91%, 77%, and 62%, respectively, for patients
with iodine-avid recurrent tumors [449,450]. In this
regard, 65% of patients with iodine-negative metastases
have disease that is generally limited to the neck and/or
mediastinum. For such patients, the only effective treat-
ment is radical surgery, which can result in a complete,
sustained remission in up to 50% of cases [451], confirm-
ing the importance of early recognition of recurrent differ-
entiated thyroid cancer, as well as the importance of
assessing whether it is limited to one or more organ sys-
tems. In this regard, radioguided surgery is a potentially
powerful mechanism for managing patients with iodine-
negative metastases in whom a more aggressive treatment
strategy is required.World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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Radioguided surgery of iodine-avid recurrent differentiated thyroid 
cancer and recurrent medullary thyroid cancer with iodine 
radionuclides
The experience of treating differentiated thyroid cancers
with  131I remnant ablative therapy following total thy-
roidectomy has made 131I the most logical radionuclide
for localization of iodine-avid recurrent tumors during
radioguided surgery. Due to the fact that 131I has a rela-
tively long physical half-life (approximately 8 days), as
well as the fact that it is readily available, highly affordable
[26], and can be used to distinguish tumor from that of
background with a collimated gamma detection probe, it
is an ideal radionuclide for detecting iodine-avid recurrent
disease. This approach for using 131I is well reported in the
literature. The first description of radioguided surgery for
thyroid cancer was published in 1956 by Harris et al [3]
and was later refined in 1971 by Morris et al [452], in
which they described using a CsI [Tl] gamma detection
probe to localize thyroid tissue or recurrent thyroid cancer
in patients undergoing neck exploration.
Recently, Rubello et al [446] reported an eight-day proto-
col for radioguided surgery for iodine-avid recurrent dis-
ease, which was modified from the first original protocol
reported by Travagli et al [453]. In this protocol, a thera-
peutic dosage of 100 mCi (3700 MBq) of 131I was orally
administered to hypothyroid patients (serum thyroid
stimulating hormone level > 30 μU/ml) on day 0, with a
whole-body gamma camera imaging (131I scan) per-
formed on day 3. Then on day 5, radioguided neck surgery
was performed with the assistance of a 15-mm collimated
handheld gamma detection probe, and all sites of ele-
vated activity were resected. A subsequent postoperative
neck 131I scan was obtained on day 7 to evaluate the suc-
cess of the surgery, utilizing the remaining radioactivity
from the initial oral dosage of 131I given on day 0. Of the
184 metastatic foci found within the 31 treated patients,
41.3% of extirpated metastatic foci were localized only
with the gamma detection probe and were not seen with
preoperative imaging. The postoperative neck 131I scan on
day 7 showed a negative pattern in 25 of 31 treated
patients (80.6%). As such, the remaining 6 treated
patients showed reduced 131I uptake, suggesting persistent
iodine-avid residual disease. Alternative 131I dosage regi-
mens and different timing regimens for radioguided sur-
gery have been reported. Negele et al [447] reported using
a diagnostic dosage of 131I in the range of 1.9 to 9.5 mCi
(70 to 350 MBq) and radioguided neck surgery performed
at 6 to 8 days after the original 131I dosage. Their utiliza-
tion of a significantly lower diagnostic dosage of 131I,
rather than a therapeutic dosage (100 mCi), avoided the
need for hospitalization prior to the planned radioguided
neck surgery [447]. Furthermore, Scurry et al [454]
reported that radioguided neck surgery was possible for
up to three weeks after the administration of a therapeutic
dosage of 131I.
In an effort to shorten the time interval between radionu-
clide administration and the time to radioguided surgery
for iodine-avid recurrent thyroid cancer, Gallowitsch et al
[455] reported using 123I instead of 131I for radioguided
surgery for recurrent papillary thyroid cancer using an oral
123I dosage of 2 mCi (74 MBq). The short physical half-life
of approximately 13 hours for 123I allows it to be admin-
istered on the day of or on the day prior to the planned
radioguided surgical procedure for an iodine-avid recur-
rent thyroid cancer [455,456]. Unlike 131I, 123I is a pure
gamma photon emitter, is not associated with the poten-
tial stunning effect on subsequent radioiodine uptake,
and produces less radiation exposure to the patient and
the surgeon [456]. This concept of using 123I has also been
similarly applied to recurrent medullary thyroid cancer by
Shimotake at al [457] in which they reported intrave-
nously administering 123I-MIBG at a dosage of 2.7 mCi
(100 MBq) at a time 24 hours prior to the planned radi-
oguided surgical procedure. Despite these potentially
favorable reasons for utilizing 123I instead of 131I, the
greater expense and relatively limited availability of 123I
has contributed to the more popular continued use of 131I
for radioguided surgery for iodine-avid recurrent differen-
tiated thyroid cancers.
Radioguided surgery of iodine-negative recurrent differentiated 
thyroid cancer and recurrent medullary thyroid cancer with 99mTc-
labeled radiopharmaceutical agents, 111In-labeled 
radiopharmaceutical agents, and 18F-FDG
In contrast, radioguided surgery of iodine-negative recur-
rent differentiated thyroid cancer and recurrent medullary
thyroid cancer has focused primarily upon the use of
99mTc-labeled radiopharmaceutical agents, 111In-labeled
radiopharmaceutical agents, and 18F-FDG. While 99mTc-
MIBI [458], 99mTc-dimercaptosuccinic acid (99mTc(V)-
DMSA) [459], and 99mTc-tetrafosmin [460] have all been
utilized for diagnostic gamma camera imaging of iodine-
negative recurrent differentiated thyroid cancers, only
99mTc-MIBI and 99mTc(V)-DMSA have been described for
gamma detection probe-directed radioguided surgery.
Rubello et al [461] reported on 37 patients who under-
went a previous total thyroidectomy and subsequent 131I
ablative therapy for differentiated thyroid cancer and who
later demonstrated evidence of an iodine-negative recur-
rence. Each such patient had an elevated thyroglobulin
level, a negative 131I scan, demonstration of recurrent
locoregional recurrent disease on a preoperative 99mTc-
MIBI scan and on a high-resolution ultrasound, and no
demonstration of distant metastatic disease [461,462].
Then, each patient was taken to the operating suite and,
10 minutes prior to starting the procedure, was intrave-World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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nously injected with 1 mCi (37 MBq) of 99mTc-MIBI. A
gamma detection probe was then used to guide resection
of all foci of 99mTc-MIBI uptake. In total, 66 discrete nod-
ules in 37 patients were identified by both high-resolution
ultrasound and intraoperative gamma probe detection
and were subsequently successfully resected [461]. At fol-
low-up ranging from 9 to 57 months, 27 of 37 patients
remained disease-free. In contrast to other approaches,
the use of 99mTc-MIBI and intraoperative ultrasound for
radioguided surgery of recurrent thyroid cancers is rela-
tively far less expensive and far more available to most
medical facilities.
Just as 99mTc-MIBI has proven benefit for the management
of recurrent differentiated thyroid cancer, 99mTc(V)-DMSA
has been shown to be effective in the diagnostic evalua-
tion of recurrent medullary thyroid cancer, with a detec-
tion sensitivity of 95% [459]. Adams et al [463] reported
on medullary thyroid cancer recurrences in 25 patients
evaluated by preoperative diagnostic tumor localization
imaging by computed tomography, 111In-DTPA-D-Phe1-
octreotide imaging, and 99mTc-(V)-DMSA imaging, as well
as by intraoperative surgical palpation and by radioguided
surgery using an intraoperative gamma probe detection
system. All patients were preoperatively injected with an
intravenous dose of 6 mCi (222 MBq) of 111In-DTPA-D-
Phe1-octreotide and an intravenous dose of 13.5 mCi
(500 MBq) of 99mTc-(V)-DMSA [463]. 111In-DTPA-D-
Phe1-octreotide imaging was performed 4 hours and 24
hours after injection. 99mTc-(V)-DMSA imaging was per-
formed 6 hours after injection. Radioguided surgery was
performed approximately 24 hours after 111In-DTPA-D-
Phe1-octreotide injection and approximately 6 hours after
99mTc-(V)-DMSA injection. They demonstrated lesion
detection sensitivities of 32%, 34%, and 65% for preoper-
ative diagnostic tumor localization imaging by computed
tomography, 111In-DTPA-D-Phe1-octreotide imaging, and
99mTc-(V)-DMSA imaging, respectively [463]. In addition,
lesion detection sensitivities were 65% by intraoperative
surgical palpation and 97% by radioguided surgery using
a combination of channel selection for both 111In and
99mTc on the gamma probe detection unit. In this series,
radioguided surgery detected metastases as small as 5 mm
in greatest dimension, whereas intraoperative surgical pal-
pation detected metastases only greater than or equal to 1
cm in greatest dimension. Likewise, radioguided surgery
was able to identify more than 30% more foci of recurrent
medullary thyroid carcinoma compared with conven-
tional preoperative diagnostic tumor localization imaging
and intraoperative surgical palpation. Despite these
highly encouraging results with recurrent medullary thy-
roid cancer, 99mTc(V)-DMSA is no longer commercially
available for use.
As mentioned above, 111In-DTPA-D-Phe1-octreotide has
been investigated in radioguided surgery for recurrent
medullary thyroid cancer [463]. However, the overall sen-
sitivity of detecting metastases from recurrent medullary
thyroid cancer on diagnostic 111In-DTPA-D-Phe1-octre-
otide imaging [463] is far less than the overall sensitivity
of detecting metastases from iodine-negative recurrent
differentiated thyroid cancer on diagnostic 111In-DTPA-D-
Phe1-octreotide imaging (34% versus 74%, respectively)
[464]. Despite the better overall sensitivity of detecting
metastases from iodine-negative recurrent differentiated
thyroid cancer on diagnostic 111In-DTPA-D-Phe1-octre-
otide imaging, there is no published data on the use of
111In-DTPA-D-Phe1-octreotide imaging for radioguided
surgery for iodine-negative recurrent differentiated thy-
roid cancer.
111In RIGS has been limitedly investigated for recurrent
medullary thyroid cancer in France [465-467]. These stud-
ies have used a two-step radioimmunotargeting system,
consisting of a bispecific antibody (composed of a frag-
ment of anti-CEA monoclonal IgG1 that is coupled chem-
ically with a fragment of anti-DTPA monoclonal IgG1)
and an 111In-labeled bivalent hapten (111In-di-DTPA-
tyrosyl-lysine). Patients were first intravenously injected
with 0.1 mg/kg of body weight of the bispecific antibody.
Approximately three to five day later, patients were then
injected with 2.7 mCi to 10 mCi (100 MBq to 370 MBq)
of the 111In-labeled bivalent hapten. RIGS was then per-
formed approximately two to four days later. Using this
RIGS protocol for detecting recurrent and metastatic med-
ullary thyroid cancer, de Labriolle-Vaylet et al [467] most
recently reported an accuracy of 86%, a sensitivity of 75%,
and a specificity of 90% and suggested its value in the sur-
gical management of this disease process.
The use of 18F-FDG for gamma probe-directed radiogu-
ided surgery of iodine-negative recurrent thyroid tumors
has been recently investigated in a limited fashion
[42,45,47,468-470]. It is well-established that 18F-FDG
PET imaging is particularly useful in the detection of
iodine-negative recurrent differentiated thyroid cancer
with reported sensitivities ranging from 85% to 95%
[471,472] and a specificity as high as 90% [472].
In 2005, Kraeber-Bodéré et al [42] first reported on the use
of  18F-FDG-directed radioguided surgery in 10 patients
with iodine-negative recurrent differentiated thyroid can-
cer. All 10 patients had previously undergone a diagnostic
preoperative 18F-FDG PET/CT scan demonstrating abnor-
mal hypermetabolic activity suggesting cervical recur-
rence, but with no evidence of distant disease. Then, on
the day of surgery, at approximately 30 minutes prior to
the start of the surgical procedure, patients were injected
with a mean dose of 7.2 mCi (265 MBq) of 18F-FDG andWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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a subsequent intraoperative radioguided survey of the
operative field was performed with a handheld gamma
detection probe. Likewise, a completion lymph node dis-
section was performed in all patients after the intraopera-
tive radioguided survey. A total of 12 abnormal findings
were demonstrated on both 18F-FDG PET/CT and on the
intraoperative radioguided survey, with no additional
abnormal finding demonstrated on the intraoperative
radioguided survey with the gamma detection probe.
Based on the results of the completion lymph node dissec-
tion that were performed on all of the patients, they dem-
onstrated that diagnostic preoperative 18F-FDG PET/CT
scan and intraoperative radioguided survey failed to iden-
tify all sites of additional lymph node microscopic metas-
tases in five of the patients.
More recently, Gulec et al [45] reported on four cases of
iodine-negative recurrent thyroid cancer undergoing radi-
oguided surgery among a series of 25 patients with various
malignancies [45]. In this series, patients were injected
with an intravenous dose of 5 to 15 mCi (185 to 555
MBq) of 18F-FDG at approximately 2 to 6 hours prior to
the planned surgical procedure. Subsequent radioguided
surgery was performed with successful localization of
nonpalpable metastatic lymph nodes and other target tis-
sues.
Most recently, Agrawal et al [470] reported on two cases of
iodine-negative recurrent thyroid cancer at The Ohio State
University in which a multimodality approach of periop-
erative  18F-FDG PET/CT imaging (preoperative patient
imaging, specimen imaging, and postoperative patient
imaging), intraoperative gamma probe detection, and
intraoperative ultrasound were utilized for tumor locali-
zation and resection of all sites of hypermetabolic activity.
The two patients were intravenously injected with 15 to
20 mCi (555 to 740 MBq) of 18F-FDG at approximately
120 minutes prior to the planned time of surgery and this
multimodality approach allowed for successful identifica-
tion and resection of all occult sites of iodine-negative
recurrent thyroid cancer.
Radioguided SLN biopsy
The utility of SLN biopsy for differentiated thyroid cancer
remains a topic of major debate. Although it is reported
that up to 80% of differentiated thyroid cancer patients
have neck lymph node metastases when a lymphadenec-
tomy accompanies the total thyroidectomy [473], only a
minority (3% to 30%) of patients will later develop recur-
rent neck disease [473,474]. Furthermore, in an extensive
literature review, Grebe and Hay [474] concluded that
nodal disease at presentation was not a predictor of
patient survival for papillary thyroid cancer. As a result,
the current management of the central neck compartment
lymph nodes consists of intraoperatively identifying sus-
picious lymph nodes, followed by central compartment
and superior mediastinal nodal clearance [475].
In the current literature, only a limited number of studies
have been published on the feasibility of radioguided SLN
biopsy for thyroid cancer [443,476-482]. Those available
studies report success of localization in the range of 78%
to 100%. In those studies, 0.11 mCi to 3.2 mCi (4 MBq to
120 MBq) of 99mTc colloidal human albumin was injected
intratumorally in a total volume of 0.1 mL to 0.5 mL of
normal saline. Preoperative lymphoscintigraphy was gen-
erally performed. The hemithyroidectomy or total thy-
roidectomy was generally performed first, followed by the
radioguided SLN biopsy procedure, in order to minimize
the "shine through" effect which can be especially prob-
lematic in the central neck compartment where the lymph
nodes may be otherwise within close proximity to the thy-
roid gland [476]. Despite these encouraging results, it still
remains unclear as to whether radioguided SLN biopsy
will prove to be of any prognostic value in the manage-
ment of differentiated thyroid cancer.
Parotid gland cancer
Although the generalized concept of a so-called "sentinel
node" was first coined by Ernest Gould in 1960 in parotid
gland cancer [483], only one report exists within the liter-
ature on radioguided SLN biopsy for parotid gland cancer
[484], and this single report also represents the only paper
addressing any aspect of radioguided surgery for this dis-
ease entity. In 2006, Stárek et al [484] reported on six
patients injected in eight divided portions into the parotid
gland equidistantly from the tumor with approximately
1.35 mCi (50 MBq) of 99mTc colloidal human albumin in
a total volume of 2 mL. These patients subsequently
underwent preoperative lymphoscintigraphy, radiogu-
ided SLN biopsy, and elective lymph node dissection. A
SLN was detected in all six cases. In two cases, preopera-
tive lymphoscintigraphy and radioguided SLN biopsy
revealed additional sentinel lymph nodes outside the
usual extent of elective lymph node dissection that is gen-
erally performed for parotid gland cancer. One false-neg-
ative (i.e., a positive SLN outside of the parotid gland) was
seen with demonstration of intraparotid localization only
and was explained by obstruction of the lymphatic out-
flow from the parotid gland by an intraparotid SLN metas-
tasis.
Gynecologic malignancies
Vulvar cancer
The application of the gamma detection probe in radiogu-
ided surgery for vulvar cancer has been limited to radiogu-
ided SLN biopsy. Since its first description by Decesare et
al in 1997 [485], the feasibility of radioguided SLN biopsy
for vulvar cancer has been well evaluated and reported in
the literature [268,269,485-509]. In general, 99mTc sulfurWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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colloid or 99mTc colloidal human albumin have been uti-
lized and injected into two to four intradermal sites
around the primary tumor in a total dosage range from
0.4 mCi (15 MBq) to 4.0 mCi (150 MBq). In the six most
recently published series, localization has been reported
in 93% (n = 40) by Nyberg et al [501], 98% (n = 62) by
Vidal-Sicart et al [502], 95% (n = 41) by Hauspy et al
[503], 100% (n = 43) by Rob et al [504], 95% (n = 39) by
Johann et al [508], and 98% (n = 127) by Hampl et al
[509], with false negative results reported in 0%, 0%, 0%,
0%, 2.2%, and 7.7% of patients, respectively. Bilateral
groin localization has been reported in 19% to 39%
[493,500,502], emphasizing the importance of preopera-
tive lymphoscintigraphy for most effectively performing
radioguided SLN biopsy in vulvar cancer. Currently, there
is a multi-institutional clinical trial (GOG173) for SLN
biopsy for vulvar cancer from the collaborative Gyneco-
logic Oncology Group, starting in December 1999 and as
of September 2007, has enrolled 456 patients from 40
sites [510]. Since 2001, radioguided SLN biopsy became a
mandatory component for enrollment into GOG173 and
316 such patients have been enrolled with 96% localiza-
tion accomplished using the combined radiocolloid and
vital blue dye technique. However, a full disclosure of the
results of GOG173 is still pending completion of patient
enrollment and publication of the data.
Vaginal carcinoma
Radioguided surgery using the gamma detection probe for
vaginal carcinoma has been limited to three small case
report series addressing radioguided SLN biopsy
[490,511,512]. In the largest such radioguided SLN
biopsy series reported in 2004 by van Dam et al [511],
four patients with vaginal carcinoma received a dose of
approximately 1.6 mCi (60 MBq) of 99mTc colloidal
human albumin injected into the normal vaginal mucosa
(at a depth of 4 to 5 mm) in four locations around the vag-
inal tumor. Preoperative lymphoscintigraphy was per-
formed and patients with verified localization were
subsequently taken to the operating room for laparo-
scopic radioguided sentinel lymph node biopsy approxi-
mately three to five hours after the initial 99mTc colloidal
human albumin injection. Localization on preoperative
lymphoscintigraphy was demonstrated in three of four
(75%) cases. Laparoscopic radioguided SLN biopsy was
successful in all three vaginal carcinomas showing locali-
zation on preoperative lymphoscintigraphy.
Cervical cancer
The application of the gamma detection probe in radiogu-
ided surgery for cervical cancer has been limited to radi-
oguided SLN. Since its first description by Verheijen et al
[513] and Kamprath et al [514] in 2000, the feasibility of
radioguided SLN biopsy for cervical cancer has been well
reported in the literature [505-507,515-550]. 99mTc colloi-
dal human albumin, 99mTc sulfur colloid, and 99mTc nano-
colloid have all been used as the radiocolloid. The range
of time for injection of radiocolloid varies from intraoper-
ative, to immediately preoperative, and to as long as 24
hours prior to the planned surgical procedure. Most com-
monly, a total dose of the radiocolloid, ranging from 0.5
mCi (18.5 MBq) to 3.2 mCi (120 MBq), has been recom-
mended for injection into the four quadrants of the cervix,
while attempting to avoid direct intratumoral injection.
In most series, a sentinel lymph node was generally iden-
tified in anywhere from 80% to 100% of patients, a SLN
being positive for metastatic disease in 8% to 30% of
cases, and false-negative rates were generally reported as
approximately 8% with ranges of 0–20% [505-507,515-
550]. The finding of bilateral sentinel lymph nodes is gen-
erally described in approximately half of the patients, and
in as high as 70% of patients in some series. Interestingly,
two of the most recently reported series have demon-
strated an improved detection rate in primary tumors that
are ≤ 2 cm [549,550].
The Arbeitsgemeinschaft Gynäkologische Onkologie
(AGO, German Association of Gynecologic Oncologist)
has recently published the largest series to date on radi-
oguided SLN in cervical cancer [549]. In this multicenter
prospective validation series, patients generally received
1.6 mCi (60 MBq) of 99mTc nanocolloid injected into four
sites beneath intact-appearing cervical epithelium on the
day before surgery and 4 mL of blue dye injected intraop-
eratively after induction of anesthesia in a similar manner.
Data from a total of 590 patients were used for analysis of
the detection rate and data from a total of 507 patients
were used for analysis of the diagnostic accuracy. The
overall detection rate of pelvic SLNs was 88.6%. The over-
all sensitivity was only 77.4%, and this was significantly
less (P < 0.001) than the predefined acceptability mark of
≥ 90%. Nevertheless, the sensitivity in women with
tumors ≤ 20 mm was 90.9%, and bilateral detection was
noted in 87.2% of such patients. The overall negative pre-
dictive value was 94.3% and negative predictive value was
significantly higher (P < 0.001) in patients with tumors ≤
20 mm (99.1%) as compared with patients with tumors >
20 mm (88.5%) The authors concluded that due to the
suboptimal overall sensitivity of 77.4% that complete pel-
vic lymphadenectomy cannot yet be omitted at this time
in the surgical management of cervical cancer. Neverthe-
less, they commented that SLN biopsy should continue to
be investigated in future studies in patients with tumors ≤
2 cm [549].
Finally, the Gynecologic Oncology Group (GOG) has
completed a prospective trial (GOG 206) to determine the
false negative rate in a large randomized prospective trial
in cervical cancer patients. However, their results have notWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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yet been officially reported. [507,551,552]. In this regard,
multiple authors have continued to advocate ongoing
prospective evaluation of SLN biopsy before its routine
use in the surgical management of cervical cancer can be
more universally advocated [505-507,551-554].
Endometrial cancer
The application of the gamma detection probe in radiogu-
ided surgery for endometrial cancer has been limited to
radioguided SLN biopsy. Since its first description by
Pelosi et al in 2002 [555], the feasibility of radioguided
SLN biopsy for endometrial cancer has been well reported
in the literature [505-507,556-574]. Most frequently,
99mTc colloidal human albumin has been used as the radi-
ocolloid. However, 99mTc sulfur colloid and 99mTc phytate
have also been utilized. The range of time for injection of
radiocolloid varies from intraoperative, to immediately
preoperative, and to as long as 24 hours prior to the
planned surgical procedure.
Two major injection techniques have been described for
the injection of the radiocolloid for endometrial cancer.
This includes injection into the uterine corpus and injec-
tion into the cervix. Those authors who injected into the
cervix [555-557,560,562,564,569-572] usually injected a
total dose of the radiocolloid ranging from 1.0 mCi (37
MBq) to 3.24 mCi (120 MBq) into the four quadrants of
the cervix to a depth from 0.5 cm to 1.5 cm on the day
prior to the surgical procedure. Those authors who
injected into the uterine corpus usually inject a total dose
of radiocolloid ranging from 0.8 mCi (30 MBq) to 3.0
mCi (111 MBq) into the corpus of the uterus using several
different schedules and techniques of injection
[558,559,561,563,566-568,572]. Most commonly this is
accomplished hysteroscopically by injecting the radiocol-
loid in a subendometrial fashion in juxtaposition to the
tumor at approximately 2 to 6 hours prior to proceeding
to the operating room for the staging procedure
[561,563,572]. Variations of this technique include those
by Nikura et al [559,568] in which they inject radiocolloid
hysteroscopically into the endometrium on the day before
the surgical procedure and by Delaloye [567] in which
they inject radiocolloid hysteroscopically into the
endometrium in the operating room immediately prior to
starting the staging procedure. Finally, one group [566]
attempted to inject into the subserosal myometrium of
the uterine fundus at three midline sites at the time of the
staging procedure, but achieved only limited success.
In most series, a SLN was generally identified in anywhere
from 70% to 100% of patients, a SLN being positive for
metastatic disease in 14% to 25% of cases, and false-neg-
ative rates were generally reported as 5% or less [505-
507,555-574].
It is important to note, that only one prospective rand-
omized clinical trial exists in the literature for endometrial
cancer [572] which compared the cervical injection
approach (n = 23) to the hysteroscopic subendometrial
injection approach (n = 17) for radiocolloid. There was no
difference in the SLN detection rates for the cervical injec-
tion technique (70%) versus the hysteroscopic suben-
dometrial injection technique (65%). Likewise, no false-
negative results were seen in either group. Interestingly,
this study showed that there were no identifiable aortic
SLNs in the cervical injection group as compared to find-
ing aortic SLNs in 11.8% of patients receiving a hystero-
scopic subendometrial injection.
Ovarian Cancer
Although radioguided surgery is not routinely utilized in
the current surgical management of ovarian cancer, the
application of the gamma detection probe for ovarian
cancer has been limitedly applied to the radioguided
detection of occult primary disease and recurrent disease.
No data are available on radioguided SLN biopsy for ovar-
ian cancer. However, RIGS [149,575-582] and 18F-FDG-
directed surgery [45,53,583] applications of the gamma
detection probe have been investigated.
RIGS
Since first described for ovarian cancer by Martin et al in
1988 [149,578], the feasibility of RIGS has been evaluated
by several groups of investigators [149,575-582]. The
focus of all these RIGS protocols has been the detection of
occult recurrence in those ovarian cancer patients under-
going both second look laparotomy and those undergo-
ing surgery for suspected or confirmed recurrence. Martin
et al [149,578] evaluated 125I-B72.3 murine monoclonal
antibody, McIntosh et al [582] evaluated 125I-CC49
murine monoclonal antibody, and Krag et al [580] evalu-
ated 111I-B72.3 murine monoclonal antibody. Gitsch et al
[575-577] and Jäger et al [579] evaluated 131I-OC125
(anti-CA125) murine monoclonal antibody. Finally, Ind
et al [581] evaluated 99mTc labeled murine monoclonal
antibodies SM3 and H17E2. Each of these RIGS protocols
utilized similar regimens with intravenous injection of 2
to 5 mCi (74 to 185 MBq) of the radiolabeled mono-
clonal antibody at an interval of 4 to 42 days prior to the
planned surgical procedure [149,575-582]. The reported
detection rates for RIGS in these reports ranged from 50%
to 80%. Despite these early promising results, no further
investigations into RIGS for ovarian cancer have been
made in over the last 10 years.
18F-FDG-directed surgery
Most recently, 18F-FDG-directed surgery has been evalu-
ated in the setting of recurrent ovarian cancer [45,53,583].
In 2005, Barranger et al [583] first described 18F-FDG-
directed surgery in a single patient case report for a patientWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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undergoing laparoscopic excision of recurrent ovarian
cancer using a 18F-FDG dose of 0.11 mCi/kg (4 MBq/kg).
The most recent and largest report to date is by Cohn et al
[53] at The Ohio State University. Three patients undergo-
ing laparotomy for recurrent ovarian cancer underwent
preoperative intravenous injection of approximately 10 to
20 mCi (370 to 740 MBq) of 18F-FDG at approximately 60
to 120 minutes prior to the planned surgical procedure. A
combined approach of intraoperative gamma probe
detection, specimen PET/CT imaging, and postoperative
PET/CT patient imaging was utilized, and demonstrated
the feasibility of this approach for establishing the loca-
tion and extent of disease and confirming complete
cytoreduction in selected cases of recurrent ovarian can-
cer.
Urologic malignancies
Penile cancer
The application of the gamma detection probe in radiogu-
ided surgery for penile cancer has been limited to radiogu-
ided SLN biopsy. Nevertheless, the routine use of
radioguided SLN biopsy for penile cancer remains contro-
versial and is yet to be widely adopted [584].
The generalized concept of a so-called "sentinel node" in
our modern medical literature was first coined by Ernest
Gould in 1960 in parotid gland cancer [483] and was then
later most notably attributed to the work of Ramon
Cabañas in 1977 in the area of penile squamous cell car-
cinoma [585], which was based upon Ramon Cabañas'
careful work and meticulous description of lymphade-
nography of the dorsal lymphatics of the penis [586].
Gould's [483] and Cabañas' [585] strict definition of the
"sentinel node" was based on its proximity to a static ana-
tomical landmark (i.e., the angle of the confluence of the
anterior and posterior facial veins and the superficial epi-
gastric vein, respectively) and was not based on actual var-
iations in the pattern of lymphatic drainage. In penile
cancer, based upon utilizing the superficial epigastric vein
as a static anatomical landmark for identifying the so-
called "sentinel node" of penile cancer, multiple groups
reported variable results and very high false-negative rates
[587-591]. Resultantly, controversy has continued about
whether the concept of SLN biopsy is reliable in the man-
agement of the regional lymph nodes in penile cancer.
It was not until 1993, after Krag et al [135] described the
utilization of radioguided SLN biopsy in breast cancer,
that a re-emerging interest developed in the concept of
SLN biopsy for penile cancer. Since 2000, multiple reports
have been published evaluating the feasibility and efficacy
of radioguided SLN biopsy for penile cancer [592-609]. In
general, 99mTc colloidal human albumin or 99mTc sulfur
colloid and have been utilized and injected into one to
four intradermal or subdermal sites around the primary
tumor in a total dosage range from 0.5 mCi (19 MBq) to
3.2 mCi (120 MBq).
In the four largest published series on penile cancer in
which a subsequent formal lymph node dissection was
performed only if a SLN was positive, radioguided locali-
zation was reported in 97% (n = 74) by Valdés Olmos et
al [594], 98% (n = 90) by Tanis et al [597], 98% by Kroon
et al [599], and 96% (n = 75) by Hadway et al [607]. Bilat-
eral groin localization was reported in 81%, 79%, 80%,
and 91%, respectively [594,597,599,607], emphasizing
the extreme importance of preoperative lymphoscintigra-
phy for most effectively performing accurate radioguided
SLN biopsy in penile cancer. A SLN was positive in 22%,
20%, 21%, and 25% of patients, respectively
[594,597,599,607]. In this regard, at a median follow-up
of 28 months, 7 months, and 11 months, respectively,
only 3.6%, 6.3%, and 1.9% of patients with an initial neg-
ative SLN biopsy developed a nodal metastasis in a previ-
ously SLN-negative nodal basin [594,599,607]. Despite
these encouraging results, the routine use of radioguided
SLN biopsy for penile cancer remains controversial within
the field of urological surgery and may not become widely
adopted until there is verification of this technology by a
large prospective randomized clinical trial [584].
Prostate cancer
The gamma detection probe is not routinely used in the
current surgical management of prostate cancer. Never-
theless, radioguided SLN biopsy has been thoroughly
evaluated for its potential application in the surgical man-
agement of prostate cancer and RIGS has been previously
very limitedly investigated.
Radioguided SLN biopsy
The utilization of radioguided SLN biopsy for prostate
cancer was first reported in 1999 by Wawroschek et al
[610]. Since that time, multiple reports have been pub-
lished on the potential application of radioguided SLN
biopsy in the surgical management of prostate cancer
[611-632]. Most frequently, 99mTc colloidal human albu-
min has been used. However, 99mTc phytate, 99mTc sulfur
colloid, and 99mTc rhenium sulfur colloid have also been
utilized. Patients undergo the radiocolloid injection at an
interval from 6 hours to 24 hours before the planned sur-
gery by an ultrasound-guided transrectal approach and
into one to three sites within the peripheral zone of the
prostate gland. Total dosage range for the radiocolloid is
from 1.6 mCi (60 MBq) to 10.8 mCi (400 MBq), which is
injected in a total volume of normal saline from 0.2 mL to
3.0 mL. In most series, a SLN was generally identified in
90% to 100% of patients, a SLN was positive in 12% to
25% of cases, and false negative rates were generally
reported as 5% or less.World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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The largest radioguided SLN biopsy series reported to date
was recently published by Weckermann and associates
from Augsburg, Germany [627]. In their report, they
describe 1,055 patients with clinically organ confined
prostate cancer undergoing radioguided SLN biopsy, pel-
vic lymph node dissection, and radical retropubic prosta-
tectomy. A SLN was detected in all patients. A positive
SLN were found in 205 patients (19.4%), and only two
false negative cases (< 1%) were encountered. One to
three positive lymph nodes were found in 95, 50, and 21
cases, respectively, and more than 3 positive lymph nodes
were found in 41 cases. Approximately 63% of patients
having positive lymph nodes had such positive lymph
nodes found outside the region of the standard pelvic
lymphadenectomy field. Therefore, Weckermann et al
[627] strongly recommended that patients with a positive
SLN should undergo extended pelvic lymphadenectomy
rather than standard pelvic lymphadenectomy since, in
such cases, tumor cells were also additionally detected in
non-SLNs.
Finally, several series have reported upon the feasibility of
laparoscopic radioguided SLN biopsy [622,624,629,632].
Such a minimally-invasive diagnostic approach to the
lymph nodes in the management of prostate cancer may
ultimately prove valuable in the evaluation of the lymph
node status in patients with an intermediate or high risk
of nodal metastases who are either being considered for
external beam radiation therapy or for robotic prostatec-
tomy. However, no prospective randomized data are
available at this time to more fully address this question.
RIGS
The investigation of RIGS in prostate cancer has been lim-
ited to a single report on 125I-B72.3 monoclonal antibody
and a single report on 111In-capromab pendetide. In 1993,
Badalament et al [633] from The Ohio State University
reported their RIGS feasibility study from ten patients
with prostate cancer who were planned for radical retrop-
ubic prostatectomy and bilateral pelvic lymphadenec-
tomy and that were intravenously injected with 2 mCi (74
MBq) of 125I-B72.3 monoclonal antibody at an interval
from 17 to 38 days prior to the anticipated date of surgery.
RIGS successfully localized tumor in all ten patients, iden-
tified otherwise occult bilateral intraprostatic tumor in
three patients, correctly identified regional lymph node
metastases in two patients, and demonstrated no false-
negative results. In 2000, Anderson et al [634] reported a
single case of suspected metastatic prostate cancer in
which the patient was intravenously injected with 5 mCi
(185 MBq) of 111In-capromab pendetide. Four days later,
the patient underwent RIGS with surgical excision of a
RIGS-positive lymph node in the left supraclavicular
region that confirmed the diagnosis of metastatic prostate
cancer. Despite these two early reports on RIGS in prostate
cancer, no further investigations have occurred since that
time.
Testicular cancer
The application of the gamma detection probe in radiogu-
ided surgery for testicular cancer has been only limitedly
investigated in regards to radioguided SLN biopsy and 18F-
FDG-directed surgery.
Radioguided SLN biopsy
To date, only three reports exist in the literature on radi-
oguided SLN biopsy for testicular cancer [635-637]. The
technique of laparoscopic radioguided SLN biopsy was
first described in 2002 for clinical stage I testicular cancer
by Tanis et al [635] and by Ohyama et al [636].
In a series of 5 patients, Tanis et al described the technique
of laparoscopic radioguided SLN biopsy in two patients
[635]. All patients received an intratesticular injection of
1.4 to 3.7 mCi (52 to 135 MBq) of 99mTc colloidal human
albumin in 0.15 to 0.3 ml of normal saline and under-
went subsequent lymphoscintigraphy. The last two
patients underwent same-day transperitoneal laparo-
scopic radioguided SLN biopsy, with identification of two
radioactive SLNs in one patient (with no nodal metastases
identified) and no radioactive SLNs identified in the sec-
ond patient.
In a series of 15 patients, Ohyama et al [636] described the
technique of laparoscopic radioguided SLN biopsy in five
patients. The day before surgery, each patient was injected
into the testicular tissue around the tumor in the testicular
tunica albuginea with 0.2 mCi (7.5 MBq) of 99mTc phytate
in 0.2 ml of normal saline and underwent subsequent
lymphoscintigraphy. The following day, patients one
through ten underwent extraperitoneal laparoscopic ret-
roperitoneal lymph node dissection, patients 11 through
14 underwent extraperitoneal laparoscopic radioguided
SLN biopsy (with 11 to 14 SLNs removed in each patient
and with no nodal metastases identified), and patient 15
underwent extraperitoneal laparoscopic radioguided SLN
biopsy with a subsequent confirmatory extraperitoneal
laparoscopic retroperitoneal lymph node dissection (with
the finding to two micrometastatic disease in SLNs and no
metastatic disease in any non-SLNs). Ohyama et al [636]
simply concluded that extraperitoneal laparoscopic radi-
oguided SLN biopsy is technically feasible, but requires
further clinical study.
Most recently in 2005, Satoh et al [637] reported the most
comprehensive series on radioguided SLN biopsy in 22
patients with clinical stage I testicular cancer. The day
before surgery, each patient was injected into the testicular
tissue around the tumor in the testicular tunica albuginea
with 0.4 mCi (15 MBq) of 99mTc phytate in 0.4 ml of nor-World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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mal saline and underwent subsequent lymphoscintigra-
phy. The following day, patients underwent
extraperitoneal laparoscopic radioguided SLN biopsy
with a subsequent confirmatory extraperitoneal laparo-
scopic retroperitoneal lymph node dissection. Radioactive
SLNs were identified in 21 of 22 patients (95%), with one
radioactive SLN identified in 15 patients and 2 to 4 radio-
active SLN identified in the six other patients. Only two
patients (9.5%) had micrometastatic disease in radioac-
tive SLNs. Likewise, none of the 21 patients in which a
radioactive SLN was identified had metastatic disease in
any non-SLNs harvested at the time of the subsequent
confirmatory extraperitoneal laparoscopic retroperitoneal
lymph node dissection. Two patients with no metastatic
disease in their radioactive SLNs or in their subsequent
confirmatory extraperitoneal laparoscopic retroperitoneal
lymph node dissection developed lymph node disease in
the paraaortic lymph nodes at the level of the renal vein
and in the obturator lymph nodes at 10 and 20 months
after surgery, respectively. Satoh et al [637] concluded that
extraperitoneal laparoscopic radioguided SLN biopsy is
technically feasible and has potential value in staging and
treatment of patients with early-stage testicular cancer.
Nevertheless, the lack of any other subsequent reports in
the literature or the mention of radioguided SLN biopsy in
the National Comprehensive Cancer Network (NCCN)
clinical guidelines for testicular cancer [638] leads one to
conclude that this is not yet considered an accepted stand-
ard of care.
18F-FDG-directed surgery
There is a single reported case in the literature by Gulec et
al [43] for using 18F-FDG-directed surgery for the identifi-
cation and resection of a hypermetabolic metastatic peri-
aortic lymph node in a case of seminoma.
Bladder cancer
Within the published literature, the application of the
gamma detection probe in radioguided surgery for blad-
der cancer has been limited to only a small number of
reports from Sweden on radioguided SLN [639-642]. In
all instances, 99mTc colloidal human albumin has been
utilized and injected into four peritumoral sites within the
detrusor muscle in a total dosage range from 1.4 mCi (50
MBq) to 1.9 mCi (70 MBq). In 2001, Sherif et al [639]
were the first to report on 13 bladder cancer patients in
which localization was seen in 11 of 13 patients (85%),
with four patients having a positive SLN, and with no
false-negative results. In 2003 Liedberg et al [640]
reported on 26 bladder cancer patients in which localiza-
ti o n  w a s  s e en  i n  2 1  o f  26  p a t i e n t s (8 1 % ) ,  w i th  s e v e n
patients having a positive SLN, and with one false-nega-
tive result. In 2006, Liedberg et al [641] reported on 75
bladder cancer patients in which localization was seen in
65 of 75 patients (87%), with 26 patients having a posi-
tive SLN, and with six false-negative results (19%).
Despite the higher false-negative rate reported by Liedberg
et al [641], a common theme to all these reports has been
that approximately one-quarter of all patients that local-
ized had a SLN that was anatomically located outside the
field of the normally excised lymph nodes of the obtura-
tor fossa, thus leading to improved overall lymph node
staging when radioguided SLN biopsy was used in con-
junction with standard lymphadenectomy. Finally, Sherif
et al [642] demonstrated that the use of fused single-pho-
ton emission computed tomography (SPECT) and com-
puted tomography (CT) preoperative imaging aided in
the intraoperative identification of both metastatic and
non-metastatic SLNs.
Renal cell cancer
Only two reports involving cases of renal cell cancer can
be found within the published literature that focus on the
use of the gamma detection probe in radioguided surgery
[29,643]. Both reports involve RIGS with the utilization of
monoclonal antibodies. However, only one of these two
reports describes the use of a particular monoclonal anti-
body that is specific to renal cell carcinoma [29].
Recently, in 2008, Strong et al [29], reported on two cases
of clear-cell renal cell cancer in which RIGS was performed
using the monoclonal antibody cG250 and 124I (Table 1).
cG250 is well known to bind with a high specificity to
clear-cell renal cell cancers [644-646]. The specific antigen
target of cG250 is an epitope of carbonic anhydrase IX
[29,646]. In these two RIGS cases in the Strong et al series
[29], the patients were each intravenously injected with 5
mCi (187 MBq) of 124I-labeled cG250 approximately
seven days prior to surgery. PET imaging was performed
four hours post-injection of 124I-labeled cG250 and then
again approximately seven days later at a time specifically
within three hours of the start of surgery. Intraoperatively,
both a gamma detection probe and a beta detection probe
were utilized for tumor identification. No significant dif-
ference in the ratio of tumor/background counts were
found for the two different types of radiation detection
probes utilized.
The incidental finding of metastatic renal cell cancer at the
time of RIGS performed for a presumed primary colon
cancer was previously reported by Avital et al in 1998
[643]. In this report, a 72 year old female with a remote
history of renal cell cancer requiring a right nephrectomy
some five years earlier and who was now presumed to
have a primary colon cancer underwent RIGS after receiv-
ing an intravenous injection of 2 mCi (74 MBq) of 125I-
labeled murine CC49 monoclonal antibody approxi-
mately three weeks prior to surgery. After pathologic eval-
uation of the case, it was determined that the colonic mass
was, in fact, a metastatic renal cell cancer deposit that hadWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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metastasized to and through all layers of the colonic wall.
Immunohistochemistry revealed that the tumor cells
composing the metastatic renal cell cancer were them-
selves negative for CC49 monoclonal antibody staining.
However, the normal colonic mucosa adjacent to the met-
astatic renal cell cancer demonstrated strong CC49 mono-
clonal antibody staining. Therefore, in retrospect, the
adjacent normal colonic mucosa and not the remotely
occurring metastatic renal cell cancer deposit was respon-
sible for the accumulation of the 125I-labeled murine
CC49 monoclonal antibody detected at the time of RIGS.
Thoracic malignancies
Lung cancer
The use of a gamma detection probe in lung cancer dates
back to 1984 when Woolfenden et al [647] first described
using a miniature NaI [Tl] detector during fiberoptic bron-
choscopy to attempt to detect and localize sites of deposit
of 57Co bleomycin in 34 patients with suspected lung can-
cer. Despite the promising results of this report, the
extremely long physical half-life of 57Co (271.8 days) has
made it a highly undesirable radionuclide for any further
use in radioguided surgical procedures. Since that time,
radioguided surgery for lung cancer has been further
investigated using 99mTc for radioguided SLN biopsy,
using  125I-labeled and 99mTc-labeled monoclonal anti-
bodies for RIGS, as well as using 99mTc-peplomycin and
18F-FDG for other radioguided surgical applications.
Radioguided SLN biopsy
The utilization of radioguided SLN biopsy for non-small
cell lung cancer was first reported in 2000 by Liptay et al
[648]. Since that time, multiple reports have been pub-
lished on the potential application of radioguided SLN
biopsy in the surgical management of non-small cell lung
cancer [649-668]. 99mTc tin colloid, 99mTc sulfur colloid,
and 99mTc colloidal human albumin have all been utilized
in radioguided sentinel lymph node biopsy for non-small
cell lung cancer. Some authors have advocated preopera-
tive injection of radiocolloid into or around the primary
tumor by CT guidance on the day of surgery or on the day
before surgery. Other authors have advocated intraopera-
tive injection of radiocolloid into or around the primary
tumor after direct visualization of the tumor. While still
other authors advocate intraoperative endobronchial
injection of radiocolloid into directly visualized endo-
bronchial tumor or transbronchially at the most distal
pulmonary sub-segment that could be reached endobron-
chially within proximity to the primary tumor. Total dos-
age range for the radiocolloid is from 0.25 mCi (9.25
MBq) to 8 mCi (296 MBq), which is injected in a total vol-
ume of normal saline from 0.5 mL to 2.0 mL. In all series
reporting more than one hundred patients undergoing
radioguided SLN biopsy for non-small cell lung cancer
[657,659,662,668], a SLN was generally identified in 70%
to 100% of patients and false negative rates were generally
reported as 10% or less. Despite these numerous reports
and their encouraging results, the routine use of radiogu-
ided SLN biopsy in the surgical management of non-small
cell lung cancer has not been embraced. Nevertheless,
those authors who have played an active role in its evalu-
ation in the surgical management of non-small cell lung
cancer remain optimistic about its future applications
[669].
RIGS
The application of RIGS technology to adenocarcinoma of
the lung has been previously investigated and reported in
an extremely limited fashion [670,671]. In 1998, Grazia et
al [670] intraoperatively evaluated 9 patients with adeno-
carcinoma of the lung with the gamma detection probe
after intravenous injection of 0.9 to 1.5 mCi (33 to 56
MBq) of 125I-labeled monoclonal antibody B72.3 at 11 to
44 days (mean of 20.4 days) prior to the surgical proce-
dure. Specific binding to histologically confirmed sites of
adenocarcinoma of the lung was noted in all such cases.
However, the high radioactive background counts found
in the thorax, due to the heart and major vessels, was pos-
tulated as a drawback to further investigation of this tech-
nique. Likewise, in 1998, Mansi et al [671], evaluated
both 125I-labeled monoclonal antibody B72.3 and 99mTc-
labeled fragments of the murine anti-CEA monoclonal
antibody F023C5 in lung cancer patients. In the first
phase of their study, using immunohistochemistry, they
found binding of monoclonal antibody B72.3 in only 6 of
45 primary non-small cell lung cancers. Only one opera-
ble patient was then intravenously injected with 2 mCi
(74 MBq) of 125I-labeled monoclonal antibody B72.3 and
no selectivity for neoplastic cells was seen during RIGS
using the gamma detection probe. In the second phase of
their study, 11 patients with squamous cell lung cancer
were intravenously injected with 15 mCi (555 MBq) of
99mTc-labeled fragments of the murine anti-CEA mono-
clonal antibody F023C5. Immunoscintography was then
performed six to 24 hours thereafter. Only one patient
was operable and underwent RIGS in concert with a pneu-
monectomy and lymphadenectomy at a time some 36
hours after the original intravenous injection of the 99mTc-
labeled fragments of the murine anti-CEA monoclonal
antibody F023C5. Using the gamma detection probe, in
vivo  detection of the primary tumor was not accom-
plished; however, resected neoplastic tissue demonstrated
a 2:1 tumor-to-background ratio on ex vivo counting. Like-
wise, RIGS identified a small lymph node metastasis that
was not previously identified by CT scan or immunoscin-
tigraphy. Despite these two early reports on RIGS in lung
cancer, no further investigations have occurred since that
time.World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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99mTc-peplomycin radioguided surgery
In 2003, Wang et al [672] reported on a series of 37
patients with lung neoplasms who were intravenously
injected with a non-specified dose of 99mTc-peplomycin.
Peplomycin is a semi-synthetic analog of bleomycin. Fol-
lowing injection, patients underwent preoperative scinti-
graphic imaging for identification of radiotracer uptake by
tumor-bearing tissue and were then subsequently taken to
the operating room for radioguided surgery using the
gamma detection probe. The sensitivity, specificity, and
accuracy was reported as 90%, 88%, and 89%, respec-
tively, for identifying malignant lung lesions, and was
reported as 91%, 88%, and 90%, respectively, for identi-
fying lymph node metastases.
18F-FDG-directed surgery
Much more recently, the application of intraoperative
gamma probe detection after a preoperative same-day
injection of 18F-FDG has been reported in a limited
number of selected cases of non-small cell lung cancer
[45,673,674]. First reported in 2006, Nwogu et al [673]
evaluated 10 patients with non-small cell lung cancer that
were intravenously injected with approximately 10 mCi
(370 MBq) of 18F-FDG on the day of surgery. All resected
primary tumors were FDG-avid. With regards to evalua-
tion of the thoracic lymph nodes, there were 5 cases of
true-positive FDG-avid thoracic lymph nodes, 3 cases of
false positive FDG-avid thoracic lymph nodes, and 2 false-
negative cases in which the thoracic lymph nodes were
not FDG-avid but were found to contain metastatic dis-
ease. In this regard, and of most recent note, Moffatt-Bruce
et al at The Ohio State University [674] has recently
reported a combined approach for radioguided localiza-
tion of FDG-avid tissues for a single case of lung cancer
using perioperative 18F-FDG PET/CT imaging (using a
triad of preoperative PET/CT imaging, specimen PET/CT
imaging, and postoperative PET/CT imaging) and intra-
operative gamma probe detection, in which a dose of
approximately 26.1 mCi (966 MBq) 18F-FDG was injected
intravenously approximately 98 minutes prior to the start
of radioguided localization of FDG-avid tissues.
Pulmonary nodules
The application of the gamma detection probe for the
intraoperative localization and video-assisted thoraco-
scopic wedge resection of solitary or multiple small inde-
terminate pulmonary nodules has been investigated [675-
683]. Generally, on the morning of surgery, such pulmo-
nary lesions are injected under CT guidance with 99mTc
colloidal human albumin in dosage range from 0.14 mCi
(5 MBq) to 0.30 mCi (11 MBq) and in a total volume of
normal saline from 0.1 mL to 0.3 mL. Subsequently, such
patients are taken to the operating room for video-assisted
thoracoscopic wedge resection of these previously
injected pulmonary nodules. In the largest and most
recent study conducted to date, Grogan et al (683)
reported that pulmonary nodules were successfully local-
ized and excised by this radioguided technique in 77 of 81
patients (95%), and were exclusively thoracoscopically
excised in 71 of 77 patients (92%).
Neuroendocrine tumors
Gastroenteropancreatic (GEP) neuroendocrine tumors
While GEP neuroendocrine tumors generally follow a
protracted clinical course, surgery remains integral in the
management of localized primary tumors, recurrent dis-
ease, or metastatic disease [684-687]. Therefore, the abil-
ity to detect and localize GEP neuroendocrine tumor
tissue is paramount to the effectiveness of surgical treat-
ment and was revolutionized by Krenning's landmark
description of radiolabeled octreotide scintigraphy using
111In-DTPA-D-Phe1-octreotide and 123I-Tyr3-octreotide,
which both specifically target somatostatin receptors
[688]. As a result, 111In-DTPA-D-Phe1-octreotide imaging
has been coupled with single photon emission computer-
ized tomography (SPECT) to become the primary imaging
and staging modality of patients with GEP neuroendo-
crine tumors, exceeding the sensitivity of MRI and CT
[689,690]. Despite this well-established preoperative
imaging technology, intraoperative localization of such
disease has remained a formidable challenge with nega-
tive laparotomy rates reported as high as 30% for patients
with ileal and pancreatic endocrine tumors [686,691].
The intraoperative application of ultrasound, transduode-
nal illumination, and duodenotomy has been advocated
by some [692] to pinpoint GEP neuroendocrine tumors
particularly of the duodenum and pancreatic head region,
a location historically known as the "gastrinoma triangle."
Another approach to intraoperative localization of GEP
neuroendocrine tumors is use of the gamma detection
probe for radioguided surgery. Radiopharmaceutical
agents utilized for intraoperative detection of GEP neu-
roendocrine tumors include 111In-DTPA-D-Phe1-octre-
otide [693-695], 125I-Tyr3-octreotide [696,697], 123I-
MIBG [690], and 99mTc-EDDA/HYNIC octreotate [698].
However, the use of 111In-DTPA-D-Phe1-octreotide has
become far more prevalent for several reasons. First, the
considerably shorter physical half-life of 111In (approxi-
mately 68 hours) as compared to 125I (approximately 60
days) make 111In more desirable secondary to the impor-
tance of radiation safety issues related to the storage and
disposal of radioactive materials [49]. Second, the pre-
dominant hepatobiliary excretion of 125I-Tyr3-octreotide
leads to a considerable amount of intestinal activity,
reducing the reliability of somatostatin receptor imaging
[688]. Third, the intestinal clearance of 111In-DTPA-D-
Phe1-octreotide can be overcome by the administration of
laxatives. Lastly, the intraoperative tumor to background
ratio is improved with most cases, demonstrating a ratioWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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greater than 4:1 [694]. Despite these relative advantages
and disadvantages, 111In, 125I, 123I and 99mTc radiophar-
maceutical agents have all been utilized to detect primary,
recurrent, and metastatic lesions from multiple GEP neu-
roendocrine tumors, including gastrinomas, carcinoids,
and insulinomas.
The standard technique for radioguided surgery of GEP
neuroendocrine tumors involves the intravenous injec-
tion of 111In-DTPA-D-Phe1-octreotide at dosage range of
3.0 to 6.0 mCi (110 to 220 MBq) [684,687,694] with sub-
sequent 4-hour and 24-hour whole body scintigraphy and
24-hour SPECT imaging. Surgical exploration is per-
formed approximately 48 to 72 hours post-injection and
is preceded by a bowel preparation to minimize the back-
ground radiation from physiologic bowel excretion of
111In-DTPA-D-Phe1-octreotide. A higher energy gamma
detection probe (with a gamma photon energy range at or
above the 247 keV photopeak of 111In) is required. Once
an area of high radioactivity is located, the gamma detec-
tion probe is held stationary and 10-second counts are
obtained. A tumor to background ratio of at least 1.5 or
greater is required for confirmation of the tissue localiza-
tion [687]. If 125I-Tyr3-octreotide is utilized instead of
111In-DTPA-D-Phe1-octreotide, the radiopharmaceutical
agent is given the day of the procedure with Lugol's solu-
tion (a solution containing 5% iodine [I2] and 10% potas-
sium iodide [KI] in 85% distilled water with a total iodine
content of 130 mg/mL) administered three days immedi-
ately before the planned surgery to prevent excessive thy-
roidal uptake of unbound 125I [697].
As reported by Adams and Baum [684], the use of the
gamma detection probe with 111In-DTPA-D-Phe1-octre-
otide has increased the intraoperative detection of GEP
neuroendocrine tumors, thus identifying 57% more
lesions than with conventional surgical palpation. In
addition, the intraoperative gamma detection probe was
able to identify small tumors (even down to less than 5
mm in size) more efficiently than somatostatin receptor
scintigraphy (greater than 90% versus 68% to 77%,
respectively) [684]. As a result of this improved detection
rate, cytoreductive radioguided surgery for GEP neuroen-
docrine tumors has resulted in improved long-term out-
comes for patients with recurrent disease and/or
metastatic disease [685,699]. In recurrent tumor surgery,
much of the operative field is obscured with scar tissue
prohibiting accurate localization with palpation. Radi-
oguided surgery can distinguish tumor from scar tissue,
thereby significantly aiding in the surgical dissection and
extirpation of all sites of tumor [695,696]. As a result,
radioguided surgery for detection of with 111In-DTPA-D-
Phe1-octreotide with the gamma detection probe has
proven to be a useful adjunct in the management of GEP
neuroendocrine tumors.
In a recent report by Hubalewska-Dydejczyk et al [698],
they describe the use of 99mTc-EDDA/HYNIC octreotate
for radioguided surgery in patients with suspected GEP
neuroendocrine tumors who had negative results on other
preoperative imaging tests. Based on an 18.9 mCi (700
MBq) dose of 99mTc-EDDA/HYNIC octreotate intrave-
nously injected 24 hours prior to surgery, radioguided
detection of this new somatostatin analogue with the
gamma detection probe was successful in identifying both
carcinoid tumors and islet cell tumors within the study
group.
Recently, 68Ga has been labeled to octreotide by way of
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
acetic acid), a macrocyclic chelator, for the creation of
68Ga-DOTA-Tyr3-octreotide [687,700] for the preopera-
tive scintigraphic detection of GEP neuroendocrine
tumors. The radionuclide 68Ga has a physical half-life of
approximately 68 minutes and decays by 89% through
positron emission of a maximum energy of 1.92 MeV
(making it ideal for PET imaging) and by 11% through
orbital electron capture. 68Ga-DOTA-Tyr3-octreotide has
recently been described as a potentially highly desirable
radiopharmaceutical agent for radioguided surgery for
GEP neuroendocrine tumors [687]. Nevertheless, to date,
no clinical studies involving actual radioguided surgical
procedures for GEP neuroendocrine tumors have been
published to substantiate this claim for 68Ga-DOTA-Tyr3-
octreotide.
Most recently, 18F-L-dihydroxyphenylalanine (18F-L-
DOPA) was utilized for combined preoperative PET/CT
imaging and radioguided surgery with the gamma detec-
tion probe for the detection of multiple site of metastatic
GEP neuroendocrine tumor in a single patient with 111In-
DTPA-octreotide negative disease [701]. However, more
time will be needed to thoroughly assess whether this 18F-
based technology will become clinically relevant in the
surgical management of metastatic GEP neuroendocrine
tumor.
Bronchial carcinoids
Only two case reports exist in the literature describing
radioguided surgery with 111In pentetreotide for bronchial
carcinoids. In 1997 Mansi et al [702] reported on a 28 year
old male patient with Cushing's syndrome from an adren-
ocorticotrophin (ATCH)-secreting bronchial carcinoid
who, four days after receiving a 3 mCi (111 MBq) intrave-
nous injection of 111In-DTPA-D-Phe1-octreotide, under-
went radioguided surgery with the assistance of a gamma
detection probe and which allowed for accurate localiza-
tion and resection of a 1.8 cm tumor in the right lower
lobe with in vivo tumor to normal surrounding tissue
count ratios of 6:1 and ex vivo tumor to normal surround-
ing tissue count ratios of 18:1. Similarly, in 2005, Gross-World Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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rubatscher et al [703] reported on a 28 year old female
patient with Cushing's syndrome from an adrenocortico-
trophin (ATCH)-secreting bronchial carcinoid who, two
days after receiving a 4 mCi (148 MBq) intravenous injec-
tion of 111In-DTPA-D-Phe1-octreotide, underwent radi-
oguided thoracoscopic surgery with the assistance of a
gamma detection probe and which allowed for accurate
localization and resection of multiple metastatic lymph
nodes within the upper mediastinal region.
Neuroblastoma
Only very limited data are available on the use of the
gamma detection probe during radioguided surgery for
neuroblastoma [684,704-707]. This was first reported in
1995 by Martinez et al [704] in six pediatric patients with
stage II or IV neuroblastoma using an intravenous injec-
tion of approximately 0.03 to 0.2 mCi (1.1 to7.4 MBq) of
125I-Tyr3-octreotide given 1.8 to 7.5 hours prior to surgery.
The gamma detection probe found 17 sites of 125I-Tyr3-
octreotide binding, and of which 15 sites contained neu-
roblastoma. Five of these 15 sites of neuroblastoma were
occult and were not detected by standard intraoperative
palpation and visualization. Next, in 1997, Heij et al
[705] reported on five pediatric patients with recurrent
abdominal neuroblastoma that were intravenously
injected with 5 mCi (185 MBq) of 123I-MIBG that was
given 48 hours prior to surgery. The gamma detection
probe correctly identified tumor seen on preoperative
MIGB scan in all five patients. Thereafter, in 1998, Martelli
et al [706] reported the largest series of 66 radioguided
surgical procedures in 58 pediatric patients undergoing
intraoperative localization of neuroblastoma with the
gamma detection probe and utilizing either 123I-MIBG
(mean dose of 5 mCi or 185 MBq intravenously injected
24 to 48 hours before surgery) or 125I-MIBG (mean dose
of 0.11 mCi or 4 MBq intravenously injected three to five
days before surgery). A tumor to background ratio that
exceeded 2:1 was considered positive for target localiza-
tion, and in 65% of the cases, the gamma detection probe
was considered helpful. The gamma detection probe per-
mitted detection of small, nonpalpable tumors in sites
that were difficult to access surgically as well as aided in
more accurately defining tumor margins or areas of tumor
extension. The sensitivities of the 123I-MIBG and 125I-
MIBG were similar, at 91% and 92% respectively. How-
ever, the specificity of 125I-MIBG was significantly higher
than 123I-MIBG (85% as compared to 55%, respectively).
Comparable results for 123I-MIBG and 125I-MIBG in neu-
roblastoma patients were reported by Adams and Baum
[684]. In addition, Adams and Baum [684] attempted
intraoperative neuroblastoma localization with 111In-
DTPA-D-Phe1-octreotide. However, they found the uri-
nary excretion of the radionuclide limited the use of the
gamma probe in tissues adjacent to the kidneys and ure-
ters.
Pheochromocytoma
MIBG scintigraphy, with a sensitivity and specificity as
high as 88% and 96%, respectively, is the technique of
choice for the localization of pheochromocytoma [708].
Only very limited data is available on intraoperative local-
ization of pheochromocytomas with iodine-based radiop-
harmaceutical MIBG agents, including 131I-MIBG [709],
125I-MIBG [710,711], and 123I-MIBG [463] and has con-
firmed the feasibility of this technique. The technique for
preoperative administration of the iodine-based radiop-
harmaceutical MIBG agent varies based on the physical
half-life of the agent, with Proye et al [710] reporting
intravenously injecting 0.5 mCi to 1.0 mCi (18 MBq to 37
MBq) of 125I-MIBG approximately 3 days before surgery
with thyroid blockade and with Adams et al [463] report-
ing intravenously injecting 4.9 mCi (180 MBq) of 123I-
MIBG approximately 4 to 5 hours before surgery without
thyroid blockade. Tumor to background ratios exceeding
5:1 were achieved [710,711]. Detection of tumor foci less
than or equal to one centimeter in size was demonstrated
[711]. However, Adams et al [463] suggested that avid
hepatic and biliary signals may overshadow potential
intraoperative sites of pathologic MIGB uptake seen on
whole body scanning, especially in the subdiaphragmatic/
paravertebral region, and may lead to low tumor to back-
ground ratios of 1.5:1.0. As a result, only very limited
acceptance of this radioguided surgical technique has
been given since these early published series.
Adrenocortical carcinoma
The use of the gamma detection probe in radioguided sur-
gery for adrenocortical carcinoma is virtually nonexistent.
Only one report exists in the literature that describes a sin-
gle case of 18F-FDG-directed surgery for adrenocortical car-
cinoma [45]. In this report, 18F-FDG-directed surgery was
instrumental in locating difficult to access metastatic
lymph nodes at the time of a combined sternotomy and
laparatomy.
Sarcoma
The application of the gamma detection probe for the sur-
gical management of sarcoma has been extremely limited.
The vast majority of sarcoma histologic subtypes metasta-
size only hematologically. Nevertheless, a few sarcoma
histologic subtypes have a propensity for lymphatic dis-
semination, such as rhabdomyosarcoma, epithelioid sar-
coma, clear cell sarcoma, and synovial sarcoma [712]. In
this regard, radioguided SLN biopsy has been limitedly
investigated in some of these select sarcoma histologic
subtypes [713-722]. These reports are limited to a few case
reports [714,716,717,719] and to a few small series
[713,715,718,720-722]. Most frequently, 99mTc colloidal
human albumin, 99mTc sulfur colloid, and 99mTc rhenium
sulfur colloid have been utilized. However, the timing of
injection, site of injection, and total dosage range for theWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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radiocolloid have generally not been well-characterized in
these limited reports.
The largest series reported to date was recently published
by Kayton et al [721]. In their report, they described 23
pediatric patients with sarcoma (9 rhabdomyosarcomas,
4 epithelioid sarcomas, 2 synovial sarcomas, 2 alveolar
soft part sarcomas, 2 fibrosarcomas, 2 clear cell sarcomas,
1 Ewing sarcoma, and 1 angiomatoid fibrous histiocy-
toma) undergoing radioguided SLN biopsy using a dosage
range of 0.05 mCi (1.9 MBq) to 0.8 mCi (29.6 MBq) of
99mTc sulfur colloid that was injected into one to four
locations at the site of the primary tumor. A SLN was
detected in all patients. A positive SLN was found in only
one patient (4.3%). Since the radioguided SLN biopsy was
not accompanied by a confirmatory lymph node dissec-
tion, a false negative rate could not be determined.
Brain tumors
Radioguided surgical resection of brain tumors has been
investigated in a very limited fashion [723-727]. In 2002,
Vilela Filho and Carneiro Filho [723] first described use of
99mTc-MIBI, in a dose of 30 mCi (1110 MBq), for gamma
probe-assisted resection of a metastatic renal cell carci-
noma to the right parietal lobe. In 2004, Kojima et al
[724] reported on the use of 99mTc-MIBI, in an unknown
dose, for gamma probe-assisted resection in 13 patients
with either primary or recurrent astrocytomas or meta-
static brain lesions. In 2005, Gay et al [725] reported on
the use of 111In-(DTPA)-D-Phe1 pentetreotide, an analog
of somatostatin, in a dose of 3 mCi (111 MBq), for
gamma probe-assisted resection in 10 patients with en
plaque meningiomas. In 2006, Serrano et al [726] reported
on the use of 201Tl, in a dose of 1.4 mCi (50 MBq), for
gamma probe-assisted resection of an astrocytoma of the
right temporoparietal region. Finally, in 2007, Bhanot et
al [727] reported on the use of 99mTc-MIBI, in a dose of 10
mCi (370 MBq), for gamma probe-assisted resection in 13
patients with supratentorial gliomas. However, at this
time, other methods of intraoperative neurosurgical navi-
gation, such as with magnetic resonance imaging and
ultrasound, which do not utilize radioactive substances,
remain the standard of care.
Bone lesions
The use of the gamma detection probe in radioguided sur-
gery has been extensively described for radioguided
biopsy and/or resection of benign bone lesions, such as
osteoid osteomas [728-742] and enchondromas [743], as
well as suspected bone metastases [743-755]. The applica-
tion of gamma detection probe technology for radiogu-
ided biopsy and/or resection of bone lesions in the early
1980s [728,743] truly represents some of the early for-
ward thinking that contributed to the later development
of the modern era of radioguided surgery (Table 1).
The technique radioguided biopsy and/or resection of
bone lesions utilized the same class of radiopharmaceuti-
cal agents (99mTc diphosphonates) and the same dosing
range as is utilized for diagnostic bone scanning. The most
common 99mTc diphosphonates utilized are 99mTc MDP,
99mTc HMDP, and 99mTc HDP. These radiopharmaceutical
agents are administered by a peripheral intravenous injec-
tion in a dosing range of approximately 15 mCi (555
MBq) to 30 mCi (1,110 MBq) at a time approximately 2
to 12 hours prior to the planned surgical procedure. Rea-
sonable success has been reported with guiding diagnostic
biopsy of such lesions as well as guiding the surgeon for
complete surgical resection of such lesions. Nevertheless,
this technique, as it relates to bone lesions, has not
become a part of the mainstream clinical practice for the
biopsy and/or resection of bone lesions.
Lymphoma
The application of intraoperative gamma probe-directed
biopsy of suspicious lesions for confirming the diagnosis
of lymphoma has been very limited [43,45,746,755,756].
Robinson et al [747] described using 99mTc HMDP for
intraoperative gamma probe-directed biopsy of two rib
lesions representing lymphoma. Schattner et al [756]
described using 67Ga for intraoperative gamma probe-
directed biopsy of increased activity within the left parasp-
inal and psoas muscles seen on whole body gallium scan
and single-photon emission computed tomography
(SPECT) for confirming the diagnosis of lymphoma. Bur-
dine et al [757] described using 99mTc sulfur colloid for
intraoperative gamma probe-directed biopsy of small,
nonpalpable, non-visible, suspicious pulmonary nodules
during video-assisted thoracoscopic surgery in two
patients with a history of lymphoma. Most recently, Gulec
et al [43,45] have described using 18F-FDG for intraopera-
tive gamma probe-directed biopsy of nonpalpable suspi-
cious lymph nodes seen on diagnostic whole body PET
scan for confirming the diagnosis of lymphoma.
Radioguided monitoring of isolated limb perfusion
The utility of a gamma detection probe system for intraop-
erative radioguided monitoring of systemic leakage dur-
ing isolated limb perfusion surgery for both melanoma
and sarcoma has been previously investigated [758-767].
The basic principles of this technique were first described
in 1961 by Stehlin et al [758] using a single, large, over-
head-mounted scintillation detector that displayed con-
tinuous tracing results, in counts per minute, on a
rectilinear recorder for detecting 131I-labeled human
serum albumin. The principles of this technique using a
more modern handheld gamma detection probe system
within the operating room were later described in 1989 by
Sardi et al [759] at The Ohio State University. This system
by Sardi et al [759] consisted on two handheld gamma
probes, with one positioned over the precordial area andWorld Journal of Surgical Oncology 2009, 7:11 http://www.wjso.com/content/7/1/11
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one positioned over the distal aspect of the thigh. Each
patient received 0.8 mCi (29.6 MBq) of 99mTc pentetate
through the perfusate circulation. The percentage of 99mTc
pentetate leakage was calculated by a simultaneous read-
ing of the two gamma detection probes at one-minute
intervals. When compared to a method of intermittent
simultaneous blood sampling from the perfusate and sys-
temic circulations at 15 minutes intervals, essentially
identical percentage of leakage was detected by both
methods. However, the minute by minute monitoring of
the two handheld gamma probe system allowed for a
more instantaneous and real-time indication of any fluc-
tuations in the percentage of leakage than did the inter-
mittent (every 15-minute) blood sampling from the
perfusate and systemic circulations.
Since that time, multiple variations of this technique have
been described [760-767]. Manner et al [760] have advo-
cated the use of a two-probe system (precordial and thigh)
with 0.50 mCi (18.5 MBq) of 111In-labeled red blood cells
injected into the perfusate circulation. Sprenger et al [761]
have advocated the use of a three-probe system (precor-
dial, thigh, and perfusate circuit) with low-dose (i.e.,
0.004 mCi or 0.15 MBq) of 111In-labeled red blood cells
injected into the systemic circulation (to establish a mini-
mum baseline reference activity within the systemic circu-
lation) and a subsequent high-dose (i.e., 0.32 mCi or 12
MBq) of 111In-labeled red blood cells injected into the
perfusate circulation. Sandrock et al [763] have advocated
the use of a precordial one-probe system with 99mTc-
labeled red blood cells (0.4 mCi or 15 MBq) injected into
the perfusate circulation. Barker et al [762] have advo-
cated the use of a precordial one-probe system with a
combination radionuclide design consisting of a low-dose
(i.e., 0.02 mCi or 0.74 MBq) of 131I-labeled human serum
albumin injected into the systemic circulation and a sub-
sequent 10-fold higher dose (i.e., 0.20 mCi or 7.4 MBq) of
131I-labeled human serum albumin injected into the per-
fusate circulation. Similarly, Daryanani et al [764] and
Van Ginkel et al [765] have advocated the use of a precor-
dial one-probe system with a combination radionuclide
design consisting of a low-dose (i.e., 0.014 mCi or 0.5
MBq) of 131I-labeled human serum albumin and 0.3 mCi
(10 MBq) of 99mTc-labeled human serum albumin
injected into the systemic circulation and a subsequent
10-fold higher dose (i.e., 0.14 mCi or 5 MBq) of 131I-
labeled human serum albumin injected into the perfusate
circulation. Finally, Casara et al [766,767] have advocated
a precordial one-probe system with 0.014 mCi/kg (0.5
MBq/kg) of 99mTc-labeled human serum albumin injected
into the perfusate circulation at the time of the isolated
limb perfusion surgery and in conjunction with prior sim-
ulation testing with 0.0014 mCi/kg (0.05 MBq/kg) of
99mTc-labeled human serum albumin injected into the
systemic circulation of the patient at a time 48 to 72 hours
prior to the isolated limb perfusion surgery. Despite vari-
ations in these techniques, all have verified the potential
utility of the gamma detection probe for intraoperative
radioguided monitoring of systemic leakage during iso-
lated limb perfusion surgery.
Conclusion
Radioguided surgery using gamma detection probe tech-
nology has tremendously expanded and has evolved into
what is now considered an established discipline within
the practice of surgery. It has been investigated in and
applied to almost every imaginable neoplastic disease
entity that is surgically managed, and it has revolutionized
the surgical management of breast cancer, melanoma,
colorectal cancer, and parathyroid disease. The impact of
radioguided surgery on the surgical management of can-
cer patients includes providing vital and real-time infor-
mation to the surgeon regarding the location and extent of
disease, as well as regarding the assessment of surgical
resection margins. Additionally, it has allowed the sur-
geon to minimize the surgical invasiveness of many diag-
nostic and therapeutic procedures, while still maintaining
maximum benefit to the cancer patient. As we move for-
ward through the 21st century, we hope to continue to
build upon our current technological platform of radiogu-
ided surgery and further integrate advanced medical imag-
ing within the operative arena in order to supplement
intraoperative gamma detection probe technology
[16,768].
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